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Research summary 
Mixed tumours are characterised by the histological identification of two or more 
cell types (1). Commonly, a mixture of epithelial and myoepithelial cells is embedded in 
abundant stroma, which can consist of myxoid, chondroid or bony matrices (2). These 
spontaneously arising mixed tumours are uncommon in the human breast but are 
frequently found in human salivary glands and canine mammary glands (3). Subtle 
histopathological characteristics and overlapping attributes of malignant lesions with 
other benign lesions can lead to diagnostic challenges (4).  In humans, malignant mixed 
mammary tumours are also known as “metaplastic breast cancers” (MBCs) and benign 
mixed mammary tumours are otherwise known as “pleomorphic adenoma of breasts” 
(PABs) (4, 5). Malignant mixed tumours are quite rare in the human breast, and have a 
poor prognosis (6-8). Unlike humans, mixed mammary tumours are one of the most 
common types of tumours in dogs (3). In addition, canine mixed mammary tumours 
(CMMTs) tend to be benign rather than malignant (2, 9). There are three types of CMMTs: 
benign mixed mammary tumours (BMTs), carcinoma in benign mixed tumours (CBMTs) 
and carcinosarcomas (CSs). These are characterised by the presence of benign or 
malignant epithelial and mesenchymal elements (cartilage and/or bone). Information on 
human MBCs is minimal, however, one way to improve outcomes of patients with MBCs 
is to improve the understanding of this tumour type by using an appropriate animal model.  
The first aim of this study was to characterise the CMMTs immunohistochemically. 
It was necessary to establish the expression of markers known to be important in human 
breast cancers (HBCs) in CMMTs. These include the estrogen receptor (ER), 
3 
 
progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki-67, 
cytokeratin 5/6 (CK5/6), tumour protein p63 (p63), E-cadherin, CKAE1/AE3 and vimentin. 
To achieve this aim, immunohistochemistry (IHC) was carried out on formalin-fixed 
paraffin-embedded tissue sections (FFPE) from 101 spontaneously arising CMMT 
samples [88 benign and 13 malignant (eight CBMTs and five CSs)]. This study showed 
that benign and malignant forms of CMMTs share similar histopathological and molecular 
features with PABs and MBCs. The antigen localisation for ER, PR, HER2, p63, CKs, 
vimentin and E-cadherin was determined, indicating common pathogenetic mechanisms 
in the histogenesis of these tumours. ER+/PR+ was the most common status in BMTs and 
CBMTs, while ER-/PR- was the commonest status in CSs. 
In addition, osteopontin (OPN), SRY (sex-determining region Y)-box 9 (Sox9), 
bone morphogenetic protein 4 (BMP4) and Runt-related protein 2 (Runx2) expression 
patterns were examined using CMMTs to investigate their diagnostic and prognostic 
value, and to see if there were potential roles for these biomarkers in chondrogenesis and 
bone formation in these tumours. In addition, differences in the immunostaining amongst 
the different histological types of CMMTs were determined. Before this current study, 
there was no information about the roles of Runx2, BMP4, OPN and Sox9 in bone and 
cartilage formation in CMMTs. FFPE tissue sections from 101 spontaneously arising 
CMMT samples [88 benign and 13 malignant (eight CBMTs and five CSs)], and 13 normal 
mammary gland tissues were immunostained with antibodies specific for Runx2, BMP4, 
OPN and Sox9 in CMMTs. The results demonstrated a potential role for Sox9 and BMP4 
in tumourigenesis, and in chondrogenesis within CMMTs. However, high expression of 
OPN in CMMTs does not appear to be related to malignancy. Although Runx2 expression 
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was higher in malignant than normal and benign samples, there was no significant 
difference in Runx2 expression between the different sample groups in this study. Other 
studies suggest that high expression of Runx2-target genes is present with triple negative 
breast cancers (10, 11). 
The third aim was to determine whether argyrophilic nucleolar organiser region 
(AgNOR) expression can differentiate between normal mammary tissue, BMTs and 
malignant CMMTs. Also, to investigate if there is any relationship between the following 
measure of tumour growth: mean AgNOR count/nucleus, mean AgNOR area 
(pixels2)/nucleus, the mitotic index and the Ki-67 labelling index. Tissue sections from 77 
spontaneously arising CMMT samples [68 benign and nine malignant (five CBMTs and 
four CSs)] and 30 normal mammary tissues were studied with histochemical, 
immunohistochemical and morphometrical methods. The results showed that AgNOR 
quantification could be a simple and cheap method to assist in the differentiation of benign 
and malignant tumours. In this study, there was a positive correlation between the mitotic 
index and AgNOR count/nucleus. There was also a positive correlation between the mean 
mitotic index and the AgNOR area/nucleus. 
Sigl et al. (2016) were able to demonstrate that RANK and RANKL are also 
important regulators of BRCA1-mutation-driven human breast tumours (12). A BRCA1 
mutation is expected to promote tumour development in all tissues. More specifically, 
BRCA1-mutation carriers develop breast and ovarian tumours more regularly than non-
carriers (13). Therefore, the localisation of RANKL and RANK was investigated in CMMT 
tissues. FFPE tissue sections from 47 spontaneously arising CMMT samples [37 BMTs 
and 10 malignant (five CBMTs and five CSs)], and 20 normal mammary tissues were 
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immunostained with antibodies specific for RANKL and RANK. RANKL and RANK had a 
widespread distribution in the cytoplasm of epithelial cells of the ducts. They were also 
localised in the cytoplasm of mesenchymal stromal (chondrocytes) of BMTs, CBMTs and 
CSs. Strong RANKL and RANK staining had a significant association with CSs. 
In conclusion, spontaneous CMMTs could be a good animal model for the study 
of PABs and MBCs. There appears to be a key role for OPN, Sox9, Runx2 and BMP4 in 
the chondrogenesis and formation of CMMTs. Immunohistochemical examination of 
CMMT samples showed that increased RANKL and RANK expression indicate that these 
biomarkers could play crucial roles in the progression of CMMTs. Finally, in this study, a 
low-cost method that might be able to be used to increase diagnostic objectivity and 
reliability in evaluating mitosis in tumours was presented. 
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1.0 Introduction 
1.1 Human breast cancer 
Breast cancer is the most common form of cancer in women (14). Although the 
bulk of affected people are women, mammary tumours can also occur in men (14). 
Mammary tumours have varying prognoses and treatments—regardless of the 
histological subtypes, tumour grade and stage (15). The incidence rates of breast tumours 
differ around the globe; the highest occurrence is observed in developed Western nations, 
whilst in the developing nations in Africa, the occurrence is comparatively low (16, 17). 
The possibility of being diagnosed with breast cancer is 1 in 8 for women in Australia (18). 
In 2014, there were 16,753 new cases of breast cancer identified in Australia. In 2019, it 
is projected that 19,535 new cases of breast cancer will be diagnosed in Australia (18). 
It is crucial to differentiate patients who do not require further treatment from those 
with a worse prognosis and who need additional treatment. Traditionally, prognostic 
indices that categorise mammary tumours were used and these involved a number of 
factors including age and whether the patient was menopausal or not. Up to now, one of 
the most highly effective predictors of mammary tumour recurrence is tumour staging. 
The TNM (tumour, lymph node and metastasis) system for cancer staging is dependent 
on the size of the tumour, the involvement of the axillary lymph nodes and the existence 
of metastases (19). 
Most breast tumours develop in the epithelium of the terminal duct lobular unit and 
this categorises them as breast carcinoma (20). Then, they are broken down according 
to their developmental pattern (20). The majority of breast carcinomas (approximately 
Chapter 1 - Introduction  
8 
 
60%) are invasive ductal carcinomas (IDC) also known as invasive carcinomas of no 
special type (IC NST) (20, 21). However, other histopathological subtypes of breast 
cancers are invasive lobular carcinomas, medullary carcinomas, mucinous carcinomas, 
tubular carcinomas and metaplastic breast cancers and these are designated as “special 
subtypes” (20). Approximately 10-15% of all breast tumours are lobular carcinomas and 
they are the next most frequent histopathological subtype, after IDC (20). The rest of the 
unique types of mammary carcinomas are less than 5% of all breast cancers and 
metaplastic breast cancer (MBC) is seen in less than 1% of cases (20).  
Comparative oncology assists us in the study of a disease in distinct species (22). 
This allows us to link the spontaneously occurring tumours in veterinary patients with 
more general studies of tumour biology in humans (22). Animals as biological models 
have played a key role in clarifying the physiological processes, including in the 
progression of cancer. With the practical and ethical problems increasing in human 
studies, animals have  become more important in cancer research (23). Developments in 
cancer care are dependent on the utilisation of pre-clinical in vivo model systems to 
examine efficacy and safety. Generally, the optimal animal model should be: (I) similar to 
the human disease in terms of molecular features, (II) developed from an applicable cell 
line that is employed in in vitro research, (III) dependable and predictable, (IV) capable of 
displaying survival variations, (V) able to allow for precise treatment evaluation, (VI) easily 
imaged, and (VII) in a comparable background conditions as the human disease (23). 
Spontaneously-arising canine mammary tumours have been shown to share several 
attributes with their human counterparts. Canine mammary tumours are an attractive 
alternative to mouse models, including transgenics or xenografts, where the tumour is 
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synthetically induced. Dogs have tumours that mirror the features of human disease, such 
as clinical manifestation, histopathology, metastasis, recurrence, genetic susceptibility 
and patterns of response or resistance to therapy (23). Because the nature of the tumour 
is spontaneous, the complex tissue interactions can be studied, which is often difficult in 
other animal models (23). Any animal model used for identification of efficacy has to be 
supported by natural history studies that demonstrate the resemblance to humans in 
pathophysiology of disease, which include the progression and manifestation of 
symptoms and pathology. National Cancer Institute’s Comparative oncology trials present 
an iterative approach where research on dogs can inform studies on humans, with the 
total gain in knowledge advancing the understanding of tumour and potential therapies. 
For instance, initial studies on dogs with tumours can produce data about targeted 
treatments, which include activity, toxicity, and pharmacodynamics (24).  
For several gene families, specifically those related to cancer, the resemblance 
between dog and human gene sequences have been demonstrated to be more similar 
than the corresponding counterparts in mice (25). Molecular cytogenetic examination of 
canine haematological tumour cells demonstrated the retention of ancestral 
chromosomal aberrations in similar human tumours (26). It was also found that 
comparable mutations in oncogenes could cause tumours in humans and dogs. For 
instance, identical mutations in KIT, a tyrosine kinase growth factor receptor, have been 
detected in both human gastrointestinal stromal cancers and canine mast-cell tumours 
(27). Furthermore, comparative histological examinations suggest that the intratumoural 
(cell-to-cell) heterogeneity found in human breast cancers also occurs in  canine tumours 
(28). The outcome of this heterogeneity highlights the dangerous characteristics of 
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human cancers, especially in recurrence and metastasis. There are other advantages 
with dogs. They have a large body size and are comparatively outbred as compared to 
other laboratory animals, thus providing genetic variation identical to that observed in 
humans (29). In addition, a number of important genes that were expressed differentially 
in human breast cancers, when compared with normal specimens, were also found to be 
deregulated in the canine model (30). Furthermore, a pathway-focused study of these 
genes showed a large degree of parallels in the up- and down-regulation of many tumour 
related pathways (30). 
Animal experimentation remains important in the understanding the basic 
mechanisms that underlie the development of cancers and to help uncover improved 
approaches to identify, prevent and treat diseases. Moreover, animal studies are also 
required by regulatory authorities for the approval of new drugs (31). Some mouse tumour 
models have produced false positive results; the drug worked in mice but not in humans 
(31). This problem with conventional transplantation models drove the development and 
use of transgenic mice (32). The main limitation with utilising animal models to understand 
human diseases is, that there are significant species variations in anatomy, physiology, 
metabolism and pharmacology due to underlying genetic differences, involving genes 
(33). These differences between species can limit the translation of laboratory animal 
findings directly to humans (34). Mice primarily tend to develop tumours of mesenchymal 
origin, while human age-related tumours  mostly originate from epithelial progenitor cells 
(35). In addition to, the apparent environmental variables, including alcohol, diet and 
tobacco, there are obvious biological variations between mice and humans that  
contribute to discrepancies in tumour risk and spectrum (35). One main difference 
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includes telomere erosion during malignant alteration of human cells. Contrary to human 
cells, mouse somatic cells express active telomerase, an enzyme that is needed for the 
regulation of chromosome ends (36).  
MBC is a mixed tumour, containing malignant epithelial and mesenchymal 
components (37). A mixed tumour is a biphasic tumour that originates from more than 
one type of tissue (38). MBC is rare, however, metaplastic carcinoma with cartilaginous 
and/or osseous metaplasia is even rarer (2, 3). These tumours are known to have basal-
like characteristics (5). Canine mixed mammary tumours (CMMTs) and human MBCs 
share several histopathological features and risk factors. In both species, these tumours 
display epithelial and stromal components. Given their rarity, large cohort studies are 
often difficult. Interestingly, canine metaplastic tumours—otherwise known as ‘canine 
mixed tumours’ in the veterinary community—occur at a higher frequency. Unlike in 
humans, metaplastic mammary tumours are one of the most common types of tumours 
in dogs. In addition, these canine tumours tend to be benign rather than malignant. 
Consequently, determining both the presence and the role of genes and proteins in both 
bone and cartilage formation and cancer, could help shed light on the development of 
cartilaginous and/or osseous metaplasia in breast cancers.  
1.1.1 Human mammary gland structure 
The breast consists of glandular and adipose tissues reinforced by a loose fibrous 
tissue named Cooper’s ligaments (39). The glandular tissue is evacuated by a ductal 
system that supplies and carries milk to the nipple during breast feeding (39). Glandular 
tissue is composed of a system of ducts. The large ducts drain into retroareolar ampullae 
that meet in the nipple, beyond a dilated element known as the lactiferous sinus. Then, 
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each duct splits into smaller ducts. This whole network comprises the ductal tree (40). 
Mammary lobules are situated right behind the ducts. These are the units of the mammary 
gland that provide the production of milk (40). Each lobule includes about 20 tiny glandular 
components, known as acini, which drain into the terminal duct. This is referred to as the 
terminal duct lobular unit (TDLU) (40). Mammary ducts and lobules are surrounded by 
connective tissue consisting of blood and lymphatic capillaries, nerves, fatty and fibrous 
tissue, which provide nutrition and support (40). 
Histologically, the breast is composed of ductal epithelial tissue with a fibrous 
stroma. The wall of each duct is covered by two layers of epithelia: an internal layer that 
lines the lumen of the duct — which consists of cuboidal epithelial cells — and an external 
layer of contractile myoepithelial cells that firmly encompass the luminal layer and have 
the attributes of smooth muscle cells (41). The basal layer is situated on the basement 
membrane (41, 42). Lineage tracing has underlined the presence of bipotent mammary 
stem cells (MaSCs) in situ and long-lasting unipotent cells that drive origin and 
development of the ductal system (42). In addition, there is evidence for a heterogeneous 
MaSC compartment consisting of fetal MaSCs with both long-term and short-term 
repopulating cells. Different luminal progenitor subtypes have been recognised in parallel 
in human and mouse breast tissues (42). Similar to the ducts, the wall of the acini is 
covered by two layers of epithelial cells. Most pathological changes develop from the 
TDLU and its surroundings. However, a few conditions, particularly ductectasia and 
papillomas, develop in the main ducts (43).  
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1.1.2 Genes associated with breast carcinogenesis 
There are two important types of genes that can be involved in the breast cancer: 
tumour suppressor genes and oncogenes. 
1.1.2.1 Tumour suppressor genes 
Breast cancer 1 and 2 (BRCA1 & BRCA2) genes code for proteins that are 
associated with DNA repair, cell cycle regulation and in several transcriptional functions. 
They could also be involved in apoptosis and genomic stability (44, 45). Women and men 
with BRCA mutations have a higher risk of breast cancer. Mutated BRCA genes could 
cause hereditary breast-ovarian cancer syndrome (46). Generally, BRCA-related breast 
cancers are more aggressive than non-BRCA-related breast cancers (47, 48). BRCA1-
related cancer is usually categorised as basal-like subtype tumour (see 1.1.3) with the 
localisation of CK5/6 and is more deadly than BRCA2-related cancer which is identified 
as luminal A-like subtype tumour (see 1.1.3) (49, 50). 
The tumour suppressor p53 gene (also called tumour protein p53 gene and TP53) 
is located on chromosome 17p13.1 and it codes p53 protein. TP53 is the most commonly 
mutated gene in sporadic breast tumours (51). The majority of mutations are point 
mutations generating a long-acting p53 protein which interferes with the activation of the 
cell cycle suppressing genes and apoptotic genes, and leads to unmanageable cellular 
progression (51).  
Another gene associated with carcinogenesis of breast cancer is the 
retinoblastoma gene (RB1). Retinoblastoma gene mutation is frequently seen in basal-
like tumours (52). Checkpoint kinase 2 gene (CHEK 2), phosphatase and tensin homolog 
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gene (PTEN), ataxia-telangiectasia mutated, ATM serine/threonine kinase gene (ATM) 
and E-cadherin gene (CDH1) may also play a part in breast cancer pathogenesis (53-
56). 
Somatic and germline mutations in genes related to the DNA double-strand break 
repair pathway including ATM, ATR (ataxia telangiectasia and Rad3), PALB2 (partner 
and localizer of BRCA2), RAD51C, RAD50, TP53, CHEK2 and BRIP1 (BRCA1 interacting 
protein C-terminal helicase 1) were found in 560 breast cancers (57). In addition, somatic 
mutations in TP53, PIK3CA and GATA3 had an incidence rate of less than 10% across 
all breast tumours. Nevertheless, there were many subtype-associated and new gene 
mutations, which include the enrichment of particular mutations in GATA3, PIK3CA and 
MAP3K1 (mitogen-activated protein kinase kinase kinase 1) with the luminal A subtype 
(58). 
1.1.2.2 Oncogenes  
Oncogene HER-2/neu has been localised to chromosome 17q12-q21, and it 
encodes a protein tyrosine kinase (59). The HER2 gene is amplified and overexpressed 
in about 30% of invasive breast carcinoma. It has been proposed that HER2 amplification 
is related to poor patient outcome, especially with nodal metastasis (60).  
A number of oncogenes like apoptosis regulator BAX (Bax), B-cell lymphoma 2 
(Bcl-2) and P53 are involved in the control of pro-apoptosis in breast cancer (61). The 
Bcl-2 controls generation of cytochrome C. Cytochrome C combines with other elements 
to produce an initiating complex, named apoptosome (61). The effective apoptosome 
stimulates the caspases, which results in apoptosis (61). 
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  The estrogen receptor gene (ER) has been localised to chromosome 6q25.1. It is 
a very important nuclear receptor in hormone-dependant breast tumourigenesis. ER can 
work as a cancer initiator resulting in direct DNA destruction or by activating cell 
development and growth in malignancy (62). Overexpression of ERα (ESR1) is usually 
noted in earlier stages of breast tumours (45). The importance of ERβ in breast carcinoma 
is significantly less than that of ERα (62).  
Molecular diagnostics have changed anatomical pathology and have 
revolutionised the practice of medicine (63). Several techniques can be utilised for 
molecular pathology including: molecular, chromosomal and biochemical genetic tests to 
study the amount of proteins; defects in either gene or protein could indicate changes to 
the DNA that causes the disorder (63). The usefulness of presurgical genetic testing has 
been shown the lowering of need for surgery (63, 64). However, there is no evidence that 
bilateral mastectomy in patients who have a pathogenic mutation in breast cancer genes 
has any impact on the patient outcome (63, 64). Radiotherapy, appears to be safe and 
efficient in lowering ipsilateral tumour recurrences in BRCA1 and BRCA2 mutation 
carriers (63, 64). Animal research has highlighted some concerns demonstrated about 
toxicity of radiotherapy in ATM mutation carriers, but this has not been proven in humans. 
The advantages of radiotherapy in breast cancer patients who undergo surgery outweigh 
the disadvantages. Nonetheless, additional studies are needed to completely understand 
the long-term effects of radiotherapy in ATM mutation carriers (65). In the setting of 
advanced breast cancer, PARP inhibitor and platinum-based chemotherapy have been 
effective in BRCA1 and 2 mutation carriers. For BRCA1/2 carriers—with HER2-negative 
breast cancers who previously failed for chemotherapy—treatment using olaparib or 
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talazoparib has improved survival rates (66). More breast cancer research related to 
germline mutations in genes other than BRCA1 and 2 is required to understand the 
biology of these cancers and to determine potential targets for new therapeutics (67). 
Molecular genetics and the phenotypic variation of breast tumours has 
demonstrated some interesting genotypic–phenotypic correlations (68-70). Cancers 
arising in BRCA1 germline mutation carriers demonstrate particular kinds of 
morphological attributes and these characteristics are comparable to those outlined in 
basal-like breast tumours (71). These include high histological grade, high proliferation 
indices and obvious lymphocytic infiltrates (72, 73). Experts in breast tumour molecular 
profiling have suggested that this molecular profiling may have histogenetic implications 
(74). For example, basal-like tumours may be derived in basal cells, while luminal tumours 
may originate from luminal cells (75-77). Nonetheless, there is evidence to propose that 
specific genetic aberrations could cause phenotypic changes during breast tumour 
progression (75-77). Genomic profiling of invasive breast cancers has displayed that 
breast tumours can be categorised into two groups based on the pattern of genetic 
aberrations they carry. The genomic profiles are first categorised as ‘simplex’ or 
‘complex’. The ‘simplex’ group is characterised by large segments of duplications and 
deletions, often comprising entire chromosomes, with sporadic isolated narrow peaks of 
amplification. This group is associated with good prognosis. However, the complex 
pattern is associated with poor prognoses (78). The second complex group, called 
‘firestorm’, looks like the simplex type, however demonstrates one or more localised 
region of clustered, comparatively narrow peaks of amplification, each one limited to a 
single chromosome arm (79). 
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1.1.3 Molecular subtyping of human breast cancer 
Perou et al. (2000) demonstrated evidence for breast tumour subtypes 
characterised by gene expression patterns. From the findings of a hierarchical clustering 
of 65 breast tumours and normal mammary specimens (depending on their expression 
pattern of 496 genes), Perou and colleagues defined four subtypes: luminal-like, basal-
like, HER2-overexpressing-like and normal-breast-like (79).  
Sorlie et al. (2003) found that breast cancers can be classified into various 
molecular subtypes (49, 79). These subtypes depend on the expression of the ‘intrinsic’ 
groups of 534 genes (49). Sorlie et al. (2003) have used DNA microarrays to measure 
gene expression levels (49). The molecular classification of breast cancer categorises 
tumours into five intrinsic subtypes and this profiling has been heralded as leading to 
better clinical outcomes (49). These five intrinsic subtypes are: the luminal subtype which 
is additionally stratified into luminal A- and luminal B-like tumours, the HER2-
overexpressing tumours, basal-like and normal-like tumours (see Table 1.1). This 
classification can assist in determining different treatment regimens. For example, 
patients with luminal A-like subtype tumours may only require hormonal treatments. 
Variations in gene expression patterns among these subtypes indicate fundamental 
changes in their cellular biology and these variations can give rise to different outcomes 
(see Figure 1.1) (49). Patients with basal-like tumours have the poorest prognosis, as 
basal-like tumours lack ER, PR and HER2 (49). Most but not all basal-
like tumours are triple negative (80).  Additionally, Sabatier et al. (2014) showed that most 
of the metaplastic carcinomas in their study were claudin-low (81). Thus, surgery and 
chemotherapy, individually or in combination, often are the only accessible therapeutic 
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modalities. Nevertheless, certain receptors have been identified as targets for novel 
therapeutic drugs including epidermal growth factor receptor (EGFR), fibroblast growth 
factor receptor 2 (FGFR2), vascular endothelial growth factor (VEGF) and the mammalian 
target of rapamycin (mTOR) (49). 
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Table 1.1 Characteristics of intrinsic subtypes of human breast cancers (82, 83). 
Molecular 
subtype 
Molecular status Tumour histological grade  
Normal breast-
like  
ER+, PR+, HER2-, Ki-67- and 
CK5/6- 
Low or intermediate 
Luminal A-like ER+, PR+, HER2-, Ki-67- and 
CK5/6-  
Low 
Luminal B-like ER+ PR+, HER2-, Ki-67+ and 
CK5/6- 
or 
ER+,PR+,HER2+, Ki-67+ and 
CK5/6- 
Intermediate or high 
HER2-
overexpressing  
ER-, PR-, HER2+, Ki-67+ and 
CK5/6+ 
High  
Basal-like  ER-, PR-, HER2-, Ki-67+ and 
CK5/6+ 
High  
 
Claudin-low ER-, PR-, HER2-, Ki-67+, CK5/6+, 
CLDN3-, CLDN4-, CLDN7- and E-
cadherin- 
High  
CK5/6, cytokeratin 5/6; CLDN3, claudin 3; CLDN4, claudin 4; CLDN7, claudin 7; ER, estrogen 
receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor. 
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Figure 1.1 Outcomes of the intrinsic subtypes of breast cancer. Triple 
negative/basal-like subtypes have a poorer prognosis compared to the luminal A, luminal 
B and HER2-overexpressing tumours, adapted from Dai et al. (2015) and Dai et al. (2017) 
(83, 84).  
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1.1.4 Immunohistochemical subtyping of human breast cancer  
After the preliminary presentation of these subtypes via microarray analysis, IHC 
was used because it was a less time-consuming and more affordable identification 
method (17, 85, 86). The subtypes were demonstrated by utilising panels of antibodies. 
All panels included ER, PR and HER2 or HER1. Hormone receptor studies including ER, 
PR and HER2 are routinely performed in breast cancers. ER and PR receptors are found 
on the mammary cells that the particular hormones bind to causing cell growth. By 
combining ER with estrogen-response elements present in the promoter region of 
particular genes, gene expression is modulated and eventually leading to the biological 
impacts of estrogen (87). When a tumour is ER+ then estrogen can stimulate tumour 
growth (87). Likewise, the cancer is PR+ if it has receptors for the hormone progesterone. 
Again, this means that the cancer cell growth can be stimulated by the presence of this 
hormone (88). HER2 is found on mammary cells and often amplified in breast cancers 
(87). Additionally, HER2+ status of breast cancer indicates that the HER2/neu gene can 
produce more HER2 protein. Normally, HER2 regulates healthy mammary cell growth. 
However, in about 30% of breast tumours, the HER2/neu gene has extra copies (89) and  
this can lead to mammary cells to divide in an uncontrolled way (89). 
One of the most interesting aspects is the assortment of basal cell markers (86). 
Some researchers have used cytokeratin 8/18 (CK8/18) as a basal cell marker (86). This 
was supposed to enable the differentiation of luminal tumours from basal-like tumours, 
despite the fact that CK8/18 is also a luminal cell marker (86), it has been found in about 
80% of basal-like tumours. Therefore, CK8/18 may not be a good marker for 
differentiating luminal from basal tumours (86). 
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Breast tumours can have various histopathological and biological attributes, which 
show specific behaviours that cause distinct treatment responses and have to be given 
various therapeutic approaches. Therefore, classifying breast tumours into different 
molecular subtypes has assisted in giving patients better targeted treatment (90). 
Classical IHC markers such as ER, PR, HER2 and Ki-67 along with clinicopathological 
factors, which include tumour grade and axillary nodal involvement are regularly used to 
help to make treatment decisions (15, 91, 92). CK5/6 is apparently the most commonly 
used basal cytokeratin, either alone or with CK14 and/or CK17. Several groups have 
attempted to characterise surrogate IHC markers to determine the molecular subtyping 
that originates from the microarray data (93). The IHC panel comprised of prognostic 
biomarkers for breast tumour include ER and PR and markers of oncogene 
overexpression, including HER2 (93). The luminal A-like (ER+ and/or PR+ and HER2-) 
subtype has better prognosis. Luminal B-like (ER+, PR+ and HER2+) subtype has a 
worse prognosis compared to luminal A-like, but better than the HER2-overexpressing 
and basal-like subtypes (94). The HER2-overexpressing subtype is more aggressive, but 
treatment with anti-HER2 drugs (i.e. Herceptin) the outcome has marginally improved. 
Overall, the basal-like subtype has the worst prognosis (95). 
Nielsen et al. (2004) proposed that a panel of four antibodies composed of ER, 
HER2, HER1 and cytokeratin 5/6 (CK5/6) would be all that was needed to diagnose basal 
tumours (17). Others have suggested that an increased number of antibodies are required 
(85, 86, 96). Cheang et al. (2008) compared the predictive significance of a three-
biomarker (ER, PR and HER2) to a five-biomarker (ER, PR, HER2, HER1, and CK5/6) 
panel on the intrinsic breast tumour subtypes. The results of their study showed that using 
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a five-biomarker panel offered a more accurate characterisation of basal-like tumours and 
this allowed a better prediction of outcomes (96).  
Vimentin is a protein that can help distinguish mesenchymal cells from epithelial 
cells (96). Livasy et al. (2006) showed that most of the basal-like tumours in their study 
were positive for vimentin while all of the luminal or HER2-overexpressing tumours were 
negative (85, 86). Therefore, vimentin could be more helpful than other basal cell markers 
including p63 and CK5/6 in determining basal-like tumours (86, 97).  
Matos et al. (2005) defined each tumour molecular subtype depending on the 
expression of ER, HER2, p63, CK5, Bcl-2, Placental (P)-cadherin and Ki-67 (98). Onitilo 
et al. (2009) compared the clinicopathological characteristics and survival rate in the four 
subtypes of breast cancer identified by IHC localisation of ER or PR and HER2 and found 
that the basal-like subtype has the worst overall outcome (99). Livasy et al. (2006) carried 
out IHC using a panel of antisera against ER, HER2, HER1, p63, α-smooth muscle actin 
(αSMA), CK5/6, CK8/18, CD10 and vimentin on 46 invasive breast carcinomas (86). This 
group found that basal-like tumours were negative for ER and HER2 and positive for 
vimentin, HER1, CK8/18 and CK5/6 (36). Another molecular subtype called claudin-low 
was reported by Prat et al. (2010) (82). Prat and colleagues discovered that the claudin-
low subtype lacks the expression of hormone receptors (ER, PR and HER2) and has a 
poor prognosis (82). Perou (2010) reported that claudin-low tumours are triple negative, 
and so could be considered another subtype of triple-negative tumours, along with the 
basal-like group (see Figure 1.1) (100). In addition, claudin-low tumours are typically 
negative for claudin 3 (CLDN3), claudin 4 (CLDN4), claudin 7 (CLDN7) and epithelial (E)-
cadherin (see Table 1.1) (82). 
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The introduction of anti-HER2 therapy has revolutionised the treatment of HER2-
overexpressing breast carcinoma (101). The combination of Herceptin with 
chemotherapy is the standard treatment for a HER2-positive carcinoma (102). Disease 
relapse rates have been documented in 15%–20% of patients with HER2-overexpressing 
breast tumours after both neoadjuvant and adjuvant therapies (103). Thus, the 
development of novel treatments is required for HER2-positive breast tumours (102). 
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1.2 Canine mammary tumours  
As in humans, the canine mammary gland has a tubulo-alveolar pattern that 
consists of two cell layers—an intrinsic luminal cell layer made up of epithelial cells and 
a distinctive external basal cell layer (104). They are adjecent to the basement 
membrane, which consists of spindle-shaped myoepithelial cells (104). Myoepithelial cells 
have a common origin, developing from progenitor cells situated in a suprabasal area 
between the luminal and basal layer (104). Spontaneous mammary gland tumours arise 
in female dogs, comprising the most frequently occurring tumour and represent 25 to 50% 
of all tumours (2). Canine mammary tumours (CMTs) mostly affect middle-aged female 
dogs and occur more frequently in caudal mammary glands and are demonstrated as 
solitary or multiple masses (105). Spaniel breeds, pointers and dachshunds appear to be 
more prone than other dog breeds (105). 
Recently, the standard classification of the World Health Organisation (WHO) has 
been adopted by the veterinary pathology community for classifying CMTs (106). CMTs 
consist of simple tumours with ductal epithelial cells only, complex tumours involve 
myoepithelial cells, and mixed tumours with mesenchymal elements including cartilage 
or osseous tissue (2, 105). All histotypes can be found in dogs as both benign and 
malignant forms: benign mixed tumours and complex adenoma represent the dominant 
benign types, while carcinomas are mostly malignant tumours (2, 107). Carcinosarcomas 
(CS) and sarcomas are present but are rare (2, 107). The current WHO classification of 
CMTs divides carcinomas into complex carcinomas, non-infiltrating carcinomas and 
simple carcinomas. Canine mixed mammary tumours (CMMTs) demonstrate a 
complicated histological pattern since they comprise components from the epithelium and 
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the mesenchyme with cartilage and/or bone formation (2). Regardless of the controversy 
about the origin of these tissue types in the mixed tumours, the latest studies strengthen 
the role of myoepithelial cells in mesenchymal differentiation (108, 109). 
Goldschmidt et al. (2011) suggested the following histologic classification of 
tumours and dysplasias of the canine mammary gland (109). Some tumours that are 
included in the new classification system are included as specific entities. These include 
the cribriform type of simple carcinoma and comedocarcinoma, each of them were 
outlined under carcinoma–in situ (109). Others have been recognised as malignant 
versions of formerly mentioned benign tumours and involve ductal carcinoma, the 
malignant variant of the ductal adenoma, but earlier categorised as a basaloid adenoma 
(109). As well as the intraductal papillary carcinoma—the malignant counterpart of the 
intraductal papillary adenoma—formerly categorised as a duct papilloma. Micropapillary 
carcinomas, a newly described entity have also been included into the classification (110). 
Other recent additions, include the carcinoma and malignant myoepithelioma, have been 
detected using IHC markers for epithelial cells (CK 7, 8, 18 and 19) and 
basal/myoepithelial cells (CK 5, 6, 14, 17, SMA, vimentin, calponin and p63) (111). Table 
1.2 shows a recent classification of canine mammary tumours. 
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Table 1.2 Proposed Histologic Classification: 2010 (109). 
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The main issue in assessing canine mammary tumours is detecting those that are 
“truly” malignant (109). The existence of some cells, with large nuclei and dominant 
nucleoli, often cause the misdiagnosis of mammary carcinoma (109). The following are 
the important criteria for the detection of canine malignant mammary cancers: tumour 
type, marked nuclear and cellular pleomorphism, mitotic index, existence of areas of 
necrosis within the tumour, lymphatic invasion, and local lymph node metastasis (109). 
Most grading systems of canine mammary carcinomas are a modification of the numeric 
scoring system of Ellston and Ellis (109). There are some variations between the criteria 
used by Pena et al. (2010) and Misdorp (2002) (105, 112). There are slight differences 
between these grading systems, although it is not known how this would influence the 
outcome of dogs with mammary tumours. This would be most important in cases of grade 
II (i.e., intermediate differentiated tumours) (109). Prognosis is poorer in cases with grade 
III carcinomas than in grade I or II. Cases with simple carcinomas have a shorter survival 
compared with other carcinomas. Undifferentiated cancer (grade III) has a greater risk of 
mortality when compared to differentiated cancer (grade I and II). As indicated in several  
studies, lymphatic and vascular invasion, and lymph node metastasis are, predictably, 
related to a poorer survival (109). In canine mammary tumours, the histological type of 
tumour, histological grade and nodal involvement are the conventional prognostic 
attributes (105). 
Ovarian hormones and their specific receptors in mammary tissue have long been 
identified as drivers of the formation of canine mammary tumours (113). The correlation 
between steroid hormonal exposure and risk for mammary neoplasms has been 
proposed by epidemiological studies demonstrating markedly reduced incidence of 
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mammary cancers in dogs having experienced pre-pubertal ovariohysterectomy 
compared with intact dogs (114). It is likely that steroid hormones are essential in the 
formation of mammary cancers (115). Several of these neoplasms express hormone 
receptors, which proposes some degree of hormone dependency that may be used in 
treatment. Contrary to, breast cancer in humans for whom hormonal therapy is used in 
patients with hormone receptor-positive tumours, there is doubt about its efficiency in 
dogs (115). 
1.2.1 Canine mammary tumours as a model for human breast cancers  
Animal tumour studies are used to increase the understanding of similar tumours 
in humans (116). Currently, there are many animal models for human breast cancers 
(HBCs), including: murine xenograft models (117), transgenic mouse models (118), virally 
induced mouse models (119), genetically manipulated mouse models (120) and 
chemically induced mouse models (121). Mice are the main models for HBC and have 
allowed scientists to recognise the basic events that trigger mammary tumour initiation 
and progression. Furthermore, mouse models have provided opportunities for examining 
breast cancer therapies and prevention (122). Mouse models have been used extensively 
to illustrate the aetiology of breast cancer as well as to elucidate the responses of breast 
cancers to different therapeutic approaches (123).  
A transgenic mouse model has many benefits which includes small size of the 
animal, short gestation periods, relatively affordable maintenance and uncomplicated 
manipulation of gene expression (124). Furthermore, mice share some physiological 
resemblances with humans and for that reason are frequently used in pharmacokinetic 
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studies (125). There are some significant dissimilarities between mice and humans which 
include a higher basal metabolic rate in mice, a changed telomere length in laboratory 
mouse strains and an altered period for cancer onset (126). Murine xenograft models 
have also been used to study the molecular subtypes of mammary cancers (127). This is 
achieved by implanting human primary breast tumour cells into immunodeficient mice 
(127). Only 10% of the xenografts in these mice persist, typifying the problem of 
generating animal models for HBCs (127). Though rats and mice are the most commonly 
used animal models in cancer research, there are several limitations. First of all, despite 
the several attempts to translate the results of mouse research to humans, scientists still 
cannot specify in advance which study in mice might benefit or clarify human biology and 
health (128, 129). In addition, the possibility of a mouse cell becoming fully transformed 
in vivo or in vitro is much greater than that of a human cell (130, 131). About half of HBCs 
are hormone-sensitive at diagnosis, while almost all of mouse mammary cancers are 
hormone-independent with significantly low ER and PR expression levels (129). While 
the morphological patterns of tumours in humans and rodents appear to be identical, the 
detailed pathological characteristics of the majority of mouse tumours are not comparable 
to HBCs and cannot be categorised in the same pathological types and grades (132).  
In contrast, clinical and molecular parallels have been determined between HBCs 
and CMTs. The clinical parallels are the spontaneous tumour occurrence, age of onset, 
hormone-dependent aetiology and a similar disease course. Moreover, the variables that 
impact on the clinical outcome includes the tumour size, clinical stage and lymph node 
metastases—are the same as in HBCs. The molecular features of CMTs including 
hormonal receptors (ER and PR), human epidermal growth factors (HER1 and HER2), 
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proliferation markers like Ki-67, and p53 mutation are like HBCs (133, 134). CMTs have 
been proposed to be a good model for HBCs, as dogs share the same environment as 
humans and are therefore exposed to the same potential carcinogens as humans (9, 
135). Nearly 94% of the canine genome has conserved synteny blocks with rodents and 
humans (136). Like humans, advancing age and obesity also raise the risk of mammary 
neoplasia in dogs (137). Dogs develop tumours spontaneously unlike other animal 
models (129). These features make dog a suitable model to examine breast cancers as 
such a model could assist in customised therapy and prevention approaches. 
Naturally occurring mammary tumours are uncommon in mice (138). Most 
spontaneous mouse mammary tumours are histologically different from HBCs whereas 
some genetically engineered mouse mammary tumours mimic HBCs (139). As with 
humans (as opposed to mice), spontaneous mammary neoplasms are the most frequent 
tumours in female dogs (2, 105). Working with data from 200 female dogs, Antuofermo 
and colleagues (2007) identified the histological and immunohistochemical resemblance 
between human and canine mammary intraepithelial lesions. From the 200 CMT samples 
that were examined, 93 non-neoplastic and 119 malignant tumours were identified. Non-
cancerous mammary tissue, ductal hyperplasia and atypical ductal hyperplasia in dogs 
were histologically consistent with similar lesions in human breast tissue. Of the 
intraepithelial lesions discovered in 60 samples, 39 of them were malignant tumours. 
Ductal carcinoma in situ (DCIS; high, intermediate and low grade) was the most prevalent 
intraepithelial lesion observed among CMTs. Ductal carcinoma in situ is also the most 
commonly detected intraepithelial lesion in humans (140).   
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1.3 Mixed tumours 
The term 'mixed tumour' was described in 1874 by Minssen as a tumour type that 
has both epithelial and stromal origins (1). In 1966, Eneroth catalogued the numerous 
other names for mixed tumours such as 'epithelial mixed tumour', 'complex adenoma', 
'pleomorphic adenoma and adenocarcinoma', 'pleomorphic sialoadenoma' and 
'epithelioma remanie' (141). 'Mixed tumour' is still the most frequently used term, not 
because of its histogenesis but due to its histological description (141). 
In humans, cases of mixed tumours have been reported in different organs 
including the salivary gland (142), mammary gland (5, 37), uterus (143), cervix (144), 
vagina (145), ovary (146), peritoneum (147), gallbladder (148), skin (149), lung (150), 
oesophagus (151), colon (152), larynx, palate, paranasal sinuses, nasal septum (5) and 
pancreas (153). Whereas in dogs, mixed tumours have been reported in the mammary 
gland (154, 155), thyroid gland (156), lung (157), salivary gland (158), 
ceruminous glands  (159) and the eyelid (160). Only a few cases of mixed tumours have 
been described in cats and they were located in the mammary gland (161, 162), pancreas 
(163), mandibular salivary gland (164), biliary system (165) and lung (166). 
Spontaneously arising mixed tumours have also been observed in the mammary gland, 
uterus and skin of rats (167). 
Mixed tumours can be benign or malignant. The former are identified by the 
presence of benign epithelial components and mesenchymal cells with cartilage and/or 
bone development, combined with myxoid fibrous tissue (2). The latter consists of 
epithelial and stromal components, both of which are malignant (168-170). Very little is 
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known about the processes which underlie the pathophysiology of mixed tumours. The 
various forms and types of mixed mammary tumours in different mammals will be 
discussed further below. 
1.3.1 Mixed mammary tumours in humans 
In humans, mixed tumours are more common in the salivary gland than in the 
breast. However, mixed tumours in dogs are found most frequently in the mammary gland 
(3). In humans, mixed mammary tumours can be benign or malignant. 
1.3.1.1 Benign mixed mammary tumours in humans  
Benign mixed tumours of the breast were first described  by Lecéne in 1906 (171). 
They are also known as “pleomorphic adenomas of breast” (PAB) (5). This tumour type 
has a wide histomorphologic diversity but an excellent prognosis (172).  
Less than 100 cases of PAB have been reported (see Table 1.3) (5, 171, 173-219). 
PAB is seen more commonly in females than in males (10:1 ratio) (5) and can be found 
in individuals of all ages. However, it is most common in the second to seventh decades. 
In their study, Sato et al. stated that there is a tendency for the tumours to occur in the 
right breast (R: L=3:2). PAB are more likely to be located in the sub-areolar region, which 
indicates that the tumour is likely to have arisen from the large duct (174). 
PAB is often asymptomatic and is usually only recognised through imaging carried 
out for other reasons. PAB mainly affects women aged 23 to 73 years of age and typically 
appears as a single palpable lump (172, 175). This tumour type can vary in size between 
0.6 cm and 17 cm in diameter, but most were around 2 cm in diameter (176). 
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Microscopically, PAB is a mixture of epithelial and myoepithelial cells in abundant 
stroma, which may consist of myxoid, chondroid or osseous matrices. These tumour cells 
can form lobules and ducts. Epithelial cells vary from cuboidal to columnar with bland 
cytological nuclear attributes and low mitotic activity, which can be organised as tubular 
structures, islands, cords or sheets and can display apocrine differentiation. The 
surrounding myoepithelial cells are polygonal, plasmacytoid, fusiform or stellate, with 
small nuclei and cytoplasm that varies between clear and eosinophilic. The myoepithelial 
cells are either combined with the epithelial cells or distributed throughout the stroma, 
where the stroma may range from loose to myxoid, to chondroid or osseous (5).  
 
 
 
 
  
Chapter 1 - Introduction  
35 
 
Table 1.3 The reported cases of mammary pleomorphic adenoma in humans (1906-
2016). 
Number 
of 
cases 
Author (reference) 
 
Metaplastic tissue type 
(number of cases) 
Patient 
age 
Sex  
1 Reid-Nicholson et al. (5) Myxoid matrix (1) 59  F 
2 Lecéne (171) Chondroid matrix (2); Osteoid 
matrix (2) 
25 F 
2 Nadal (173) N/A 54 
44 
F 
F 
2 D’ Allianes (177) N/A 19 
NA 
F 
F 
1 Gioia (178) N/A 42 M 
1 Nabert (179) N/A 38 F 
1 Poluektov and Shestakova 
(180) 
N/A 63 F 
9 Smith and Taylor (181) Chondroid matrix (9); Osteoid 
matrix (6) 
23-77 
(Median 
age 55) 
F 
1 Paikova (182) N/A 39 F 
1 Kermarec et al. (183) NA 68 F 
1 William and Leach (184) Chondroid matrix (1); Osteoid 
matrix (1); Myxoid matrix (1) 
72 F 
3 Jakimowicz and  
Gramata (185) 
N/A 57 F 
1 Sheth et al. (186) Chondroid matrix (1); Osteoid 
matrix (1); Myxoid matrix (1) 
78 F 
1 Medina and Uehlinger(187) NA 78 F 
3 Makek and Von 
Hochstetter (188) 
Chondroid matrix (2); Osteoid 
matrix (2); Myxoid matrix (2) 
35 
 60 
78 
2 F 
1 M 
1 McClure et al. (189) Myxoid matrix 46 F 
1 Van der Walt and Rohlova 
(190) 
Chondroid matrix (1); Osteoid 
matrix (1); Myxoid matrix (1) 
67 F 
1 Spagnolo and Shilkin (191) Chondroid matrix (1); Osteoid 
matrix (1); Myxoid matrix (1) 
46 F 
1 Zafrani et al. (192) N/A 66 F 
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1 Cuadros et al. (193) Chondroid matrix (1); Myxoid 
matrix (1) 
65 F 
1 Segen et al. (194) Chondroid matrix (1); Myxoid 
matrix (1) 
75 F 
1 Willen et al. (195) Chondroid matrix (1); Myxoid 
matrix (1) 
76 F 
1 Kjell et al. (196) Chondroid matrix (1); Myxoid 
matrix (1) 
61 F 
1 Balance et al. (197) Chondroid matrix (1); Osteoid 
matrix (1); Myxoid matrix (1) 
77 F 
6 Moran et al. (198) Chondroid matrix (6); Myxoid 
matrix (6) 
37, 58, 
61,76, 81 
and 85 
F 
2 Chen et al. (176) Chondroid matrix (2); Myxoid 
matrix (2) 
58-75 F 
1 Nevado et al. (199) Chondroid matrix (1); Myxoid 
matrix (1) 
84 F 
10 Diaz et al. (200) Chondroid matrix (6); Osteoid 
matrix (4); Myxoid matrix (10) 
50-67 
(median 
age 65) 
F 9 
M 1 
1 Simha et al. (201) Chondroid matrix (1); Myxoid 
matrix (1) 
65 M 
1 Agnantis et al.(202) Chondroid matrix (1); Osteoid 
matrix (1); Myxoid matrix (1) 
62 F 
1 Narita and Matsuda (203) Chondroid matrix (1); Osteoid 
matrix (1); Myxoid matrix (1) 
70 F 
1 Moshinaga et al. (204) Chondroid matrix (1); Myxoid 
matrix (1) 
74 F 
1 Parham and Evans (205) Chondroid matrix (1) NA F 
1 Ficks (206) Chondroid matrix (1); Osteoid 
matrix (1); Myxoid matrix (1) 
43 F 
1 Kumar et al. (207) Myxoid matrix (1) 47 F 
1 Sato et al. (174) Chondroid matrix (1); Myxoid 
matrix (1) 
55 F 
1 Molland et al. (208) Chondroid matrix (1); Myxoid 
matrix (1) 
24 M 
1 Dominicis et al. (209) Chondroid matrix (1); Myxoid 
matrix (1) 
59 F 
1 Iyengar et al. (175) Myxoid matrix (1) 72 F 
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1 Shum et al. (210) Chondroid matrix (1); Myxoid 
matrix (1) 
85 F 
1 Mizukami et al. (211) Chondroid matrix (1); Myxoid 
matrix (1) 
76 F 
1 Djakovic et al. (212) Chondroid matrix (1); Osteoid 
matrix (1); Myxoid matrix (1) 
NA F 
1 Leekha et al. (213) Chondroid matrix (1); Myxoid 
matrix (1) 
60 F 
1 Khamechian et al. (214) Chondroid matrix (1); Myxoid 
matrix (1) 
61 F 
1 Gupta et al. (215) Chondroid matrix (1); Myxoid 
matrix (1) 
NA F 
1 Kelten et al. (216) Chondroid matrix (1); Osteoid 
matrix (1) 
57 
78 
F 
F 
1 Ginter et al. (217) Chondroid matrix (1); Myxoid 
matrix (1) 
42 F 
1 Radu et al. (218) N/A 60 F  
2 Han et al. (219) Chondroid matrix (2); Myxoid 
matrix (2) 
28 
47 
F 
F 
F, female; M, male; N/A, not available. 
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Eighty cases of PAB have been described (see Table 1.2). Table 1.2 lists the 
clinicopathological characteristics of cases reported in the literature. All cases were 
confirmed as PAB. There were 75 (93.75%) women compared to only five men, indicating 
a female: male ratio of 15:1. Patients’ ages ranged from 19 to 85 years. Myxoid matrix 
was present in 46 (57.5%) of cases, chondroid matrix in 51 (63.75%) of cases and osteoid 
stroma in 23 (28.75%) of cases. No histopathological descriptions were available for 14 
(17.5%) of these cases.  
The PAB and pleomorphic adenomas of the salivary gland have similar 
immunohistochemical characteristics. PABs are positive for ER and negative for PR (174, 
200, 206). PAB is also positive for cytokeratin 7 (CK7) in the ductal epithelial cells, positive 
for S100 and smooth muscle actin (SMA) in myoepithelial cells (219). The spindle and 
satellite myoepithelial cells nuclei are positive for high mobility group protein isoform C 
(HMGI-C) and high mobility group protein with two isomers—I and Y (HMGI (Y)) proteins, 
suggesting a histogenesis similar to that of pleomorphic adenoma of  the salivary glands 
(174).  
1.3.1.2 Malignant mixed mammary tumours (human metaplastic 
breast cancers) 
Metaplastic breast cancer (MBC) was identified in 1973 by Huvos and colleagues 
(220). This tumour type is aggressive and often results in metastasis (220). The 
pathogenesis of MBC is not well understood, but it has been suggested that the tumour 
develops from an adenocarcinoma undergoing metaplasia to non-epithelial stromal 
cancer (37). MBCs often overexpress epidermal growth factor receptor (HER1) (37, 221). 
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MBCs are mostly triple negative tumours (lack of ER, PR and HER2 expression). One 
study showed some MBCs are not triple-negative because they express ER and PR and 
others express HER2 (222). Lim et al. (2010) showed that triple-negative features were 
found in 77% of MBCs (222). Patients with metaplastic carcinomas often do not benefit 
from a classical adjuvant chemotherapy regimen (223).  
In 1989 a comprehensive study of MBCs was undertaken by Wargotz and Norris 
(224). They categorised MBCs into five subtypes which include spindle-cell carcinoma, 
squamous cell carcinoma, matrix-producing carcinoma, CS and osteoclastic giant cell 
(224-228) (see Table 1.4). The WHO in 2012 subdivided MBC into two types (229): (1) 
the epithelial sub-group without stromal elements that includes squamous cell carcinoma, 
fibromatosis-like metaplastic carcinoma, low grade adenosquamous and spindle cell 
carcinomas and (2) the mixed sub-group with mesenchymal components, which includes 
carcinoma with chondroid and/or osseous metaplasia and CS (230-233) (see Table 1.4). 
The term “carcinosarcoma” is formally reserved for tumours where the demarcation 
between epithelial and mesenchymal elements is distinct (234). The 5-year survival rate 
of breast CS is 49%, worse than other MBCs (235). The Wartgotz and Norris’s 
classifications of MBCs continue to be used within the WHO classifications (see Table 
1.4).  
As opposed to other breast cancers, most MBCs demonstrated a remarkable similarity 
to a “tumourigenic” signature characterised by using CD44+/CD24- breast tumour–
initiating stem cell–like cells. MBCs are enriched in EMT and stem cell–like attributes, and 
can arise from a preceding, more chemo-resistant mammary epithelial precursor than 
basal-like or luminal cancers (236). 
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MBC represents 0.25–1% of breast cancer cases diagnosed annually (6). CS of 
the breast accounts for 0.08–0.2% of all breast cancers (234). MBC usually affects 
women over 50 years of age (237). Metaplastic squamous cell carcinoma of the breast is 
also an extremely rare breast cancer, comprising less than 0.1% of all breast cancers 
(238). 
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Table 1.4 Wartgotz and Norris classification and the WHO classification of MBCs. 
 Wartgotz and Norris classification 
(1989) 
 WHO classifications (2011) 
 
1 Squamous cell carcinoma 1 Low-grade adenosquamous 
carcinoma 
2 Fibromatosis-like metaplastic 
carcinoma 
2 Spindle cell carcinoma 3 Myoepithelial carcinoma  
4 Squamous cell carcinoma 
5 Spindle cell carcinoma 
3 Matrix producing MBC 6 Carcinoma with mesenchymal 
differentiation (chondroid and 
osteoid)  
4 Carcinosarcoma 7 Carcinosarcoma  
5 Osteoclastic giant cell 
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Clinical imaging features of MBC can resemble IDC NST or non-malignant lesions. 
Imaging can demonstrate an uneven or circumscribed palpable lump with spiculated 
portions on a mammogram and an ultrasound shows a solid asymmetrical mass or 
combined cystic mass. MBCs can resemble benign lumps with regular, round/ ovoid 
masses on a mammogram and circumscribed hypoechoic solid masses on magnetic 
resonance imaging. MBC presents frequently as a rapidly growing mass that is often 
larger (i.e. >2 cm) than the more common types of breast cancer (239, 240). 
Histologically, MBC is a poorly differentiated tumour that contains ductal carcinoma 
cells combined with spindle, squamous, chondroid and/or osseous components. The 
spindle cell subtype is characterised by cohesive sheets of spindle cells. The spindle cell 
element usually resembles a low-grade sarcoma or granulation tissue, which may be 
difficult to distinguish microscopically (241). The squamous cell carcinoma subtype is 
classified by the presence of polygonal cells, eosinophilic cytoplasm and possible ‘keratin 
pearl’ development (241). CS consists of both malignant epithelium and malignant stroma 
(241). The matrix-producing subtype consists of an obvious carcinoma with chondroid 
and/or osseous stromal matrix without  a spindle cell element (242). MBC less commonly 
displays axillary nodal metastases than invasive breast cancer, regardless of the larger 
tumour size. The incidence of axillary lymph node involvement ranges from 6% to 26% 
(243).  
Lien et al. (2007) conducted transcriptional profiling using microarray to clarify the 
genetic expression profiles of MBCs and the differences from breast ductal carcinoma 
using four MBCs and 34 ductal carcinomas (244). This study established that there are 
unique gene expression patterns for metaplastic carcinomas and adenocarcinomas of the 
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breast. In MBCs, eighty-seven genes were overexpressed and 121 genes were 
underexpressed (244). Many of the 87 upregulated genes were associated with the 
production of extracellular matrix (ECM), such as genes associated with ECM synthesis, 
remodelling and adhesion/motility/migration and with skeletal development and/or 
chondro-ossification (244). On the other hand, genes coding for proteins associated with 
maintaining epithelial structures, such as the cytoskeleton, cell–cell adhesion molecules 
and tight junctions, were downregulated (244). In MBCs, the overexpression of ECM-
related genes and the underexpression of epithelial-related genes (particularly in mixed 
mesenchymal and epithelial MBCs) could be the reason for the sarcomatous alteration 
together with ECM development, when compared with adenocarcinomas of breast (244).   
When bony or cartilaginous elements are detected in any tumour, the 
microscopical diagnosis becomes challenging because these ectopic elements could be 
wrongly diagnosed as a breast osteosarcoma (244). Therefore, it is important that breast 
tumours with prominent sarcomatous elements are analysed immunohistochemically 
(245). Marian et al. (2013) examined a case of carcinosarcoma and demonstrated focal 
expression of actin, CD10 and p63 and overexpression of CK5/6, CK17 and 
CK34betaE12 (CK34βE12). The localisation of these proteins verified the myoepithelial 
origin of this tumour (246). Moreover, the expression of these markers suggested that 
MBCs are part of the ‘basal-like subtype’ of breast tumours (246). This research group 
also demonstrated that mesenchymal elements of this tumour type were positive for 
osteopontin (OPN), vimentin, CD56 and HER1, and lacked ER, PR and HER2 
expression. The sarcomatous tumour cells were also negative for synaptophysin, S100 
and CD34. MBCs are strongly positive for vimentin and focally positive for claudins and 
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E-cadherin (247). Cimino-Mathews et al. (2013) demonstrated that MBCs were positive 
for SRY (Sex Determining Region Y)-Box (Sox10), indicating that these subtypes of 
tumours might have a myoepithelial origin (248).  
Treatment of MBC is similar to that of IDC NST. The standard treatment can 
include surgery (lumpectomy or mastectomy), radiation, adjuvant chemotherapy, 
hormone treatment and targeted therapy. In some cases, several types of therapy are 
used together to accomplish the most effective results (7, 239, 249). The 5-year disease-
free rate for MBC is around 40%, with an overall survival rate that varies from 49% to 
68% (7). Comparing patients with MBC and IDC NST, MBC has a worse 5-year disease 
free survival rate of 39–56% versus 60.3–77% (8). 
 
1.3.2 Mixed mammary tumours in non-human mammals 
1.3.2.1 Mixed mammary tumours in dogs 
More mixed tumours have been described in dogs than in any other domestic 
animals (154, 155). The mammary gland of female dogs is the most common site for 
these lesions (154). CMMTs have complicated morphology, developing epithelial, mixed 
and mesenchymal tumours (9, 109, 250) (see Figure 1.2).  
Chapter 1 - Introduction  
45 
 
 
 
Figure 1.2 Canine mixed mammary tumours. (A) Photomicrograph of a benign mixed 
mammary tumour with clusters of cuboidal epithelial cells in tubular formation (thick black 
arrow). (B) Photomicrograph showing the carcinosarcoma with both carcinomatous (thick 
red arrow) and sarcomatous elements (thin black arrow). (C) A mixed mammary tumour 
with chondro/osteosarcomatous components, chondroid areas consist of pale blue matrix 
(thin black arrow) with pinkish bone matrix (asterisk) between the osteoblasts. H&E. Bars, 
100µm. 
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CMMTs appear in female dogs from six to ten years of age (251). Based on the 
literature, mixed tumours constitute 50% to 66% of all canine mammary tumours (154). 
Approximately 40% to 50% of benign canine mammary tumours are mixed tumours (252). 
Malignant mixed mammary tumours represent 20% to 32% of all malignant mammary 
tumours (252). Mulligan (1949) observed the high occurrence of mixed mammary 
tumours in the breeds of Fox Terrier, Cocker Spaniel and Boston Terrier (253). The sizes 
of CMMTs can vary from a few millimetres to 20 cm (254). They have a firm and generally 
cartilaginous or bony consistency (254). Metastases from malignant CMMTs have been 
detected in the lymph nodes, lung, liver, kidney and occasionally in other organs (254).  
There are three types of CMMTs: benign mixed mammary tumours (BMTs), 
carcinoma in benign mixed tumours (CBMTs) and carcinosarcomas (CSs). These are 
characterised by the presence of benign or malignant epithelial and mesenchymal 
components. 
BMTs are usually encapsulated and composed of epithelial elements (i.e. ductal 
and/or acinar epithelial cells and myoepithelial cells) (Figure 1.2A) within an obvious 
mesenchymal element, capable of producing myxoid, cartilaginous or osseous tissue to 
various extents (2). In this neoplasm, the epithelial element can show low cellular atypia 
and a low mitotic index (2). The ductal epithelial element can present with different growth 
patterns and the gland lobules are often poorly preserved (255). This epithelial element 
is usually compressed by the stromal element of the tumour (255). The myoepithelial cells 
display a fusiform morphology and are usually surrounded by abundant fibrillar myxoid 
matrix. The chondroid tissue consists of mature and immature chondrocytes. When 
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osseous material is present, it can consist of osteoid-producing osteoblasts, trabeculae 
and calcified bone (109). 
In the classification suggested by Misdorp et al. (1999) the phrase “malignant  
mixed  tumour”  was  discontinued  and  the carcinomas  associated   with  BMTs  started  
to  be  named carcinomas in benign mixed tumours (CMBTs) or complex carcinomas (2, 
255). Microscopically, CMBTs consist of malignant epithelial and benign mesenchymal 
elements that can be chondroid, osteoid or adipose tissue (255). The epithelial element 
is seen as foci or nodules of cuboidal to columnar epithelial cells with different 
pleomorphisms, cellular atypia and atypical mitoses. Carcinomatous proliferation can 
invade or even entirely alter pre-existing benign tumours (255).  
CSs are rare tumours in canine mammary glands, compared with CBMTs and 
mimic those seen in humans. Presently, the word “carcinosarcoma” is applied to mixed 
tumours with both malignant epithelial and stromal mesenchymal elements (2) (Figure 
1.2B). These neoplasms could be well circumscribed and encapsulated, with a nodular 
shape or infiltrative edges (226). The epithelial element of these tumours can exhibit  
adenomatous, mucinous, squamous or anaplastic growth patterns (255). The 
mesenchymal element can also differ from fibrous tissue to cartilage to bone (Figure 
1.2C) (2). The metastasis in dogs is comparatively common compared to CBMTs.    
Surgical removal is suggested in the treatment of all canine mammary tumours. 
Surgical delay can result in larger tumours and make their elimination more complicated. 
CBMTs have a survival rate that is 2- to 3-times greater than that of other canine 
mammary carcinomas (256).   
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Therefore, animals presenting with CBMTs have a good prognosis in comparison 
to animals with other forms of carcinomas. CSs are aggressive tumours and have a 
poorer prognosis (257). The average time between diagnosis and death for CS is 18 
months (170). 
1.3.2.1.1 Molecular subtyping of CBMTs and CSs 
CMTs can be classified into the same five molecular subtypes as human breast 
cancers. Immunohistochemical biomarkers have been suggested to help establish the 
molecular classification and describe these subtypes. These subtypes are classified into 
two hormone (ER and/or PR-positive subtypes: luminal A-like and luminal B-like) and 
three hormone receptor-negative subtypes (HER2-overexpressing, basal-like and 
normal-like). Sassi at al. (2010) used a panel of antibodies specific for ER, PR, HER2, 
CK5/6 and CK14 on a series of 45 CMTs to characterize the molecular subtypes of human 
breast cancer and identified three tumour subtypes (luminal A-like, luminal B-like and 
basal-like) but there were no HER2-overexpressing or normal-like subtypes were present 
in their study (258). Gama et al. (2008) used an immunohistochemical panel specific for 
ER, HER2, CK5, p63 and P-cadherin with a group of 102 CMTs and identified four tumour 
subtypes (luminal A-like, luminal B-like, basal-like and HER2-overexpressing) (110). 
Saad et al. (2017) used a panel of six antibodies specific for ER, PR, HER2, CK5/6, p63 
and vimentin on a series of 101 CMMTs (including eight CMBTs and five CSs) to identify 
the molecular classification of CBMTs and CSs. They found basal-like (31%), luminal B-
like (38%), HER2-overexpressing (23%) and luminal A-like (8%) subtypes (9). 
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1.3.2.2 Mixed mammary tumours in cats 
Mammary tumours are the third most common type of cancer in cats, following 
cutaneous tumours and lymphoma (161, 259). Benign tumours of the feline mammary 
gland are rare and account for only around 10% of all mammary tumours (260). Although 
the majority of feline mammary tumours are of epithelial origin, malignant changes may 
arise in mesenchymal tissues, causing the formation of mixed mammary tumours and 
sarcomas (261). Feline mixed mammary tumours are less common than carcinomas 
(260).  
CSs are a highly malignant mixed mammary tumour which contains a combined 
cell population with malignant proliferation of both mesenchymal and epithelial elements 
(262). In cats, CSs are rare (263). Only two cases have been reported, so it is impossible 
to know how prevalent CS is in cats. The age of both cats studied was 13 years old (161, 
162). 
1.3.2.3 Spontaneously occurring mixed mammary tumours in rodents 
Mixed mammary tumours do occur spontaneously, or they can be chemically 
induced in rodents. Usually both elements (epithelial and mesenchymal) are malignant 
(167). Naturally-occurring mixed adenocarcinomas of the mouse mammary gland 
generally contain a minimum of two cell types. First, cuboidal or columnar epithelial cells 
form nests and/or glandular or papillary structures (264). These cells may develop from 
either the mammary alveoli or from the ducts (264). Second, the tumour elements that 
present may be of mesenchymal or myoepithelial origin (264). Reham et al. (1989) 
examined three spontaneously arising and eight chemically-induced mixed mammary 
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tumours in mice. The neoplastic glandular structures were surrounded by spindle-shaped 
cells that were markedly eosinophilic. These spindle-shaped cells initially appeared 
almost identical to fibroblasts and were considered to have a myoepithelial origin (264). 
Rare strands of connective tissue were identified with Masson’s trichrome stain (264). 
Metaplastic cells in the spontaneous and chemically induced mixed mammary tumours 
were positive for keratin (264). Myoepithelial cells in these tumours were also positive for 
keratin and actin but negative for vimentin and desmin indicating their epithelial 
differentiation (264).  
1.3.2.4 Mixed mammary tumours in rabbits  
Malignant mixed tumours of the mammary gland are unusual in rabbits and to the 
best of our knowledge only one case of a mixed mammary tumour has been reported. 
The 8-month old animal had a large lobulated mass in the mammary gland region. 
Microscopically, malignant epithelial cells and malignant connective tissue components 
were described (169).  
1.3.2.5 Mixed mammary tumours in other large domestic animals   
One case of a mammary gland CS in one 16-year-old female horse has been 
reported. The mass was discovered by the owner during regular cleaning. 
Histopathological and immunohistochemical examinations reported that the tumour was 
a CS (265). There are no reports of mixed mammary tumours in other large domestic 
animals. 
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1.3.2.6 Mixed mammary tumours in wild eutherian mammals 
Malignant mixed tumours of the mammary gland are unusual in wild eutherian 
mammals. There has been only one case of mixed mammary tumour reported in a female 
gray squirrel (Sciurus carolinensis) (266). The morphology of this tumour was similar to 
the CSs seen in domestic animals (i.e. dogs and cats) (266).  
1.3.2.7 Mixed mammary tumours in non-domestic cats 
Most mammary tumours in zoo cats are malignant, resembling those that occur in 
domestic cats (267). One case of a malignant mixed mammary tumour has been reported 
in a captive lion (Panthera leo) (268). The tumour had tubulopapillary, solid and 
cartilaginous elements and a mitotic index of 50 per 10 consecutive high-power fields. 
One case of a mixed tumour has been also reported in a captive tiger (Panthera tigris) 
and that tumour contained myoepithelial cells and adenocarcinomatous cells with 
squamous metaplasia (269).  
1.3.2.8 Mixed mammary tumours in marsupials and monotremes  
There are no reports of mixed mammary tumours in marsupials or monotremes. 
They do not develop mixed mammary tumours. Although marsupials and monotremes do 
share some features of mammary gland development (mammary hairs, areolar patches) 
with eutherian mammals, in marsupials, the teat usually does not differentiate from  
mammary cells, and each teat commences as an individual analge (270).     
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1.3.3 Histogenesis of mixed mammary tumours in eutherian mammals 
The histogenesis of the different components of mixed mammary tumours is not 
fully understood. In terms of MBC, epithelial mesenchymal transition (EMT) is considered 
to be a key process in tumour progression (271). Gwin et al. (2010) demonstrated that, 
MBCs with chondroid differentiation, showed both epithelial and mesenchymal elements, 
which included a cartilaginous matrix with morphological features analogous to EMT 
(271).  EMT is characterised by loss of epithelial phenotype proteins such as CKs and E-
cadherin and gain of mesenchymal proteins including vimentin (244, 272) .  
Several studies have suggested a monoclonal origin of the epithelial and stromal 
components in human MBCs (273-276) and other studies have proposed that these 
tumours could be derived from myoepithelial cells (277, 278). Whether the cell origin is 
luminal or myoepithelial may not be crucial, as recent data has suggested that the 
mutations in PIK3CA were present in luminal or myoepithelial cells in MBCs. PIK3CA is 
a subunit p110 alpha of phosphatidylinositol 3-kinase and it is one of the most commonly 
mutated genes in breast cancer (279).  
Similar to human MBCs, the source of the various elements of mixed neoplasia in 
dogs is still unknown (109). It has been suggested that the chondroid tissue in canine 
mixed mammary tumours is derived from epithelial cells (280, 281). In addition to the 
epithelial cells, myoepithelial cells are present in MBCs and it has been suggested that 
these cells have a role in the origin of this type of tumour (2, 9, 282-286). Another 
hypothesis is that these elements arise from stem cells that have a high capacity for 
divergence (282, 287, 288). In contrast, other studies have suggested that cartilage 
and/or bone in MBCs are produced from the mesenchymal connective tissue (280, 289). 
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In terms of CSs in cats, the histogenesis of this tumour type has been outlined in 
two hypotheses: (1) the multiclonal theory proposes that both epithelial and  
mesenchymal elements came from two or more stem cells; (2) the monoclonal theory 
proposes that the epithelial and mesenchymal elements came from totipotent stem 
cells that can undertake several routes of terminal differentiation (161).  
1.4 Prospective diagnostic and prognostic markers for CMMT  
An important benefit of using CMMTs as a model for HBCs is an advantage to 
canine patients’ diagnoses and possible therapy. Furthermore, there is a lack of important 
validated of diagnostic and prognostic markers for CMMTs in veterinary pathology. A 
number of biomarkers, particularly those seen as targets for cancer treatments will be 
discussed further here. IHC localisation of ER, PR and Ki-67, which are applied as 
predictive biomarkers will be discussed below in 1.4.1, 1.4.2, and 1.4.3. Other markers 
such as CKAE1/AE3, CK5/6, vimentin, E-cadherin and p63 can help with the identification 
of morphological tumour type will be discussed in 1.4.4, 1.4.5, 1.4.6 and 1.4.7. In addition, 
a group of biomarkers with prognostic potential could involve those are related to cartilage 
and bone formation such as Runt related transcription factor 2 (Runx2), bone 
morphogenetic protein 4 (BMP4), osteopontin (OPN) and SRY-Box 9 (Sox9). These 
proteins have been also proven to play roles in development of the mammary gland (290-
293). The roles of Runx2, BMP4, OPN and Sox9 will be discussed below in 1.4.8, 1.4.9, 
1.4.10 and 1.4.11. Moreover, the role of RANKL and its receptor RANK in the growth and 
development of breast cancer will also be discussed further in 1.4.12.  
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1.4.1 Estrogen receptor 
Estrogen receptors (ERs) are members of the steroid receptor gene superfamily 
(294). They function as ligand-induced transcription factors. Two different isoforms of the 
ER —ERα and ERβ—have been recognised (294). In humans, ERα is encoded by an 
eight exon gene on chromosome 6 (295), however the ERβ gene is located on 
chromosome 14 (296). Although both receptors have high binding affinity for estrogen, 
the variation in their transactivation domains is indicative of their different roles in gene 
activation (296). Estrogen is an essential sex hormone produced predominantly in the 
ovaries in females and testes in males. This hormone controls the growth, and physiology 
of the genital system in humans (294). ERα appears to be a crucial prognostic factor for 
breast cancer (297) and is recognised as one of the most significant classifiers in breast 
tumours (298). 
In CMTs, ER is found in all mammary tissues and is one of the biomarkers for 
breast tumours (299). Estrogen receptors arise from two variant gene products referred 
to as ERα and ERβ. In HBC, it has been established by IHC and reverse transcription-
polymerase chain reaction (RT-PCR) that ERα is the most important isoform in breast 
cancer (300). In CMTs, a reduced amount of ERα antigen was associated with a poor 
prognosis, a larger tumour size and cutaneous ulceration (301). The presence of ERβ in 
HBC is associated with an improved survival rate compared to patients with ERα negative 
cancers (281). ER positive breast tumours can be treated with hormone (or endocrine) 
therapy (302). In CMTs, the presence of ERβ is more commonly associated with benign 
tumours. Even in malignant CMTs, the presence of ER is associated with a better 
prognosis (301). These variations in ERs have a significant impact on treatment of HBC 
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and therefore selective ER modulators could be valuable in the treatment of CMTs, 
particularly as chemo-prevention approaches (297). 
1.4.2 Progesterone receptor 
Progesterone receptor (PR) is a member of a superfamily of ligand-activated 
nuclear transcription factors and is expressed as two isoforms, PRA and PRB proteins 
(303). It is likely that the expression of PRA and PRB can determine the cellular response 
to progesterone (303). Progesterone is also an important regulator of normal female 
genital system function in the uterus, ovaries, breast and brain, and also plays a key role 
in other tissues including the circulatory system, skeleton and the nervous system, 
indicating the role of this sex hormone in normal physiology (304). 
In HBCs, PR has been reported to be a useful marker of recurrence. For example, 
a lack of PR is associated with a poor prognosis (305). In humans, benign tumours are 
characterised by the presence of ER and PR, whilst malignant cancers are positive for 
PR and negative for ER (306). As the tumours become more malignant, they have a 
propensity to eliminate their hormonal reliance and metastatic malignant cancers lack 
both PR and ER (306). Patients with tumours that are negative for ER and PR usually 
have a poor prognosis (306). In dogs, normal tissues and benign CMTs are frequently 
positive for ER and PR (306). 
1.4.3 Proliferation marker Ki-67 
Ki-67 is a nuclear protein and is the most common proliferative marker that has 
been demonstrated in a large number of cancers (307). Ki-67 is expressed in all stages 
of the cell cycle, except G0, which is a period in the cell cycle in which cells exist in a 
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quiescent state (307). Ki-67 expression is low in the G1 and S phases and increases in 
G2 and M phases (307, 308). Therefore, it is the most useful proliferative marker in IHC 
of malignant cancers including breast cancer (307). In addition, immunostaining studies 
with Ki-67 antibody have found this antigen to be a useful prognostic marker in human 
breast cancer (309, 310). In CMTs, increased Ki-67 positivity has been associated with a 
worse prognosis. In addition, the localisation of Ki-67 in CMTs is similar to HBCs. It is 
associated with the presence of distant metastasis (311, 312).  
1.4.4 Cytokeratins  
Cytokeratins (CKs) are the common intermediate filament proteins of epithelial 
cells. These proteins are important for normal tissue morphology and function (313). The 
human keratin family contains 54 different members. CKs are encoded by KRT genes 
that are grouped on paralogous regions of 12q and 17q chromosome arms (314). 
CKAE1/AE3 is a combination of two various clones of the anti-CK monoclonal antibodies. 
CKAE1 recognises the high molecular weight CKs 10, 14, 15 and 16 and also the low 
molecular weight CK19. Clone CKAE3 recognises the high molecular weight CKs 1, 2, 3, 
4, 5 and 6 and the low molecular weight CKs 7 and 8. CKAE1/AE3 antibody has been 
used in human epithelial tissues (315). 
CK5/6 is a marker of basal and squamous differentiation in normal epithelium and 
human cancers and is also proposed to be a marker of stem cells in specific stratified 
epithelia (316, 317). In normal mammary glands, CK5/6 is primarily present in the 
basal/myoepithelial cell layer (316). CK5/6 is also present in benign and malignant 
cancers of myoepithelial origins (316). The expression of basal-type CKs such as CK5/6 
has been related to a poor prognosis (317). In dogs, normal mammary gland cells have 
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a specific immunoprofile: luminal epithelial cells are indicated by the expression of 
keratins CK18 and CK19 and CK7 and CK8 (318). Myoepithelial cells express CK14, 
CK17, CK5 and CK6 (318). In dogs, depending on IHC—the normal mammary gland 
three layers express several markers: the luminal epithelium is labelled by CK19 and the 
basal cells and myoepithelial cells are labelled by CK5/6 and CK14 (318). 
1.4.5 Vimentin  
Vimentin is an intermediate filament protein that in humans is encoded by 
the VIM gene (319). Vimentin is the main cytoskeletal element of mesenchymal cells 
(319). EMT is a mechanism where the epithelial cells lose their epithelial features and 
gain mesenchymal ones. Vimentin has been identified as a marker for EMT (320, 321). 
Because of its overexpression in tumours and its correlation with cancer development 
and metastasis, vimentin can act as an important potential target for tumour treatment 
(319). 
1.4.6 Epithelial cadherin 
Epithelial (E-) cadherin is a calcium-regulated adhesion protein expressed in the 
majority of normal epithelial tissues (322). The E-cadherin gene is located on 
chromosome 16q22.1 and the protein encoded involved in gland development and 
epithelial polarisation (322-324). A reduced amount of E-cadherin has been associated 
with increased invasiveness in human cancers (325). The loss of E-cadherin has been 
found in a number of human breast cancers, such as lobular breast cancer (326). Restucci 
et al. (1997) reported a reduced membranous expression of E-cadhein in malignant 
tumours, particularly in poorly undifferentiated tumours (327-329). Reis et al. (2003) also 
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observed that a decrease of E-cadherin expression was associated with malignancy, 
whereas all benign cancers had stronger intercellular staining of E-cadherin (327). Loss 
of E-cadherin can indicate invasiveness in human cancers and this has been seen in 
aggressive cancers of the oesophagus, stomach, mammary gland and ovaries (330, 331). 
The localisation of E-cadherin has been assessed in CMTs (332). Previous studies have 
found an association between E-cadherin expression and the histological grade (328, 
332).  
E-cadherin also has an important function in normal physiologic processes 
including development, cell polarity, and tissue morphology (333). One of the 
characteristic features of epithelial cell layers is the expression of E-cadherin on either 
side of the basement membrane at the adherent junctions linking adjacent epithelial cells 
by calcium-dependent interactions, while in the intracytoplasmic area it cooperates with 
other elements primarily β-catenin. The changes in adhesion junctions—primarily its 
interactions with E-cadherin and β-catenin—have been demonstrated to play a key role 
in the initiation of the EMT process (334, 335). One feature of aggressive cancers, is that 
the EMT loses E-cadherin expression with an increase of N-cadherin expression. This 
provides a stroma-oriented cellular adhesion profile with increased cancer cell motility 
and invasive features, and this molecular profile has  been demonstrated in many tumours 
(336). 
1.4.7 Tumour protein p63 
Tumour protein p63 is a recently recognised member of the p53 gene family (337). 
Overexpression of p63 has been detected in normal basal mammary epithelial tissues 
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(338). P63 controls growth in human epithelial cells (98). In HBCs, it also appears to be 
a specific protein for myoepithelial elements and an increased amount of this marker 
signifies myoepithelial differentiation (339). In HBCs, Ribeiro-Silva et al. (2003) found a 
relationship between p63 expression, higher grade, larger neoplasms, lymph node 
metastasis and lack of ER expression (340). In CMTs, p63 has been identified as a useful 
myoepithelium marker and it can differentiate epithelial or myoepithelial elements from 
mesenchymal elements (286). 
1.4.8 Runt-related transcription factor 2 
The Runt family transcription factors are composed of Runx1, Runx2 and Runx3. 
Runx1 plays a crucial role in neuronal development. Runx1 is also involved in 
haematopoiesis and immune functions (341). It is also a key factor in the maturation of 
chondrocytes during the early stages (284). Runx2 is a main transcription factor for 
chondrocyte maturation. Ferrari et al. (2013) reported that Runx2 is a crucial factor in 
osteoblast differentiation and bone formation (342). Runx3 has important roles 
in immunity and inflammation and could thereby have secondary effects on epithelial 
tumour development (see Figure 1.3) (341).  
Runx2 has been shown to be involved in human mammary tumour development, 
especially in ER and PR negative tumours (342) and it is considered to be an independent 
predictive factor (342). Therefore, the presence of Runx2 in CMMTs may be significant 
and might be a potential prognostic marker. In humans, Runx2 has been shown to have 
functions within a broad range of tissues (290). One of these tissues is breast tissue 
where Runx2 is known to be expressed and controls a number of mammary specific 
genes (290). No previous study has looked for the presence of Runx2 in CMMTs. 
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Figure 1.3 Fundamental roles of RUNX family transcription factors. Runx1 is involved 
in haematopoiesis and immune functions. Runx2 regulates a number of target genes, and 
is an important regulator for processes required for chondrogenesis and osteogenesis. 
Runx3 is involved in immunity, inflammation and gastric mucosa endothelium 
development, adapted from Wysokinski et al. (2015) (341). 
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1.4.9 Bone morphogenetic proteins  
Bone morphogenetic proteins (BMPs) are a set of growth factors with more than 
20 members that have been determined in humans (343, 344). They were initially 
identified by their ability to stimulate bone and cartilage development (345). The distinct 
BMPs have different roles during growth (345). Even though some BMPs have significant 
roles in secondary tumours in bone (346), they have been suggested to be a factor in the 
development of primary bone cancers (347).  
Additionally, it has been suggested that BMPs have a role in human breast cancer 
metastasis (348), but metastases are rare in dogs (2). Klopfleisch et al. (2010) (349) 
reported that BMP2 has an essential role in angiogenesis in HBCs, the control of cancer 
cell migration and prevention of cell death (349-353). Another study showed that the role 
of BMP2 in canine cancer development is unclear, but the gene is overexpressed in 
malignant CMTs (354). It has also been reported that BMP4 is weakly positive in normal 
breast tissue but strongly positive in breast tumours. Tumours that have high BMP4 levels 
have lower growth rates with higher recurrence (355). No previous study has looked for 
the presence of BMP4 in CMMTs. 
1.4.10 Osteopontin  
Osteopontin (OPN) is an important protein in the fibrous portion of the mammary 
gland; it is also expressed in osteoblasts (356). OPN is a secreted phosphorylated 
glycoprotein that induces various biological functions. It is initially found in bone, and has 
been subsequently demonstrated to have a wider distribution. In humans, OPN 
expression is normally restricted to the skeleton, epithelial linings, kidney, and is secreted 
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in milk, blood and urine. OPN is both an element of the extracellular matrix and a soluble 
cytokine (357). In addition, OPN has a role in chronic inflammatory and autoimmune 
diseases (357). OPN regulates vascular endothelial growth factor (VEGF) expression via 
the activation of different signalling pathways (358), and cooperates with members of the 
integrin family, to stimulate downstream processes associated with tumour development 
and cellular transformation (359). Moreover, OPN activates the expression of the 
urokinase-type plasminogen activator and increases the migration of tumour cells, which 
may cause more cellular transformation and metastasis (360). 
OPN is an indicator of prognosis, with increased levels seen in the tumours and 
plasma of patients with metastatic breast cancers (356). OPN is associated with an 
increase of the aggressiveness of the cancer and a lower survival time (356). Mazzali et 
al. (2002) reported that OPN could have a role in the growth of fibrous connective tissue 
as it plays an important role in the development of fibrosis and tissue scarring, especially 
in renal disease (361). Moreover, Das (2005) reported that OPN plays an important role 
in the regulation of cell motility, the prevention of calcification and control of the cancer 
cell phenotype in humans (362). Ozmen et al. (2015) reported that OPN expression was 
associated with malignancy of feline and canine tumours including hematopoietic tissue 
malignancies, soft tissue tumours, mammary tumours, skin tumours and primary bone 
tumours (osteosarcomas) (363). 
1.4.11 SRY (sex determining region Y)-box 9 
SRY (sex determining region Y)-box 9 (Sox9) is one of the 20 various Sox genes 
in humans (364-367). Overexpression of the Sox9 gene is linked with testis development 
and chondrogenesis (368). Sox9 gene is also associated with poor survival in patients 
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with mammary tumours (248, 369). It has been also reported that the Sox9 stimulates the 
epithelial mesenchymal transition (369). Sox9 protein is a nuclear transcription factor and 
is expressed in invasive and metastatic mammary tumours (364). MBCs are uncommon 
tumours with a poorer prognosis unlike other types of breast cancers. Some metaplastic 
breast cancers show chondroid metaplasia, which suggests that Sox9 could be present 
in these tumours. The nuclei of mesenchymal cells have increased levels of Sox9 when 
compared to carcinomatous epithelial cells (370). As a result of the presence of Sox9 
protein in the nucleus and/or the cytoplasm of some ovarian tumours, mammary tumours 
were examined (370). No previous study has looked for the presence of Sox9 in CMMTs. 
1.4.12 Receptor activator of nuclear factor kappa-B ligand and its 
receptor (receptor activator of nuclear factor kappa-B)  
Receptor activator of nuclear factor kappa-B ligand (RANKL) is a tumour necrosis 
factor-related molecule (371). It is important in the development and function of 
osteoclasts and their survival through its binding with its receptor (receptor activator of 
nuclear factor kappa-B) abbreviated to RANK (371). The RANK/RANKL/osteoprotegerin 
(OPG) system has been implicated in several physiological and pathological processes 
including bone metabolism, mammary gland development and the regulation of the 
immune system function (see Figure 1.4) (372, 373). 
RANK/RANKL has recently been identified as a target of BRCA1-mutation carriers 
(374); Denosumab, a monoclonal antibody to the RANKL, might be a treatment choice 
for these sufferers (374). Denosumab is currently used for the treatment of 
postmenopausal osteoporosis (375). RANKL binds to RANK producing 
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osteoclastogenesis signals (374, 376). RANKL and RANK have been identified as a 
treatment target for bone diseases including osteoporosis (377). However, it has been 
confirmed that the OPG is a decoy receptor for RANKL and is also essential for the growth 
and activation of the osteoclasts (378). Progesterone is important in the mammary 
tumourigenesis of BRCA1/p53 mutant mice, therefore, RANKL may be controlled by this 
female sex steroid (379). Breast tumourigenesis driven by BRCA1 mutations depends on 
autocrine or paracrine RANKL/RANK signaling in mammary stem cells (380). Breast 
cancers developing as a result of BRCA1 mutations also rely on progesterone signalling, 
most likely as a consequence of PR-driven RANKL expression and resulting proliferation 
of mammary progenitor cells (380). The process linking the accumulation of genetic 
abnormalities to tumourigenesis via the RANKL/RANK system, in addition to the possible 
effect of RANKL/RANK signaling in the breast epithelium on anticancer 
immunosurveillance remain to be resolved (380). Gonzalez-Suarez et al. (2010) also 
showed that RANKL and RANK are not merely present in pre-neoplastic and neoplastic 
lesions but are also in normal mammary epithelia (381). They indicated that in the earlier 
stages of tumourigenesis, the inhibition of RANKL is acting directly on hormone-induced 
mammary epithelium. Their study highlights a possible role for RANKL inhibition in the 
management of proliferative breast lesions (381). No previous study has looked for the 
presence of RANKL and RANK in CMMTs. 
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Figure 1.4 RANKL and RANK are expressed in a range of cell types. RANK and 
RANKL are localised in cells from healthy tissues, cancerous cells and immune cells, 
adapted from Sisay et al. (2017) (372). 
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1.5 Argyrophilic nucleolar organizer regions  
The Argyrophilic nucleolar organiser region (AgNOR) is a biomarker used to 
examine the cell proliferation in different types of cancers (382). The role of AgNORs has 
been utilised in the diagnosis of breast, oral, lymphoma and prostatic tumours. Nucleolar 
organiser regions (NORs) are loops of DNA in the nucleoli. These carry genes that code 
for ribosomal RNA, which are then transcribed by RNA polymerase I (382). NORs appear 
to be aggregated in proliferating cells of cancers into nucleolar structures. These are 
visible as brown to black dots after silver staining in tissue sections (383).  
Abnormalities of the nucleolus have been long considered as being a feature of 
cancerous cells. Subsequently, the nucleolus has been shown to consist of relative 
electron dense and filamentous nucleolonema, and rounded zones of light density that 
are identified by different names (pars amorpha, pars fibrosa and fibrillar centre) (384). In 
interphase these components are similar to nucleolar organiser regions and are 
visualised at the ultrastructural and light microscopy levels by selective staining by using 
a silver technique (384). Using a light microscope, NORs are small black dots when 
stained with this stain (384). The AgNOR silver staining method demonstrates the 
presence of nuclear proteins including phosphoprotein C3 (nucleolin), B23 (numatrin) and 
the elements required for ribosomal DNA transcription and early rRNA processing (385, 
386). 
The most appropriate, economical and simplest way to determine the cell 
proliferation rate is by examining the mitotic figures in H&E stained sections and AgNOR 
counting. AgNORs can be detected on FFPE tissues (387). The AgNOR staining method 
allows for the study of the number, area and shape of NORs. The quantity of silver 
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deposits in the nucleus reflects the amount of NORs that are involved in protein synthesis 
and is associated with the proliferative activity of that cell (388). Thus, the study of 
AgNORs could be a useful tool to examine the aggressiveness of the tumours when more 
expensive methods [IHC and in situ hybridization (ISH)] are not available (388). 
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1.6 Aims and hypotheses of this study 
In this project we proposed to use CMMTs to expand sample cohorts to 
validate biomarkers. The project will determine if canine mixed tumours exhibit 
a similar localisation of molecular markers equivalent to breast cancers with 
cartilaginous/osseous metaplasia using IHC so CMMT can be used as a model 
to improve outcomes of patients and tounderstand the process about the 
clinical habits of this tumour subtype. 
This project aims to: 
1. Characterise the CMMTs immunohistochemically. It was necessary to establish 
the expression of markers known to be important in human breast cancers (HBCs) 
in CMMTs. These include the ER, PR, HER2, Ki-67, CK5/6, p63, E-cadherin, 
CKAE1/AE3 and vimentin. 
2. Examine the presence of OPN, Sox9, BMP4 and Runx2 in CMMT tissues. 
3. Examine the immunohistochemical localisation of OPN in CMMTs. 
4. Determine whether AgNOR expression can differentiate between normal 
mammary, benign and malignant CMMTs. Also, to investigate if there is any 
relationship between the following measure of tumour growth: mean AgNOR 
count/nucleus, mean AgNOR area (pixels2)/nucleus, the mitotic index and the Ki-
67 labelling index. 
5. Investigate the localisation of RANKL and RANK in CMMT tissues. 
The hypotheses of this research are: 
1. CMMT is a good model for human mixed mammary tumours. 
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2. BMP4, Sox9 and Runx2 are present in CMMTs. 
3. Strong expression of OPN in CMMTs is associated with malignancy. 
4. AgNOR staining is a useful tool for distinguishing benign from malignant mixed 
mammary tumours.  
5. Increased RANKL and RANK localisation is associated with increased malignancy. 
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1.7 Significance of research 
          This research concentrates on a particular breast cancer type that is difficult to treat 
effectively. Metaplastic carcinoma is rare in humans (less than 1%) but as a consequence 
there is no standard treatment and patients have extremely poor survival (243). The 
research has provided clear insights into the utility of CMMTs as a model for human 
metaplastic breast cancers. Unlike humans, these tumours are often larger and more 
advanced by the time of diagnosis (105). This is understandable as regular breast exams 
of pet dogs are not common practice. This not only provides researchers with a greater 
opportunity to research advanced breast cancers; both primary tumours and distant 
metastases, but also to generate a more widely researched sample cohort as tumours 
are much larger than those seen in humans. Another distinct advantage of this cancer 
model is that dogs currently only have surgical treatment so the tumours have not been 
exposed to chemotherapy or radiotherapy (389). Given the shorter lifespan of dogs, 
breast cancer studies have a much shorter timeframe. Despite the suitability of canine 
breast cancer as a model for human breast cancer, it has been significantly underutilized 
in medical research. Metaplastic breast cancers develop ectopic elements such as 
cartilage and bone, and are rare in women representing less than 1% of cases (243). 
These tumours have been shown to be aggressive in their characteristics (390). Given 
their rarity, large cohort studies are difficult. Interestingly, in dogs metaplastic tumours, 
known as mixed/complex tumours in the veterinary community, occur at a higher 
frequency. Unlike humans metaplastic mammary tumours are one of the most common 
types in dogs. In addition, these canine tumours tend to be benign rather than malignant. 
Consequently, determining both the presence and the role of genes in both bone and 
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cartilage formation and cancer could help shed light on the development of osseous 
metaplasia in breast cancers. This data will act as a resource for future studies. 
    73 
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2.0 Materials and Methods 
2.1 Materials 
2.1.1 Ethics  
An Animal Ethics application was submitted to the Animal Ethics Committee (AEC) 
at RMIT University. The committee decided that, because the tissues were removed from 
the animals as part of their normal treatment and not for the purpose of research, an AEC 
approval for this project was not required (AEC-letter). 
2.1.2 Tissue samples 
2.1.2.1 Canine mixed mammary tumour samples 
In this research, a total of 101 (88 benign and 13 malignant) CMMTs were used (see 
Appendix 1). Formalin-fixed tissue samples were collected from the Australian 
Specialised Animal Pathology Laboratory (ASAP), Mulgrave, VIC, Australia. In addition, 
FFPE blocks of CMMTs were either collected from the Australian Veterinary Cancer 
Biobank (AVCBB) at RMIT University, Bundoora, VIC, Australia or received from the 
Pathology Unit of the School of Veterinary Sciences, University of Bristol, Bristol, UK. All 
samples were properly fixed prior to macroscopic dissection. Tumours were reviewed 
with boarded veterinary pathologists to ensure all tumour samples were classified 
according to standard schemes (Dr. Judith Nimmo and Emeritus Professor Michael Day). 
2.1.2.2 Normal canine control tissues  
Normal canine control tissues (ovary, uterus, skin, mammary tissue, tonsil, spleen 
and cartilage) and blocks of a canine HER2-positive carcinoma were collected from the 
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ASAP Laboratory and from The University of Melbourne Veterinary Hospital, Werribee, 
VIC, Australia. 
2.1.3 Reagents and solutions 
The following reagents and solutions that were used in the present study were 
purchased from various companies. All materials used in this research are mentioned in 
Table 2.1. 
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Table 2.1 Details of reagents and solusions used for different tehniques. 
Reagent Manufacturer City, State, 
Counntry 
Catalogue number  
 
Eosin solution and 
Mayer’s 
haematoxylin 
Amber Scientific Midvale, WA, 
Australia  
MH-5L  
 
Toluidine blue O BDH Laboratory 
Chemicals 
Palmerstone North, 
New Zealand  
34077 
Sodium chloride AR Chem-supply Gillman, SA, 
Australia 
SA046 -5KG 
Epitope retrieval 
solution with high 
pH (pH 9.0)  
CINtec® Sydney, NSW, 
Australia 
9511  
 
Peroxidase blocking 
reagent 
CINtec® Sydney, NSW, 
Australia 
9511  
 
Negative reagent 
control 
CINtec® Sydney, NSW, 
Australia 
9511  
3,3’-
diaminobenzidine 
tetrahydrochloride 
(DAB) buffered 
substrate and DAB 
chromogen 
CINtec® Sydney, NSW, 
Australia 
9511  
 
Visualisation 
reagent 
CINtec® Sydney, NSW, 
Australia 
9511  
 
Epitope retrieval 
solution (pH 6.0) 
Agilent 
Technologies 
Sydney, NSW, 
Australia 
K8005 
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Epitope retrieval 
solution with high 
pH (pH 9.0)  
Agilent 
Technologies 
Sydney, NSW, 
Australia 
K8000/K8010 
Mouse anti-rabbit 
immunoglobulins 
IgG (MR12/53) 
Agilent 
Technologies 
Sydney, NSW, 
Australia 
M 0737 
Rabbit linker  Agilent 
Technologies 
Sydney, NSW, 
Australia 
k8009 
Rabbit anti-goat 
immunoglobulins/ 
HRP  
Agilent 
Technologies 
Sydney, NSW, 
Australia 
P0160 
EnVision™+ Dual 
link system-HRP  
Agilent 
Technologies 
Sydney, NSW, 
Australia 
K4063 
EnVision FLEX 
antibody diluent  
Agilent 
Technologies 
Sydney, NSW, 
Australia 
K8006 
EnVision FLEX+ 
Rabbit (linker) 
Agilent 
Technologies 
Sydney, NSW, 
Australia 
K8009 
Instant skim long 
life milk powder 
Woolworths  Melbourne, VIC, 
Australia 
- 
Triton X-100 Sigma-Aldrich Castle Hill, NSW, 
Australia 
9002-93-1 
Gelatine powder Ajax Finechem 
Chemicals 
Wollongong, NSW, 
Australia 
AJAX-1080-500G 
Formic acid  Ajax Finechem 
Chemicals 
Wollongong, NSW, 
Australia 
AJA233-500ML 
Silver nitrate, AR Ajax Finechem 
Chemicals 
Wollongong, NSW, 
Australia 
AJA449-25G 
Brilliant crocein Ajax Finechem 
Chemicals 
Wollongong, NSW, 
Australia 
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Acetic acid Ajax Finechem 
Chemicals 
Wollongong, NSW, 
Australia 
64-19-7 
Aniline blue Fronine PTY Ltd Riverstone, NSW, 
Australia 
- 
Ethanol absolute Grale Scientific Ringwood VIC, 
Australia 
AL048/20P  
 
Xylene  Grale Scientific Ringwood, VIC, 
Australia 
XL005/20  
 
Tissue embedding 
medium (Paraplast)  
Leica  Mount Waverley, 
VIC, Australia  
39601006  
Neutral buffered 
formalin (10%)  
Grale Scientific  
 
Ringwood, VIC, 
Australia  
XL005/20  
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2.1.4 Antibodies 
IHC was performed using a panel of antibodies specific for ERα, PR, HER2, Ki-67, 
vimentin, CK5/6, CKAE1/AE3, E-cadherin, p63, BMP4, Runx2, Sox9, OPN, RANKL and 
RANK. The details for each antibody are shown in Table 2.2. Positive and negative 
controls were used in each assay. 
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Table 2.2 Primary antibodies used in IHC. 
Antibody 
specificity  
Type Manufacturer Clone Code No.  Positive 
control tissue 
Biomarker function  
CK5/6 Mouse 
monoclonal 
Agilent, Sydney, 
NSW, Australia 
D5/16 B IR780 Tonsil Basal and squamous differentiation 
in many normal epithelia and human 
tumours (316, 317).  
CKAE1/AE3 Mouse 
monoclonal 
Agilent AE1/AE3 M3515 Mammary 
tissue 
Epithelial differentiation (315). 
Vimentin Mouse 
monoclonal 
Agilent V9 IR630 Skin 
 
Distinguishing epithelial and 
mesenchymal tumours (319). 
Ki-67 Mouse 
monoclonal 
Agilent MIB-1 IR626 Tonsil Ki-67 is a proliferation marker (307). 
p63 Mouse 
monoclonal 
Leica,  
Mount 
Waverley, VIC, 
Australia 
7JUL NCL-L-
p63 
Tonsil and  
mammary 
tissue 
Tumourigenesis and epidermal 
differentiation (98, 339). 
 Sox9 Mouse 
monoclonal 
Abcam, 
Melbourne, VIC, 
Australia 
3C10 ab76997 Spleen Development of cartilage and bone 
(368).  
E-cadherin Mouse 
monoclonal 
Agilent NCH-38  IR059 Skin Cell adhesion molecule in the 
epithelial tissues (322) 
Estrogen 
receptor  
Rabbit 
monoclonal 
Agilent EP1 IR084 Ovary, uterus 
and 
mammary 
tissue 
Proliferation of mammary gland (294). 
ERα appears to be a 
crucial prognostic factor (297). 
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Progesterone 
receptor 
Rabbit 
polyclonal 
Santa Cruz, 
Scoresby, VIC, 
Australia 
C-19 sc-538 Uterus Proliferation of mammary gland (303). 
PR appears to be a 
crucial prognostic factor (305). 
c-erbB-2 
Oncoprotein 
Rabbit 
polyclonal 
Agilent - A0485 HER2-
positive 
carcinoma 
HER2 over-expression has been 
displayed to play a role in the 
development of aggressive types of 
breast cancer (391). 
 BMP4  Rabbit 
polyclonal 
Abcam - ab39973 Mammary 
tissue 
Bone and cartilage formation (345). 
 Runx2 Rabbit 
polyclonal 
Abcam - ab23981 Mammary 
tissue 
Osteoblast differentiation (342). 
OPN Rabbit 
polyclonal 
Abcam - ab8448 Mammary 
tissue 
Bone formation (356). 
RANKL Goat 
polyclonal  
R&D Systems, 
Noble Park, 
VIC, Australia 
- AF462 Mammary 
tissue and 
skin 
RANKL Regulates osteoclast 
differentiation. Associated with 
mammary gland development (371). 
RANK Mouse 
monoclonal 
Abcam - ab13918 Mammary 
tissue and 
skin 
RANK Regulates osteoclast 
differentiation. Associated with 
mammary gland development (371). 
BMP4, bone morphogenetic protein; CK, cytokeratin; HER2, human epidermal growth factor receptor 2; OPN, osteopontin; RANKL, 
receptor activator of nuclear factor kappa-B ligand; RANK, receptor activator for nuclear factor Kappa-B; RTU, ready to use; Runx2, 
Runt-related transcription factor 2;  Sox9, SRY-Box9.  
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2.2  Methods  
2.2.1 Macroscopic description and dissection 
The formalin-fixed samples were received from ASAP and from the University of 
Melbourne Veterinary Hospital where they were previously dissected. For each case, a 
total sample size and description were registered with representative specimens being 
positioned into cassettes for processing. The gross description and dissection of 
specimens followed the recommendations made by Lester’s Manual of Surgical 
Pathology (392). The gross description of each fixed-tissue sample included: the number 
of sample jars submitted with the labels on the sample jar, which included: the date, age, 
breed of dog, the tissue dimensions, consistency of the tissue, the number of pieces 
sampled and whether or not the fixed-tissue sample was processed. 
2.2.2 Preparing tissues for staining  
CMMT samples were cut-up, put in tissue cassettes and processed in an enclosed 
tissue processor (Leica PSA200S, Sydney, NSW, Australia) according to the following 
processing protocol (see Table 2.3). The processed tissues were embedded in a paraffin 
block using the Shandon Histocentre 3 (Thermo Fisher Scientific™, Scoresby, VIC, 
Australia). The embedded blocks were cut using a rotary microtome (RM2235) (Leica, 
Mount Waverley, VIC, Australia) with a Feather disposable microtome blade (S35 Fine). 
Serial sections of 4 μm were cut and each section was placed in a warm water bath at 
46-49 °C. The sections were then mounted onto positively charged glass slides 
(Superfrost Plus, Thermo Scientific™, Australia) and incubated for at least 30 min at 60 
°C. The slides were then moved to plastic boxes and stored in the dark in preparation for 
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the next steps. Serial sections were put onto microscope slides (Shandon™ 
Colormark™ Slides, Thermo Fisher Scientific™, Scoresby, VIC, Australia) and stained 
with H&E and other special stains. 
 
 
 
 
  
Chapter 2 – Materials and Methods 
84 
 
Table 2.3 Canine tissue processing protocol for the Leica PSA200S processor. 
Station  Reagent solution Duration 
(Hour) 
Temp (ᵒC) P/V Drain duration 
(Sec) 
1 Neutral buffer formalin  00:20 37 V 140 
2 70 % ethanol  00:45 37 V 80 
3 90 % ethanol  00:45 37 V 80 
4 100% ethanol  01:00 37 V 80 
5 100% ethanol  01:00 37 V 80 
6 100% ethanol  01:00 37 V 140 
7 Ethanol/xylene (50/50) 01:00 37 V 80 
8 Xylene  01:00 37 V 80 
9 Xylene  01:00 37 V 80 
10 Xylene  01:20 37 V 140 
11 Paraffin wax 01:30 62 P/V 140 
12 Paraffin wax 01:30 62 P/V 140 
13 Paraffin wax 02:20 62 P/V 140 
P, pressure; Sec, second; Temp, temperature; V, vacuum. 
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2.2.3 Histochemistry 
2.2.3.1 Haematoxylin and eosin (H&E) staining  
Serial sections from each block were stained with progressive H&E staining (393) 
and were used as a reference and to ensure the presence of epithelial and mesenchymal 
elements in the section of each tumour. The progressive H&E stain protocol was modified 
from Bancroft et al. (2008) (393) (see Appendix 2).  
2.2.3.2 Toluidine blue staining  
Toluidine blue stain was used to identify any chondroid components within the 
tumour region. The toluidine blue staining protocol was modified from Schmitz et al. 
(2010) (394) (see Appendix 3). 
2.2.3.3 Masson’s trichrome staining 
Masson’s trichrome stain was used to identify any potential fibrosis within the 
tumour region. The Masson’s trichrome staining protocol was modified from Schmitz et 
al. (2010) (394) (see Appendix 4). 
2.2.3.4 Von Kossa staining 
The von Kossa stain was used to visualise any calcium deposits in CMMT paraffin 
sections. The von Kossa saining protocol for calcium was modified from Clark (1981) 
(395) (see Appendix 5). 
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2.2.3.5 The silver-staining technique for nucleolar organizer 
regions (AgNORs) 
Silver staining was used for the evaluation of nucleolar proteins. The 'agryrophil 
method' was performed as described by Ploton et al. (1986) (396) (see Appendix 6). By 
light microscopy, the NORs were viewed as small brown to black dots of various sizes.  
 
2.2.4 Immunohistochemistry 
2.2.4.1 Immunohistochemical characterisation of CMMTs using a 
panel of antibodies 
Prior to sectioning, the CMMT blocks were cooled on an ice block for a minimum 
of 1 hour. Serial sections were sectioned at 4 μm and put on positively charged glass 
slides. Sections were then dried in an oven at 60 oC for 30-45 minutes. The sections were 
then deparaffinised and rehydrated followed by epitope retrieval (Agilent PT Link 
machine, Agilent Technologies, Sydney, NSW, Australia). The antigen retrieval conditions 
for each antibody are summarised in Table 2.4. Following antigen retrieval, the sections 
were manually stained (see Table 2.5). Sections were washed twice in Tris-buffered 
saline (TBS). Sections were then rinsed with 1% Triton X-100 for 30 minutes. 
Endogenous peroxidase was blocked using 3% H2O2 for 10 minutes. Nonspecific 
antibody binding was reduced by using 0.4% casein protein block for 30 minutes before 
using the primary antibody. The secondary antibody was used for 30 minutes. Next, the 
reaction was viewed by applying DAB for 3-8 minutes. Sections were washed twice in 
TBS between each treatment step. 
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Tumour tissue sections were incubated with primary monoclonal antibodies 
against ERα, Ki-67, p63, CK5/6, CKAE1/AE3, E-cadherin and vimentin (see Table 2.4). 
The tumour tissue sections were also incubated with primary polyclonal antibodies 
against PR (PR-A and PR-B) and c-erbB 2 (see Table 2.4). EnVision FLEX+ Rabbit linker 
(Agilent Technologies, Sydney, NSW, Australia) was utilised to amplify the signal of ERα 
antibody. In addition, positive and negative control tissue sections (see Table 2.2) were 
stained applying the same manual protocol as the test tissue sections. 
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Table 2.4 Optimisation of conditions for the panel of antibodies used in 
characterisation of CMMTs. 
Antibody Antigen 
retrieval 
Primary 
antibody 
dilution 
Primary 
antibody 
incubation 
time  
(min) 
Secondary antibody 
dilution and 
incubation 
Anti- CK5/6 pH 9, 20 min at 
97 °C   
 RTU 30  
 
CINtec® 
visualisation 
reagent, RTU for 30 
min  
Anti-
CKAE1/AE3 
pH 9, 20 min at 
97 °C 
 
RTU 30  CINtec® 
visualisation 
reagent, RTU for 30 
min  
Anti-vimentin pH 9, 20 min at 
97 °C   
RTU 30 CINtec® 
visualisation 
reagent, RTU for 30 
min  
Anti- Ki-67 pH 9, 20 min at 
97 °C   
RTU 30  CINtec® 
visualisation 
reagent, RTU for 30 
min  
Anti- p63 
 
pH 6, 20 min at 
97 °C   
1:25 30  CINtec® 
visualisation 
reagent, RTU for 30 
min  
Anti- ERα pH 9, 20 min at 
97 °C   
RTU 30  Agilent EnVision™+ 
Dual Link System-
HRP for 30 min  
Anti-PR pH 6, 20 min at 
97 °C   
1:40 60  Agilent EnVision™+ 
Dual Link System-
HRP for 30 min  
Anti- c-erbB-2 
Oncoprotein 
pH 6, 20 min at 
97 °C   
1:50 60  Agilent EnVision™+ 
Dual Link System-
HRP for 30 min  
Anti-E-
cadherin 
pH 9, 20 min at 
97 °C   
RTU 30  
 
CINtec® 
visualisation 
reagent, RTU for 30 
min  
RTU, Ready to use 
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Table 2.5 Manual protocol of IHC for localisation of targeted antigens, modified 
from, Taylor and Shi (2013) (397). 
Step Reagent  Time  (min) 
1 Xylene 3 
2 Xylene 2 
3 100% alcohol 1 
4 100% alcohol 1 
5 70% alcohol 1 
6 Wash, tap water 1 
7 Wash buffer 5 
8 1% Triton X-100 30 
9 Wash buffer   5 
10 3%  H2O2 10 
11 Wash buffer 5 
12 0.4% Casein  30 
13 Wash buffer 5 
14 Primary antibody at RT  30 
15 Wash buffer 5 
16 Secondary antibody  30 
17 Wash buffer 5 
18 DAB 3-8 
19 Wash buffer 5 
20 Distilled water 1 
21 Mayer’s haematoxylin 3 
22 Wash, tap water 2 
23 Scott’s tap water 1 
24 Wash, tap water 1 
25 70% alcohol 1 
26 100% alcohol 1 
27 100% alcohol 1 
28 Xylene  2 
29 Xylene  3 
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2.2.4.2 Immunohistochemical localisation of cartilage and bone 
biomarkers in CMMTs 
CMMTs were stained to exhibit the presence of BMP4, Runx2, OPN and Sox9. 
The immunostaining conditions were optimised by examining the following parameters 
including: antigen retrieval, primary antibody dilution and protein blocking steps. The final 
conditions for each antibody are summarised in Table 2.6. All sections were cut and 
stained using the same method that was used to characterise the CMMTs. In addition, 
positive and negative control tissue sections (see Table 2.2) were stained with the same 
manual protocol as the test tissue sections. 
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Table 2.6 Optimisation of IHC conditions for cartilage and bone markers. 
Antibody Antigen 
retrieval 
Primary 
antibody 
dilution 
Primary antibody 
incubation time  
(min) 
Secondary antibody 
dilution and 
incubation  
Anti- 
BMP4 
pH 9, 20 
min at 97 °C   
1:100  
 
30  Agilent mouse anti-
rabbit, 1:50 for 30 
min then CINtec® 
then visualisation 
reagent, RTU for 30 
min  
Anti- 
Runx2 
pH 9, 20 
min at 97 °C   
1:600  30 Agilent mouse anti-
rabbit, 1:50 for 30 
min then CINtec®  
then visualisation 
reagent, RTU for 30 
min  
Anti-OPN None    1:300  30 Agilent mouse anti-
rabbit, 1:50 for 30 
min then CINtec®  
then visualisation 
reagent, RTU for 30 
min 
Anti- Sox9  pH 6, 20 
min at 97 °C 
1:100 40   Agilent goat anti-
mouse antibody RTU 
for 30 min  
 RTU, Ready to use. 
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2.2.4.3 RANKL and RANK localisation in CMMTs 
 
The CMMTs were stained to investigate the presence of RANKL and RANK. 
Immunostaining conditions were optimised by examining the following parameters 
including: antigen retrieval, primary antibody dilution and protein blocking steps. The final 
conditions for each antibody are summarised in Table 2.7. All sections were cut and 
stained using the same method that was used to characterise the CMMTs. In addition, 
positive and negative control tissue sections (see Table 2.2) were stained with the same 
manual protocol as the test tissue sections.  
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Table 2.7  Optimisation of conditions for RANKL and RANK IHC. 
Antibody Antigen 
retrieval 
Primary 
antibody 
dilution 
Primary antibody 
incubation time  
(min) 
Secondary antibody 
dilution and incubation 
Anti- 
RANKL 
pH 6, 20 
min at 97 °C   
1:200 30  
 
Agilent polyclonal rabbit 
anti-goat, 1:100 for 30 
min then CINtec® 
visualisation reagent, 
RTU for 30 min  
Anti-
RANK 
pH 6, 20 
min at 97 °C 
 
1:100 30  Agilent EnVision™+ 
Dual Link System-HRP 
for 30 min 
  RTU, Ready to use. 
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2.3 Image scoring and analysis 
2.3.1 Immunohistochemistry interpretation  
After labelling, the slides were scanned digitally to prepare the whole slide images 
using an Aperio ScanScope XT Pathology Digital Imaging System (Aperio Technologies, 
Chester Hill, NSW, Australia). The data from each slide was captured and filed in the 
Aperio Spectrum version 12 database. Each whole slide image was annotated to choose 
tumour areas for further analysis. All tissue areas in each image were analysed using the 
Aperio ImageScope software (Aperio Technologies, Ashgrove, Australia). Since the 
Aperio software does not have the capability to detect the areas of highest labelling, we 
identified the region of interest on the digital slides by visually choosing the areas of 
highest immunostaining. A subset of slides was reviewed to ensure that the chosen fields 
did not include extensive areas of cell-poor matrix or necrosis. The IHC staining results 
were manually evaluated for labelling specificity and quality prior to scanning, scoring and 
analysis. 
The Aperio “Nuclear” V9 algorithms (see Appendix 7) were used to calculate the 
total number of cells and to measure the labelling intensity for each cell. The percentage 
of positively labelled cells and the labelling intensity in each tumour were measured and 
filed in the Aperio database. The nuclear algorithm parameters were adjusted to improve 
cell detection or to alter the intensity cut-off values used to score cells. Nuclear labelling 
intensity was categorised as: 0, no nuclear labelling; 1+, faint nuclear labelling; 2+, 
moderate nuclear labelling; or 3+, strong nuclear labelling. ERα, PR, Ki-67, p63 and 
Runx2 were analysed using the ImageScope ‘IHC Nuclear V9’ algorithm. The Nuclear V9 
algorithm was adjusted to involve cytoplasmic rejection as the mode of segmentation, 
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because some sections exhibited nonspecific cytoplasmic staining. Applying a 
cytoplasmic rejection analysis within the nuclear algorithm indicates that detection of 
nuclei is conducted on the statistics of the positive staining channel, presuming a bimodal 
distribution. 
For Ki-67 expression, ten high power (×400) fields of representative tumour areas 
were selected using the whole slide image. The number of positive cells were stated as 
a percentage of total cells. A cut-off point of 10% was applied to differentiate between the 
low- and high-proliferative tumour groups (398). For ERα, a value was represented as an 
Allred score (399) and a histochemical score (H-score). The H-score was calculated 
automatically using the ImageScope ‘IHC Nuclear V9’ algorithm. The Aperio ‘IHC Nuclear 
V9’ algorithm identified nuclei, calculated a labelling intensity and determined the 
percentage of positively stained cells. From these calculations, Allred score was 
computed. The Allred scoring system summed the percentage of positive cells and the 
labelling intensity of the cells in the evaluated fields (0, 1+, 2+ and 3+). The two values 
were added to give a final score with 8 probable values (399). Scores of 0-2 were 
considered negative and scores of 3-8 were considered positive (399). The highest H-
score was 300, which was equivalent to 100% of the cells having a strong intensity (3+). 
Demonstration of H-scores was as follows: 0, negative; 1–100, weak positive; 101–200, 
moderately positive; >200, strongly positive (400, 401). H-score of 1 or more was 
considered a positive cut-off for ERα. 
For PR, p63 and Runx 2, a value was represented as an immunoreactive score 
(IRS). The Aperio ‘IHC Nuclear V9’ algorithm identified, calculated a labelling intensity 
and determined the percentage of positively stained cells. From these values, IRS score 
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was computed. Tumours were regarded as positive when 10% or greater of the tumour 
had nuclear staining with an intensity of 1 or higher (402). Scores of 0–1 were considered 
negative, scores of 2–3 were considered weakly positive, scores of 4–8 were considered 
moderately positive and strongly positive scores were defined as 9–12 (402). 
HER2 and E-cadherin were analysed applying the ImageScope ‘IHC Membrane 
V1’ algorithm Aperio imagescope (see Appendix 8). For the HER2 scoring system, the 
Aperio ImageScope created a scanned image of the whole tissue and calculated the 
HER2 labelling intensity score on a scale of 0 to 255. It also delivered a score that 
corresponded to the HercepTest scoring system (i.e. 1+, 2+ or 3+). Cases with 0 or 1+ 
scores were considered negative, while cases interpreted as 2+ or 3+ were considered 
to have HER2 overexpression (318, 403, 404).  
To assess the localisation of RANKL and RANK for each tumour, the H-score was 
obtained for each sample to perform a statistical analysis. The H-score was calculated 
using the ImageScope ‘IHC Cytoplasmic V2’ algorithm (see Appendix 9). The H-score 
cut-off value ≥8.5 was used to determine cases with a high localisation of RANKL and 
RANK according to Pfitzer et al. 2014 (405). 
E-cadherin labelling in CMMTs was categorised according to the pattern of 
localisation as either membranous or cytoplasmic. Additionally, based on the percentage 
of epithelial E-cadherin positive cells, E-cadherin expression in CMMTs was analysed 
using the Aperio Imagescope and categorised into three grades: the group of cases 
demonstrating >75% labelling (E-cadherin-positive group) were considered as having a 
preserved E-cadherin expression type (Pr type); the group of cases showing 25–75% 
labelling (E-cadherin heterogeneous group); and the group showing <25% of positive 
Chapter 2 – Materials and Methods 
97 
 
cells (E-cadherin negative group). The latter two groups were considered as having 
reduced E-cadherin expression type (Rd type) (328). 
The sections that were stained for the localisation of CK5/6, CKAE1AE3, Sox9, 
vimentin, BMP4 and OPN were assessed and analysed with the cellSens Dimension 
Microscope Imaging Software (version 1.14, Olympus). Expression levels were evaluated 
quantitatively by measuring the percentage of positive cells and negative cells in the 
selected areas. For each tumour, five fields were assessed and the mean average was 
calculated. An IRS for CK5/6, CKAE1AE3, Sox9, vimentin, BMP4 and OPN was 
calculated by assessment of both the intensity of staining and the percentage of positive 
cells. The IRS provides a value of 0-12 as a multiplying product between positive cell 
percentage score (0–4) and staining intensity score (0–3). Tumours were regarded as 
positive when 10% or greater of the tumour had cytoplasmic staining with an intensity of 
1 or higher (402). Scores of 0–1 were considered negative, scores of 2–3 were considered 
weakly positive, scores of 4–8 were considered moderately positive and strongly positive 
scores were defined as 9–12 (402). 
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2.3.2 NOR silver staining and morphometric AgNOR analysis 
Microscopic fields (representative of the lesion) were examined. Images were 
taken with a DMD108 Digital Microscope (Leica, Mount Waverley, VIC, Australia) of 10 
different fields. The best five images, with regards to image quality, were chosen for each 
case.  The morphometric analysis of AgNOR dots was performed using ImageJ v.1.52a 
software (406-408).  AgNORs from 100 randomly chosen nuclei of epithelial cells were 
evaluated in five fields at 100X magnification for their number and area. The image was 
first converted to an 8-bit greyscale image then ‘thresholded’ and analysed by clicking on 
‘tools’ then ‘region of interest’ (ROI) manager (see Figure 2.1). ROIs for each AgNOR dot 
were defined. Hundreds of additional ROIs were generated (for each dot in the entire 
image) in the ROI Manager and using this, the mean AgNOR count/nucleus and mean 
AgNOR Area (pixels2)/nucleus were measured for each case. 
Mean AgNOR count/nucleus= Total AgNOR count/100 
Mean AgNOR area (pixel2)/nucleus= Total AgNOR area/100 
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Figure 2.1 Photomicrograph demonstrating analysis of AgNOR area and count 
through ImageJ v.1.52a software. 
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2.4 Mitotic index determination  
The mitotic index was evaluated in the most cellular area of the tumour. The 
mitotic index was the sum of the number of mitotic figures counted on 10 consecutive 
high-power fields using a light microscope. Mitotic counts were performed by two 
pathologists independently. Based on Elston  and Ellis’ grade (15), the scores applied 
were as follows: 1 point when <9 mitotic figures/ field were counted, 2 points when 10–
19 figures/ field were counted and 3 points if figures/ field were ≥20 per 10 fields. The 
mitotic index was considered low if the score was equal to 1 or 2 and high if the score 
was equal to 3.  
2.5 Statistical analysis 
 
All the data were tested for similarity of variance and for normality.  If the variances 
across the samples were equal, parametric tests were applied. For unequal variances, 
non-parametric tests were used. The data were also tested for normality (i.e. the 
distribution of observations from which samples were collected is a normal ‘bell-shaped’ 
curve). D'Agostino-Pearson and/or Shapiro-Wilk’s W tests (409) were used to check for  
normality.  
The following flow chart explains the statistical tests that were applied for the 
analysis of the data (see Figure 2.2). All statistical analyses were carried out using Prism 
6.07 software for Windows (GraphPad Inc., La Jolla, California, USA). 
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Figure 2.2 Flow chart for choosing the statistical analyses used to analyse CMMT 
samples, adapted from Kobayashi et al. (2014) (410). 
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2.5.1 Immunohistochemical characterisation of CMMTs using a panel 
of antibodies 
To analyse the staining results of CK5/6 and Ki-67, the associations between 
benign and malignant CMMTs were compared using a Student’s t-test (411). To analyse 
the staining results of vimentin, ERα, PR, p63, E-cadherin and CKAE1/AE3, the 
associations between benign and malignant CMMTs were evaluated by use of the Mann-
Whitney U test (412). The associations between E-cadherin expression grade, pattern 
and different histological types were evaluated with Fisher’s exact test (413). Pearson’s 
correlation coefficient was computed between Allred and H-score groups of ERα antigen  
(413). Scores that displayed a p-value of < 0.05 were considered significant. 
2.5.2 Immunohistochemical localisation of cartilage and bone 
biomarkers in CMMTs 
To analyse the immunostaining results of OPN, Sox9 and BMP4, the association 
between sample groups were compared using one-way analysis of variance (one-way 
ANOVA) test. To analyse the staining results of Runx2, the associations between sample 
groups were evaluated by using the non-parametric tests Kruskal-Wallis. A p-value of < 
0.05 was considered significant.   
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2.5.3 Determination of proliferative activities in CMMT samples: A 
comparison of three methods  
A univariate procedure in a D'Agostino-Pearson normality test in GraphPad Prism 
assessed the distribution of the data. Because the observations were not normally 
distributed, correlations of various proliferative parameters between various groups (with 
unequal variances) were tested by Kruskal-Wallis test. A pairwise correlation between 
various proliferative parameters (mitotic index, AgNOR values and Ki-67 labelling index) 
was evaluated by the Pearson’s correlation coefficient. When the distribution was normal, 
the parametric test one-way ANOVA was used to compare the means of various 
parameters (413).  For all analyses, the significance level was set at 0.05. 
2.5.4 RANKL and RANK localisation in CMMTs 
To analyse the staining results of RANKL and RANK, correlations of RANKL or 
RANK between various groups were carried out using one-way ANOVA test (414). For 
all analyses, the statistical significance level was set at 0.05. 
2.5.5 Effect size for power analysis 
Power values for given sample sizes, effect sizes and α levels (post hoc power 
analyses) were computed using G*Power 3.1.9.2 software (HeinrichHeine-Universitat 
Dusseldorf, Dusseldorf, Germany) (415). The software was applied to determine the 
achieved power of the t tests for ERα, PR, HER2, Ki-67, CK5/6, CKAE1/AE3, E-cadherin 
and p63 by using a power calculation where 0.05 was used as the α error probability. The 
effect size (d) variable in the power calculation was determined utilising the group means 
and standard deviations for each marker. Cohen suggested that d= 0.2 is considered a 
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small effect size; 0.5 represents a medium effect and 0.8 represents a large difference 
effect (416-418). The software was also applied to determine the achieved power of 
the F tests (ANOVA or Kruskal-Wallis test) for BMP4, Runx2, Sox9, OPN, RANKL and 
RANK by using a power calculation where 0.05 was used as the α error of probability. It 
has been suggested that the effect size (f)= 0.1 is considered a small effect size; 0.25 
represents a medium effect and 0.4 represents a large difference effect (418, 419). 
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3.0 Immunohistochemical characterisation of CMMTs using a panel 
of antibodies 
3.1 Introduction  
Breast cancer is the most common form of neoplasia in women globally, with more 
than 1.3 million cases diagnosed every year (6). The most common type of breast cancer, 
accounting for 85% of cases, is IDC NST (20). MBC is unusual. Of the 365,464 diagnosed 
cases of breast cancer reported to the US National Cancer Database between 2001 and 
2003, 892 were MBCs (6). Therefore, the incidence of MBCs was 0.24% (6, 230). PABs 
are rarer tumours, comprising less than 100 cases in the literature (5). An important 
attribute of these neoplasms is their heterogeneity both morphologically and biologically 
nature. Similar to the situation in human mixed mammary tumours (MBCs and PABs), the 
source of various elements involved in mixed neoplasia in CMMTs is not well understood 
(318).  
In HBC, molecular markers (ER, PR and HER2) are routinely used for prognostic 
assessment (420). In veterinary medicine, despite some potential prognostic biomarkers 
having been studied in CMTs such as proliferation markers, hormone receptors and 
oncogenes none have been accepted in the routine pathology of spontaneous malignant 
tumours (258, 328, 421). Therefore, the examination of molecular markers with a 
prognostic value is necessary in order to identify animals requiring adjuvant therapies. 
There are other histopathological diagnostic markers such as p63, CKAE1/AE3, CK5/6, 
vimentin and E-cadherin, which have been studied in HBC (319, 340, 422-424) but are 
not yet used in routine diagnostic practice in CMTs.  
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Despite sharing similar features, to the best of our knowledge, no comparative 
molecular investigation between human mixed mammary tumours (PABs and MBCs) and 
CMMTs has been undertaken. Therefore, this study firstly aimed to investigate CMMTs 
histopathologically and histochemically. Second, the current study aimed to characterise 
CMMTs immunohistochemically using antibodies against Ki-67, ER, PR, HER2, E-
cadherin, CK5/6, p63, CKAE1/AE3 and vimentin. The expression profiles were then 
compared with those obtained for PABs and MBCs. Finally, malignant forms of CMMTs 
(CBMTs and CSs) were classified into subtypes based on their labelling profile.  
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3.2 Results 
3.2.1 Epidemiological aspects of CMMTs 
CMMT samples were used from 55 entire and 46 neutered female dogs. They 
ranged from 3 to 15 years of age (mean ± SD = 8.94 ± 2.46; median = 9.00). The most 
frequent breeds represented were Shih Tzu (10), Labrador Retriever (7), Border Collie 
(7), Jack Russell Terrier (7), German Shepherd Dog (6), Staffordshire Bull Terrier (5), 
Springer Spaniel (5), Cocker Spaniel (4), Yorkshire Terrier (3), Fox Terrier (3) and Kelpie 
(3). Other breeds were represented by two or fewer dogs and in seven cases the breed 
was not specified. Clinicopathological data of CMMTs are presented in Appendix 1. 
3.2.2 Histopathological characteristics of CMMTs 
In this study, the 101 cases examined were classified as either benign mixed 
tumours (BMTs) or malignant mixed tumours (CBMTs & CSs) (see Figure 3.1). 
BMTs (n= 88; 87%) showed proliferation of epithelial (luminal) and/or myoepithelial 
and mesenchymal components such as cartilage and/or bone (see Figure 3.2). The 
periphery of the tumour consisted of a capsule which surrounding the majority of the 
tumour, but with differing thickness (see Figure 3.2A-3.2C). The epithelial elements 
showed a low mitotic index. Different myoepithelial cell shapes were identified (i.e. spindle 
and satellite) in a suprabasal or interstitial location. There is myxoid tissue present in all 
cases of BMTs. A glassy, pink-staining hyaline cartilage-like tissue with matrices and 
lacunar structures was observed, with cells existing within these lacunae (chondrocyte-
like cells) (see Figure 3.2D). In the mesenchymal elements in BMTs, only mesenchymal 
matrix was observed in four (5%) samples; matrix and cartilage were observed in 45 
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(51%) samples; bone in nine (10%) samples; and matrix, cartilage and bone in 30 (34%) 
samples. In nine of the 88 cases, BMTs were accompanied by a bone-like tissue. 
Furthermore, around the periphery, osteoblast-like cells were observed, with some of 
these cells present in the lacunae (osteocyte-like cells). 
Malignant mixed mammary tumours (n= 13; 13%) consisted of both epithelial and 
mesenchymal elements (see Figure 3.3) and were characterised by marked cellular 
pleomorphism and numerous mitotic figures. Five out of 13 of these tumours were 
unencapsulated, with infiltrative borders. In some cases of malignant CMMTs, the 
epithelial elements had foci of cuboidal to columnar epithelial cells with different 
pleomorphism and nuclear atypia. Epithelial components of other cases showed varying 
growth and differentiation patterns, such as spindle and squamous. In the mesenchymal 
elements of malignant tumours, only a mesenchymal matrix was observed in four (31%) 
samples; matrix and cartilage were observed in five (38%) samples; bone was observed 
in three (23%) samples; and matrix, cartilage and bone were observed in one (8%) 
sample. Chondroid areas that consisted of pale blue basophilic and eosinophilic bone 
matrix were found between the osteoblasts. The histopathological diagnosis showed that 
five (5%) of cases were diagnosed as CSs and eight (8%) of cases were regarded as 
CBMTs. 
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Figure 3.1 Graph showing histopathological types of CMMT samples in this study. 
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Figure 3.2 Benign canine mixed mammary tumours. (A) Photomicrograph showing a 
well demarcated tumour with clear borders (encapsulation; arrowhead). (B) Tumour 
showing mixed cellular components like epithelial elements (white thick arrow) and 
myxomatous stroma (orange thin arrow). (C) Photomicrograph showing epithelial areas 
(white thick arrow), which show small ducts and acini in a BMT. (D) Tumour showing 
mixed mesenchymal elements like cartilage (red thin arrow) element. H&E stain. Scale 
bar, 100 µm. 
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Figure 3.3 Malignant canine mixed mammary tumours. (A) Photomicrograph showing 
unencapsulated CS with carcinomatous proliferation in epithelial element. (B) 
Photomicrograph showing chondrosarcomatous components (red thick arrow) in a CS. 
H&E stain. Scale bar, 100 µm. 
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3.2.3 Histochemical identification of different mesenchymal elements 
in CMMTs 
The histochemical stains were used on the tissue sections to identify the cells and 
their structures and other tissue components. Collagen fibres located in the connective 
stroma were strongly positive for the Masson trichrome stain, whereas the cartilage matrix 
was weakly positive (see Figure 3.4). In all CMMT samples, collagen fibrils stained blue; 
cytoplasm, keratin and muscle fibres stained red and the nuclei stained purple-black. The 
matrix of cartilaginous tissues in the CMMTs showed metachromasia with toluidine blue 
(pH 2.5) (see Figure 3.5). Tissue staining for calcium was carried out by using von Kossa, 
which stains calcium brown-black (see Figure 3.6). The results of the histochemical 
staining are summarised in Table 3.1.  
All cases of CMMTs (100%) showed collagen fibrils that surround the foci of 
tumours which stained positively with Masson trichrome stain. Only 45 (51%) cases of 
BMTs demonstrated cartilage tissues that were positive for toluidine blue and 30 (34%) 
cases of BMTs stained positively for calcium using von Kossa stain. However, 13 (15%) 
cases of BMTs were negative for toluidine blue and von Kossa stain. In addition, five out 
of 13 cases (38%) of malignant tumours showed cartilage tissues that were positive for 
toluidine blue, only three (24%) cases of malignant tumours stained positively for calcium 
using von Kossa stain. However, five (38%) cases of malignant CMMTs were negative 
for toluidine blue and von Kossa stain (see Table 3.1). 
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Table 3.1 Toluidine blue, Masson trichrome and von Kossa stain findings in 
CMMTs. 
No. Case ID 
number  
Diagnosis   Metaplastic tissue Masson 
trichrome  
Toluidine 
blue  
Von Kossa 
1 14p4 BMT Fibres, cartilage and 
bone 
Positive  Positive  Positive  
2 14p5 CS Fibres Positive Negative   Negative  
3 14p6 BMT Fibres and bone  Positive Negative  Positive 
4 14p10 BMT Fibres and cartilage  Positive Positive Negative  
5 14P24 CS Fibres Positive Positive  Negative  
6 14p27    BMT Fibres Positive  Negative   Negative  
7 14p28 BMT Fibres and cartilage  Positive Positive Negative  
8 14p33 BMT Fibres Positive Negative   Negative  
9 14p35 CS Fibres and cartilage  Positive Positive  Negative  
10 14p48 CS Fibres, cartilage and 
bone 
Positive Positive    Positive   
11 14p54 BMT Fibres Positive Negative   Negative  
12 14p76 BMT Fibres Positive Negative   Negative  
13 14p81 BMT Fibres Positive Negative   Negative  
14 10p2 BMT Fibres Positive Negative   Negative  
15 10p8 BMT Fibres Positive Negative   Negative  
16 10p9 BMT Fibres Positive Negative   Negative  
17 10p10 BMT Fibres and bone  Positive Negative   Positive  
18 10p12 BMT Fibres Positive Negative   Negative  
19 10p26 BMT Fibres and cartilage  Positive Positive Negative  
20 10p37 BMT Fibres Positive Negative   Negative  
21 10p43 CBMT Fibres Positive Negative   Negative  
22 10p45 BMT Fibres Positive Negative   Negative  
23 10p49 BMT Fibres Positive Negative   Negative  
24 10p55 BMT Fibres and bone  Positive Negative   Positive   
25 10p60 BMT Fibres and bone  Positive Negative   Positive   
26 10p66 BMT Fibres Positive Negative   Negative  
27 10p71 BMT Fibres Positive Negative   Negative  
28 10p75 CBMT Fibres and cartilage  Positive Positive    Negative  
29 10p76 BMT Fibres Positive Negative   Negative  
30 10p84 BMT Fibres, cartilage and 
bone  
Positive Positive Positive 
31 10p87 CBMT Fibres and bone  Positive Negative   Positive 
32 10p90 BMT Fibres Positive Negative   Negative  
33 10p95 BMT Fibres Positive Negative   Negative  
34 10p98 BMT Fibres Positive Negative   Negative  
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35 10p99 CBMT Fibres, cartilage and 
bone  
Positive Positive Positive   
36 10p115 BMT Fibres, cartilage and 
bone  
Positive Positive Positive 
37 10p125 BMT Fibres, cartilage and 
bone  
Positive Positive Positive   
38 10p126 BMT Fibres and bone  Positive Negative   Positive 
39 10p137 BMT Fibres Positive Negative   Negative  
40 10p147 CS Fibres and cartilage  Positive Positive    Negative  
41 10p174 CBMT Fibres and cartilage  Positive Positive    Negative  
42 10p176 BMT Fibres Positive Negative   Negative  
43 10p210 BMT Fibres, bone and 
cartilage  
Positive Positive Positive  
44 10p213 BMT Fibres Positive Negative   Negative  
45 10p221 BMT Fibres and bone  Positive Negative   Positive  
46 10p222 BMT Fibres and bone  Positive Negative   Positive   
47 10p224 BMT Fibres and bone  Positive Negative   Positive   
48 10p232 BMT Fibres Positive Negative   Negative  
49 10p255 BMT Fibres Positive Negative   Negative  
50 10p271 BMT Fibres Positive Negative   Negative  
51 10p283   BMT Fibres and bone  Positive Negative   Positive   
52 07-1801 BMT Fibres and bone  Positive Negative   Positive   
53 06-1555 BMT Fibres, cartilage and 
bone  
Positive Positive Positive   
54 10-1089 CBMT Fibres and cartilage  Positive Positive Negative  
55 06-0926 BMT Fibres and cartilage  Positive Positive Negative  
56 04-0843 BMT Fibres and bone  Positive Negative   Positive   
57 02-1051 CBMT Fibres and cartilage  Positive Positive Negative  
58 05-1334 CBMT Fibres and cartilage  Positive Positive Negative  
59 15-0581 BMT Fibres, cartilage and 
bone  
Positive Positive Positive   
60 15-0632 BMT Fibres and cartilage  Positive Positive Negative  
61 06-0448 BMT Fibres  Positive  Negative  Negative  
62 00-216 BMT Fibres, cartilage and 
bone  
Positive Positive Positive   
63 04-0004 BMT Fibres   Positive  Negative  Negative  
64 03-0678 BMT Fibres and cartilage  Positive Positive Negative  
65 03-0511 BMT Fibres and cartilage  Positive Positive Negative  
66 03-0422 BMT Fibres and cartilage  Positive Positive Negative  
67 15-0587 BMT Fibres, cartilage and 
bone  
Positive Positive Positive   
68 05-1492 BMT Fibres and cartilage  Positive Positive Negative  
69 04-0022 BMT Fibres and cartilage  Positive Positive Negative  
70 00-1003 BMT Fibres, cartilage and 
bone  
Positive Positive Positive   
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71 02-171 BMT Fibres and cartilage  Positive Positive Negative  
72 04-0706 BMT Fibres and cartilage  Positive Positive Negative  
73 08-1087 BMT Fibres, cartilage and 
bone  
Positive Positive Positive   
74 08-0385 BMT Fibres and cartilage Positive Positive Negative  
75 07-1812 BMT Fibres, cartilage and 
bone 
Positive Positive Positive   
76 06-1351 BMT Fibres, cartilage and 
bone 
Positive Positive Positive   
77 15-0048 BMT Fibres and cartilage Positive Positive Negative  
78 14-1542 BMT Fibres, cartilage and 
bone 
Positive Positive Positive   
79 14-1315 BMT Fibres, cartilage and 
bone 
Positive Positive Positive   
80 14-0725 BMT Fibres  Positive  Negative  Negative  
81 14-0612 BMT Fibres, cartilage and 
bone 
Positive Positive Positive   
82 14-0358 BMT Fibres and cartilage  Positive Positive Negative  
83 13-1296 BMT Fibres and cartilage  Positive Positive Negative  
84 13-0372 BMT Fibres, cartilage and 
bone 
Positive Positive Positive   
85 13-0151 BMT Fibres and bone Positive Negative  Positive 
86 12-0885 BMT Fibres and cartilage Positive Positive Negative  
87 12-0419 BMT Fibres, cartilage and 
bone 
Positive Positive Positive   
88 12-0416 BMT Fibres and cartilage Positive Positive Negative  
89 11-1201 BMT Fibres, cartilage and 
bone 
Positive Positive Positive   
90 10-0781 BMT Fibres  Positive  Negative  Negative  
91 10-0302 BMT Fibres  Positive  Negative  Negative  
92 09-1075 BMT Fibres and cartilage Positive Positive Negative  
93 09-0232 BMT Fibres and cartilage Positive Positive Negative  
94 05-1434 BMT Fibres and cartilage Positive Positive Negative  
95 10p59 BMT Fibres and cartilage Positive Positive Negative  
96 07-1208 BMT Fibres Positive Negative   Negative  
97 02-1154 BMT Fibres Positive Negative   Negative  
98 05-0416 BMT Fibres Positive Negative   Negative  
99 04-1754 BMT Fibres Positive Negative   Negative  
100 03-0018 BMT Fibres Positive Negative   Negative  
101 14p60 BMT Fibres Positive Negative   Negative  
BMT, benign mixed mammary tumour; CBMT, carcinoma in benign mixed mammary tumour; 
CS, carcinosarcoma. 
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Figure 3.4 Masson's trichrome staining collagenous tissues in CMMTs. (A) A CMMT section showing a deep 
eosinophilic matrix (white thin arrow) with H&E. (B) Collagen fibres and eosinophilic matrix (black thin arrow) appeared blue 
with Masson's trichrome stain. (C) Collagen fibres (black thin arrow) appeared blue with Masson's trichrome stain. Masson's 
trichrome. Scale bar, 100 µm.  
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Figure 3.5 Mesenchymal element (cartilaginous tissue) in the CMMTs. (A) 
Cartilaginous tissue in the CMMT stained pink with H&E. H&E. Scale bar, 100 µm. (B) 
Matrix of cartilaginous tissue displayed metachromasia with toluidine blue pH 2.5. 
Toluidine blue. Scale bar, 100 µm. 
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Figure 3.6 Photomicrograph showing mineralised osseous metaplasia with 
calcium staining (black). Von Kossa with nuclear fast red counterstain. Scale bar, 100 
µm. 
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3.2.4 Ki-67 is an effective marker of cell proliferation in CMMTs and the 
Ki-67 labelling index is related to tumour type. 
The use of Ki-67 as a prognostic marker in CMMTs was examined in this study.  Ki-
67 immunolabelling was confined to the nuclei of positive control tissues (see Appendix 
13) and the epithelial cells in CMMTs (see Figure 3.7A, B). Seventy-six of the 88 BMTs 
(86%) had a low Ki-67 labelling index (see Appendix 10). The Ki-67 labelling index was 
high in 11 out of 13 (85%) malignant tumours (see Appendix 10). The mean Ki-67 labelling 
index in malignant tumours was 19%, while in BMTs the mean Ki-67 labelling index was 
4% (unpaired Student’s t-test, ****p< 0.0001; see Figure 3.7C). 
For the Ki-67 immunostaining, the post hoc power was calculated using G*power, 
and it was 0.99 (effect size d= 1.88). The calculated effect size indicated that the sample 
size was more than sufficient. 
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Figure 3.7 Localisation of Ki-67 in CMMTs.  (A) BMT with a low Ki-67 labelling index. 
(B) CS with a high Ki-67 labelling index. (C) The graph showing the proliferative activity 
of CMMTs based on the mean values of the Ki-67 index and its correlation with its 
histological type, ****p< 0.0001; p was calculated by using the unpaired Student’s t-test. 
IHC. Scale bar, 100 µm. 
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3.2.5 ERα immunostaining is significantly higher in BMTs than in 
malignant CMMTs 
The presence of ERα in FFPE samples of normal, BMTs and malignant CMMTs 
was determined using IHC. In this study, immunostaining of ERα was localised to the 
nuclei of normal, benign and malignant epithelial cells. For the analysis of ERα, both the 
Allred and the H-score systems were used. 
3.2.5.1 Allred scoring system 
The cases that were scored using the Allred score, showed that 82 of the 88 BMTs 
(93%) were positive for ERα expression (see Figure 3.8A) (see Appendix 11). Five out of 
13 (38%) malignant cases were positive for ERα expression and eight (62%) were 
negative (see Figure 3.8B) (see Appendix 11). The Allred scores of ERα were significantly 
different between benign and malignant tumours (Mann-Whitney U test, ***p< 0.0005; 
see Figure 3.8C); there was greater ERα expression in BMTs compared with malignant 
tumours. 
For the ERα immunostaining (determined by Allred scoring system), the post hoc 
power was calculated using G*power, and it was 0.99 (effect size d= 1.23). The calculated 
effect size indicated that the sample size was more than sufficient. 
3.2.5.2 H-scoring system 
The cases that were scored using the H-score, showed that 83 of the 88 BMTs 
(94%) were positive for ERα expression (see Appendix 11). Seven out of 13 malignant 
cases (54%) were positive for ERα expression (see Appendix 11). The H-scores of ERα 
were significantly different between benign and malignant tumours (Mann-Whitney U test, 
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*p= 0.039; see Figure 3.8D); there was greater ERα expression in BMTs compared with 
malignant tumours. 
 
For the ERα immunostaining (determined by H-scoring system), the post hoc 
power was calculated using using G*power, and it was 0.80 (effect size d= 0.74). The 
calculated effect size indicated that the sample size was sufficient. 
Overall, IHC detection of ERα in CMMTs was successful and meaningful as it 
distinguished benign from malignant CMMTs.  
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Figure 3.8 ERα localisation in CMMTs. (A) ERα-positive tumour cells in a BMT. (B) 
ERα-negative tumour cells in a CS. (C) The Mann-Whitney U test shows a significant 
difference in ERα Allred scores between benign and malignant tumours (***p< 0.0005). 
(D) The Mann-Whitney U test shows a significant difference in ERα H-scores between 
benign and malignant tumours (*p= 0.0391). IHC. Scale bar, 100 µm. 
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3.2.6 Relationship between Allred score and H-score for ERα 
Not all laboratories use the same method for analysing the findings of their tests 
and therefore they do not document the results in a consistent manner. In this current 
study, the H-score and Allred score for quantifying the immunohistochemical reaction for 
ERα were compared. In CMMT samples, the Allred score for ERα was significantly 
correlated to the H-score for ERα in benign tumours (Pearson correlation coefficient; r2= 
0.60; p< 0.0001) (see Figure 3.9). The Allred score for ERα was also significantly 
correlated to the H-score for ERα in malignant tumours (r2= 0.620; p< 0.0014) (see Figure 
3.9). Overall, in this current study, the use of the H-scores and Allred scores that were 
used to analyse ERα expression in CMMTs produced comparable results. 
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Figure 3.9 Correlation between Allred and H-scores for ERα. There was a significant 
correlation between Allred scores and H-scores for ERα in benign mixed mammary 
tumours, r2= 0.60, p< 0.0001, n= 88. There was also a significant correlation between the 
Allred scores and H-scores for ERα in malignant tumours, r2= 0.620, p= 0.0014, n= 13. 
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3.2.7 PR immunostaining is significantly higher in BMTs than in 
malignant CMMTs 
Because determination of PR status is an important primary evaluation at the time 
of breast cancer diagnosis (425), PR was examined in this study. PR immunolabelling 
was confined to the nuclei of benign and malignant epithelial cells. Eighty-three of the 88 
BMTs (94%) were positive for PR (see Figure 3.10A) (see Appendix 11). Six out of the 
13 malignant tumours (46%) were positive for PR and seven (54%) were negative (see 
Figure 3.10B) (see Appendix 11). The localisation of PR was significantly different 
between benign and malignant tumours (Mann-Whitney U test, *p< 0.0151; see Figure 
3.10C); there was greater PR expression in BMTs compared with malignant tumours. 
 
For the PR immunostaining, the post hoc power was calculated using G*power, 
and it was 0.91 (effect size d= 0.90). The calculated effect size indicated that the sample 
size was more than sufficient. 
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Figure 3.10 Localisation of PR in CMMTs. (A) Nuclear localisation of PR in a BMT. (B) 
PR-negative tumour cells in a CS. (C) The localisation of PR was significantly different 
between BMTs and malignant tumours (*p< 0.0151); p was calculated by using the Mann-
Whitney U test. IHC. Scale bar, 100 µm. 
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3.2.8 HER2 overexpression in CMMTs 
Breast cancer biomarkers, including HER2, are routinely evaluated to help select 
patients who are appropriate for treatment regimens that target HER2 molecules in 
humans (426). In the current study, malignant CMMTs were evaluated for the presence 
of HER2. HER2 immunolabelling was localised to the epithelial cell membranes in 
malignant CMMTs (see Figure 3.11A). There were eight (62%) HER2-positive and five 
(38%) HER2-negative malignant cases (see Figure 3.11B). Of these 13 malignant cases 
(eight CBMTs and five CSs), the distribution for IHC staining of 0, 1+, 2+ and 3+ was one 
(8%), four (30%), seven (54%) and one (8%) respectively (see Table 3.2). The overall 
HER2 overexpression rate IHC staining of 2+ and 3+ or reported as positive was 62%. 
Table 3.2 shows HER2 IHC scores in malignant CMMTs. 
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Table 3.2 HER2 IHC scores in malignant CMMTs. 
HER2 IHC score CBMTs 
n (%) 
CSs 
n (%) 
Overall  
n (%) 
0 0 (0) 1(8) 1 (8) 
1+ (weak and incomplete staining) 3 (23) 1(8) 4 (31) 
2+ (moderate or incomplete membrane staining) 5 (38) 2 (15) 7 (53) 
3+ (strong and complete membrane staining) 0 (0) 1 (8) 1 (8) 
Total  8 5 13 
CBMT, carcinoma in benign mixed mammary tumour; CS, carcinosarcoma; HER2, human 
epidermal growth factor receptor 2.  
Chapter 3 - Immunohistochemical characterisation of CMMTs  
 
131 
 
 
 
Figure 3.11 Localisation of HER2 in CMMTs. (A) Strong and complete membranous 
expression (3+) of HER2 in a malignant mixed mammary tumour. (B) HER2-negative 
tumour cells in a malignant mixed mammary tumour. IHC. Scale bar, 100µm. 
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3.2.9 E-cadherin is present in BMTs and its positivity is reduced in 
malignant CMMT tissues 
          The reduction or loss of E-cadherin has been linked to dedifferentiation of tumour 
and invasiveness (325). In the current study, the immunohistochemical pattern of E-
cadherin localisation was evaluated in FFPE sections of CMMTs. All BMTs (100%) were 
positive for E-cadherin (see Appendix 12). Only three out of the 13 malignant tumours 
(23%) were negative for E-cadherin (see Appendix 12). There was greater E-cadherin 
expression in BMTs when compared with malignant mixed tumours (see Figure 3.12A; 
Mann-Whitney U test; **p= 0.0024). 
For the E-cadhein immunostaining, the post hoc power was calculated using 
G*power, and it was 0.76 (effect size d= 0.71). The calculated effect size indicated that 
the sample size was sufficient. 
E-cadherin localisation was predominantly membranous (75%) and had the 
preserved E-cadherin expression type (Pr type) (96%) in BMTs (see Figure 3.12B). In 
malignant CMMTs, E-cadherin localisation was mostly cytoplasmic (69%) and was of the 
reduced type (Rd type) (62%) (see Figure 3.12C). There was a positive association 
between E-cadherin expression pattern (i.e. membranous versus cytoplasmic) and 
different histological types (i.e. benign versus malignant) of CMMTs (Fisher’s exact test, 
****p< 0.0001; see Figure 3.12D). There was also a positive association between E-
cadherin expression grade (i.e. preserved type versus reduced type) and different 
histological types (i.e. benign versus malignant) of CMMTs (Fisher’s exact test, ****p< 
0.0001; see Figure 3.12E). Overall, E-cadherin expression was categorised as 
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membranous when on cell-cell borders, or as cytoplasmic when it was in the form of a 
diffuse cytoplasmic staining. Furthermore, the percentage of E-cadherin-positive cells 
was graded by using Aperio Imagescope software, classifying cases into a reduced type 
group when displaying < 25% positivity or showing 25-75% positivity and a preserved 
type group when ≥ 75 % positive cells were present.  
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Figure 3.12 Localisation of E-cadherin in CMMTs. (A) The localisation of E-cadherin 
was significantly different between benign and malignant CMMTs (**p= 0.0024); the p 
value was calculated by using the Mann-Whitney U test. (B) Strong and complete 
membranous expression of E-cadherin in a BMT. (C) Aberrant (reduced) E-cadherin 
expression in a CBMT. (D) The associations between E-cadherin expression pattern and 
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different histological types were evaluated with Fisher’s exact test, ****p< 0.0001. (E) The 
associations between E-cadherin expression grade and different histological types were 
evaluated with Fisher’s exact test, ****p< 0.0001. IHC. Scale bar, 100 µm.  
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3.2.10 CK5/6 and p63 are specific markers for suprabasal and 
spindle-shaped myoepithelial cells in CMMTs.  
CK5/6 and p63 have been described as basal and myoepithelial cell markers in 
human mammary glands. Because the origin of CMMTs has not been determined, the 
roles of CK5/6 and p63 in CMMTs were investigated. 
3.2.10.1 CK5/6 IHC immunostaining 
The results of the analysis performed for CK5/6 are presented in Table 3.3 and 
Appendix 12. CK5/6-positive CMMTs showed a cytoplasmic pattern of expression (see 
Figure 3.13A). In CBMTs and CSs, the neoplastic cells showed weak to moderate staining 
for CK5/6 (see Figure 3.13B). The expression of CK5/6 differed significantly between 
benign and malignant tumours (unpaired Student’s t-test, *p= 0.0389; see Figure 3.13C). 
Cytoplasmic expression of CK5/6 was more intense in benign CMMTs than in malignant 
ones. Cartilage in CMMTs was negative for CK5/6. Overall, the suprabasal and spindle-
shaped myoepithelial cells, and chondrocytes from the mesenchymal component of 
malignant CMMTs, did not have an immunolabelling profile similar to BMTs. 
For the CK5/6 immunostaining, the post hoc power was calculated using G*power, 
and it was 0.80 (effect size d= 0.74). The calculated effect size indicated that the sample 
size was sufficient. 
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Figure 3.13 Localisation of CK5/6 in CMMTs. (A) Cytoplasmic localisation of CK5/6 in 
the suprabasal cells of a BMTs. (B) Cytoplasmic localisation of CK5/6 in the epithelial 
cells of a CS. (C) The localisation of CK5/6 was significantly different between benign and 
malignant tumours (*p= 0.0389); p was calculated by using the unpaired Student’s t-test. 
IHC. Scale bar, 100 µm.  
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3.2.10.2 P63 IHC immunostaining 
The results of the analysis performed for p63 are presented in Table 3.3 and 
Appendix 12. P63-labelled suprabasal and spindle-shaped myoepithelial cells in benign 
mixed tumours can be seen in Figure 3.14A. Three CSs had carcinomatous elements 
that were p63-negative (see Figure 3.14B), but some p63-positive myoepithelial cells 
were recognised close to these carcinomatous areas. There was greater p63 expression 
in BMTs compared with malignant tumours (Mann Whitney U test, *p= 0.0243; see Figure 
3.14C). Cartilage in CMMTs was negative for p63 expression.  
For the p63 immunostaining, the post hoc power was calculated using G*power, 
and it was 0.70 (effect size d= 0.75). The calculated effect size indicated that the sample 
size was sufficient. 
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Figure 3.14 Localisation of p63 in CMMTs. (A) Nuclear localisation of p63 protein in 
suprabasal myoepithelial cells. (B) P63-negative tumour cells in a CS.  (C) The 
localisation of p63 was significantly different between benign and malignant mixed 
tumours (*p= 0.0243); p was calculated by using the Mann-Whitney U test. IHC. Scale 
bar, 100 µm. 
Chapter 3 - Immunohistochemical characterisation of CMMTs  
 
140 
 
 
3.2.11 Vimentin is highly expressed in CMMTs and its positivity 
does not vary between different histological types 
The localisation of mesenchymal markers in CMMT tissues was evaluated. The 
results of IHC performed for vimentin are presented in Table 3.3 and Appendix 12. The 
myoepithelial cells from BMTs showed cytoplasmic localisation of vimentin. Vimentin was 
positive in the myoepithelial cells and mesenchymal elements of all CMMTs (see Figure 
3.15A). The localisation of vimentin was not significantly different between benign and 
malignant tumours (see Figure 3.15B). Overall, vimentin was detected in the cytoplasm 
of mesenchymal cells and myoepithelial cells of both the CMMT. In addition, chondroid 
matrix cells and osseous tissues were intensely stained for vimentin. 
For the vimentin immunostaining, the calculated effect size was small (d< 0.2), 
therfore a larger sample size was needed in order to detect the difference between 
studied groups. 
 
 
 
 
3.2.12 CKAE1/AE3 is present in epithelial elements of CMMTs and 
its positivity varies between different histological types 
Immunostaining for CKAE1/AE3 was essential to confirm the epithelial origin of the 
studied tumours. The results of IHC performed for CKAE1/AE3 are presented in Table 
3.3 and Appendix 12. Cytoplasmic localisation (pericellular pattern) of CKAE1/AE3 was 
observed in epithelial elements for all CMMTs (see Figure 3.15C). The pericellular pattern 
was seen as being of higher intensity at the periphery of the tumour cells. Cytoplasmic 
localisation of CKAE1/AE3 was more intense in BMTs. The localisation of CKAE1/AE3 
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was significantly different between benign and malignant tumours (Mann-Whitney U test, 
*p= 0.0259; see Figure 3.15D). This pericellular pattern indicated the epithelial origins of 
CMMTs.  
For the CKAE1/AE3 immunostaining, the post hoc power was calculated using 
G*power, and it was 0.70 (effect size d= 0.75). The calculated effect size indicated that 
the sample size was sufficient.  
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Table 3.3 Summary of the immunohistochemical localisation of CK5/6, p63, 
CKAE1/AE3 and vimentin in CMMTs.  
BMT, benign mixed mammary tumour; CBMT, carcinoma in benign mixed mammary tumour; CS, 
carcinosarcoma; CK5/6, cytokeratin 5/6. 
 
 
  
Molecular marker Benign  
(BMTs) 
Malignant 
(CBMTs &CSs) 
P value 
 Positive labelling 
n (%) 
Positive labelling 
n (%) 
 
CK5/6 81 (92) 13 (100) *0.0389 
p63 85 (97) 10 (77) *0.0243 
Vimentin 88 (100) 13 (100) 0.8149 
CKAE1/AE3 88 (100) 13 (100) *0.0259 
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Figure 3.15 Localisation of vimentin and CKAE1/AE3 in CMMTs. (A) Cytoplasmic 
localisation of vimentin in the mesenchymal elements of a BMT. (B) Cytoplasmic 
localisation of CKAE1/AE3 in the epithelial cells of a BMT. (C) The localisation of vimentin 
was not significantly different between benign and malignant mixed tumours (p= 0.8149). 
(D) The localisation of CKAE1/AE3 was significantly different between benign and 
malignant CMMTs (*p= 0.0259); p was calculated by using the Mann Whitney U test. IHC. 
Scale bar, 100 µm. 
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3.2.13 Luminal B-like tumour is the most common subtype in 
CBMTs and HER2 overexpressing tumour is the commonest in 
CSs 
Based on the localisation of HER2, ER, PR, CK5/6, p63 and vimentin, 13 cases of 
malignant CMMTs in this current study were classified into luminal A-like, luminal B-like, 
HER2-overexpressing and basal-like tumours (see Table 3.4). The luminal B-like 
immunoprofile was the most common, representing five out of the 13 (38%) samples, 
followed by the basal-like profile, which was represented by four samples (31%), the 
HER2-overexpressing profile was represented by three samples (23%) and the luminal 
A-like profile had only one sample (8%). In the malignant cases (n= 13), of the eight 
patients with CBMTs, five (63%) were luminal B-like; one (12%), was luminal A-like; one 
(12%), was basal-like; and one (12%), had an HER2-overexpressing tumour. In terms of 
CSs, of the five patients with CSs, three (60%), basal-like; and two (40%), had HER2-
overexpressing tumours.  
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Table 3.4 Molecular subtypes of malignant CMMTs. 
Subtypes ER and/ 
or PR 
HER2 P63 and /or CK5/6 and 
/or vimentin 
Frequency  
n (%) 
Luminal A-like Positive Negative Positive/negative 1 (8) 
Luminal B-like Positive Positive Positive/negative 5 (38) 
HER2 
overexpressing-like 
Negative Positive Positive/negative 3 (23) 
Basal-like Negative Negative Positive 4 (31) 
Normal-like  Negative Negative Negative 0 (0) 
CK5/6, cytokeratin 5/6; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; 
PR, progesterone receptor. 
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Positive and negative controls were used in each assay. Photomicrographs of 
positive control tissues for all the series of experiments are shown in Appendix 13. 
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3.3 Discussion  
3.3.1 CMMTs share common histopathological features with PABs and 
MBCs 
CMMTs show histological features common with pleomorphic adenomas of human 
salivary gland tumours, which have identical tissue structures and develop from exocrine 
glands (197). In humans, epithelial tumours associated with the development of the 
myxoid or chondroid/osteoid matrix are unusual in mammary glands and tend to have 
uncertain prognoses (220). In humans, PABs and MBCs are rare breast cancers (5, 6) 
and encompass a heterogeneous group of tumours with various morphological subtypes 
(5, 230). This current study bolsters CMMTs as a good model for PABs and MBCs 
epidemiologically. The mean age of the dogs presenting with CMMTs was 8.94 years, 
which was similar to human data reported by Lilienfeld et al. (1963) suggesting a higher 
prevalence in middle age. The mean age at the time of diagnosis of CMMTs is roughly 
similar for women (i.e. after the age of 40) and for dogs (i.e. after 6 years). Additionally, 
the documented peak incidence of the tumours is also similar between women (50–58 
years) and dogs (8–11 years) (427). The mean age of onset of CMMTs and PABs is also 
similar (197). 
PAB is an unusual benign tumour comparable to the benign mixed tumour of the 
canine mammary gland (428). They are circumscribed lesions with a combination of 
epithelial and myoepithelial cells, as well as abundant stroma that may consist of one or 
more of the following elements: (i) myxoid; (ii) cartilage;  (iii) or bone (5). 
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In the current study, different cellular features were identified in mixed mammary 
tumours, which included epithelial, and/or myoepithelial cells, mesenchymal fibrous 
tissue, cartilage and bone. It has been shown that myxoid tissue—as a tissue element in 
mixed tumours—could be a precursor for chondroid tissue (429). The routine stain for a 
light microscopic examination of CMMT tissues is haematoxylin and eosin. Additional 
stains that are specifically useful are toluidine blue for chondroid tissue, Masson’s 
trichrome for connective tissue and von Kossa stain for highlighting bone. Cartilage and 
bone are a feature of the extracellular matrix, but the amount of these tissues varies and 
each tissue has specific amounts (430).  
Cartilage is categorised into three different types: hyaline cartilage, elastic cartilage 
and fibrocartilage, which vary in relative quantities of collagen and proteoglycan. Hyaline 
cartilage is the most common and its matrix mainly consists of collagen II and 
proteoglycans (431). In this current study, the predominance of the myxochondroid 
stroma was clear. The matrix of hyaline cartilage-like tissue showed metachromasia with 
toluidine blue staining at a pH of 2.5. Similar findings were found in PABs in which 
extracellular matrix stained metachromatically with toluidine blue (370). Hyaline 
cartilaginous tissue is the most common cartilage type in CMMTs (432). Chondroblasts 
are active cells that undergo mitotic divisions, develop daughter cells responsible for the 
production of the extracellular matrix, are enclosed by a cartilaginous cavity and develop 
into chondrocyte (433). Toluidine blue binds to the glycosaminoglycans in cartilage 
extracellular matrix, and results in a purple colour (434).  
In this study, paraffin sections of CMMTs were stained with Masson's trichrome to 
detect collagen. The images (see Figure 3.4) showed differing amounts of collagen in 
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tumours. Smith et al. (1969) also utilised Masson’s trichrome staining to study a group of 
human breast tumours containing cartilage and bone (181). They found that cartilage 
tissue was the predominant tissue type in all breast tumour cases in their study. Masson’s 
trichrome staining is used to differentiate collagen fibres from muscle tissues in 
histological sections. It allows for better characterisation of fibroblastic metaplasia (435). 
Osteoid tissue in mixed tumours contains osteoclasts and mineralised bone (155). In this 
study, osteoblast-like cells formed matrix-mediated mineral (calcium) shown by von 
Kossa staining. Similar findings were found in human osseous metaplasia in which the 
mineralisation of bone was confimed by von Kossa stain (436, 437).  
3.3.2 ER+/PR+ was the most common status in BMTs and CBMTs, while 
ER-/PR- was the commonest status in CSs 
Most of the BMTs in this current study were ER positive (93%) and ER expression 
was absent in 62% of malignant CMMTs. Many studies have found that reduced 
localisation of ER is associated with an increasing malignancy grade in CMTs (438-440). 
Nearly 94% of BMTs were positive for PR whereas only 46% of malignant tumours were 
positive. Benign mammary tumours and well-differentiated breast cancers in humans are 
more likely to be ER positive, whereas undifferentiated tumours are more likely be ER 
negative (441). In HBCs, PR is reported to be a useful marker of recurrence and a lack 
of PR expression is associated with a poor prognosis (305). Sato et al. (2005) reported 
that the immunohistochemical results of PAB were similar to those of salivary gland 
pleomorphic adenoma (174), and Glas et al. (2001) demonstrated PR activity (61%) in 
salivary gland pleomorphic adenoma (442). Malignant tumours are more likely to lose 
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hormonal dependency as the tumour progresses towards metastasis (306). Thus, these 
tumours and their metastases have a propensity to be ER−/PR− (306). In HBCs, the 
ER−/PR− status is related to a poorer prognosis. MBCs are believed to be triple-negative 
tumours, but some have ER and PR positivity and others HER2 positivity (222). Some 
studies reported that the triple negative phenotype was found in 77% of MBCs (222, 443, 
444).  
In this study, 62% of malignant CMMTs overexpressed HER2. There is limited 
information about HER2 overexpression in MBC. Most previous studies have reported 
HER2 overexpression varying from 17% to 34%, although Bellino et al. (2003) 
documented HER2 overexpression in 72% of  MBC cases (445-448). It has been reported 
that, because of the aggressive nature of basal-like breast cancer, a higher percentage 
could be assessed by molecular profiling that normally is carried out with HER2 testing in 
the laboratory. One interesting pattern of HER2 positivity became obvious with the direct 
comparison of HER2 status across many tumour types, is that overexpression of HER2 
is found in tumours of epithelial origin (449). For tumours derived from mesenchyme and 
neuroendocrine tissue, HER2 expression and HER2 gene amplification are insignificant 
(449).  
HER2 overexpression is related to many factors, which include the sensitivity of 
the detection technique, the level of protein expression and the stages of tumour samples. 
Gouvea et al. (2006) examined the capability of various antibodies to detect HER2 
expression in HBCs by IHC and found that monoclonal antibodies correlated with gene 
amplification that was evaluated by fluorescent in situ hybridisation than the IHC that 
utilised polyclonal antibodies as it was used in this study (450).  
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Although the localisation of HER2 has been widely investigated in HBCs, a limited 
number of studies investigated HER2 localisation in CMTs, using the HercepTest scoring 
system and the related Agilent (Dako) polyclonal antibody (445, 446, 451-454). Studies 
that assessed HER2 gene overexpression or protein localisation in CMTs demonstrated 
that, HER2 was expressed immunohistochemically in a half of benign tumours and in less 
than 20% of malignant CMTs (455). Though, another study addressed HER2 gene and 
protein status, observed no HER2 amplification in protein overexpressing breast tumours 
(451). In CMTs, HER2 protein overexpression correlated with established parameters of 
poor prognosis such as Ki-67 labelling index and histological grade (445). Nevertheless, 
the most recent studies demonstrated no relationship with prognostic parameters or 
survival rates in malignant CMTs with HER2 overexpression (452, 454). 
  As reviewed by Pena et al. (2014), the HER2 protein expression in canine 
mammary tumourigenesis is inconclusive (318). Furthermore, none of the formerly cited 
studies carried out methods (such as western blot, mass spectrometry or reverse phase 
protein lysate microarray) that can overcome the difficulty of applying an antibody 
particularly designed to detect the human HER2 protein in CMTs (445, 446, 451-454). 
Burrai et al. (2015) examined the specificity of the most commonly used polyclonal 
antibody and the one that I used (Agilent c-erbB-2 oncoprotein) towards HER2 protein 
and HER2 gene expression in canine mammary lesions (456). No significant differences 
were observed in HER2 expression between benign and malignant CMTs, indicated that 
there was not a role for this marker as a prognostic indicator (456).  
The cytoplasmic immunostaining of HER2 has considered as an 
immunohistochemical artefact in human, feline and canine tumour tissues because of 
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absence of IHC protocol standardisation (456). Burrai et al. (2015) further examined this 
problem using different methods, such as Western blot, mass spectrometry and reverse 
phase protein lysate microarray (456). Overall, their findings support the suggestion of 
the lacking of specificity of the HER2 Agilent polyclonal antibody. Their results propose 
that, at least in the two CMT tissues with IHC HER2 (3+), with the most strong signal 
detected also in Western blot, HER2 was not overexpressed, and additionally support the 
absence of specificity of the Agilent polyclonal antibody in recognising HER2 protein in 
CMT tissues (456). The study conducted by Burrai et al. (2015) demonstrated—through 
IHC methods—that the application of the Food and Drug Administration (FDA)-approved 
Agilent polyclonal antibody in CMT tissues produced unclear results that were related to 
a diffuse, non-specific cytoplasmic staining (456). Moreover, the IHC analysis showed 
results that are incompatible with the assessment of canine HER2 gene amplification by 
qRT-PCR.  
There have been reports that antibodies, particularly polyclonal antibodies, can 
cross react with other antigens (457). Furthermore, these antigens could be localised in 
multiple cell types (458). But this is usually because of poor antibody design and many 
tumour antigens are found in normal tissues and are overexpressed in cancerous tissues. 
When testing a new antibody, it is “best practice” to stain a panel of normal tissues to 
characterize the test tissue (459). Despite the fact that CMTs have been reported as a 
model for studying HBCs (460), there is a study by Burrai at al. (2015) that shows that a 
HER2 rabbit polyclonal antibody used in humans did have a cytoplasmic staining pattern 
in CMTs. This staining pattern is considered non-specific staining in both HBCs (461) and 
CMTs and this study backed up this finding with western blotting and real time PCR in 
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CMT samples (456). In our laboratory we characterize each antiserum thoroughly with 
both human and canine normal tissues and tumours. The localisation pattern of each 
antiserum must match in both species before we would even optimise the antisera. It did 
take some time before our laboratory found suitable ER antisera that worked well in 
CMTs. 
This study showed that, of the malignant cases of CMMTs, 31% were basal-like 
tumours, 38% were of luminal B-like subtype, 23% were HER2-overexpressing like and 
8% were of luminal A-like subtype. It was found that the luminal B-like profile was the 
more common tumour type in CBMTs and that the basal-like profile was more common 
in CSs and this may indicate that CBMTs may have an intermediate prognosis compared 
with CSs. Sassi et al. 2010 showed that the most frequent immunophenotypic profile was 
luminal B-like (48%), followed by basal-like (28%) (258). The results of this current study 
suggest that CBMTs may have a better prognosis than CSs. It has been reported that 
HER2-overexpressing subtypes have the worst prognosis, followed by basal-like subtype 
tumours and lastly luminal A and B-like tumour type, which have the best prognosis (404). 
In this study, it was concluded that the malignant samples were predominantly the luminal 
B-like subtype and demonstrated the morphological features that are associated with 
better prognoses than HER2-overexpressing and basal-like tumour types. In humans, the 
inclusion of trastuzumab (Herceptin) to standard therapy effectively improved the 
prognosis for patients with HER2-overexpressing breast cancer, and became a milestone 
in the cure of these patients (462). The other anti-HER2 agent that was added into the 
routine practice of HER2-overexpressing tumours was lapatinib, a tyrosine kinase 
inhibitor that inhibits HER1 and HER2 kinases (463).  
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Various studies have attempted to classify canine mammary carcinomas using 
IHC. Most of these studies categorised canine mammary carcinomas with IHC and 
correlated this with other prognostic factors (histological grade, presence of metastasis 
and invasion) (110, 258, 464). The American Society of Clinical Oncology and the College 
of American Pathologists (ASCO/CAP) identified that breast tumours with ≥1% of ER or 
PR immunolabelling have to be considered hormone receptor–positive tumours (398, 
465). Likewise, the basal marker cut-offs of at least 10% labelling for CK 5/6 and p63 
correlated well with the previously mentioned prognostic factors (318, 402). A positive 
cut-off score for the HercepTest was a score of 2+ (318, 403, 404).  
In this current study, the H-scores and Allred scores in benign and malignant 
CMMTs were compared. The H-score for ERα in CMMTs correlated with the Allred score 
of CMMTs. This indicates that the H-score and Allred score systems produce comparable 
results. The H-score provides a total score (0–300). Dabbs (2017) reported that the H-
score is the preferred method of reporting as it has a wider dynamic range compared with 
the Allred score (466).   
3.3.3 Ki-67 labelling can be an important biomarker for proliferation in 
CMMTs 
In this study, 85% of malignant CMMTs had high Ki-67 labelling indices. In human 
MBCs, high Ki-67 proliferation indices have been reported (467). In human salivary gland 
pleomorphic adenomas, low Ki-67 labelling indices have been also reported (468). In 
CMTs, Ki-67 has been shown to increase with increasing histologic grade (421, 469, 470). 
There was a higher Ki-67 labelling index in malignant tumours compared to benign ones 
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in this study. Immunohistochemical staining with the Ki-67/MIB1 antibody showed a 
robust cell proliferative marker in CMMTs and the Ki-67 labelling index was linked with 
tumour histological types. Therefore, Ki-67 immunolabelling can be useful as a biomarker 
for proliferation in CMMTs. 
3.3.4 Similar antigenic localisations (vimentin, CKAE1/AE3, CK5/6, p63 and 
E-cadherin) were detected between CMMTs and human PABs and 
MBCs 
Vimentin was detected in the mesenchymal elements of all CMMTs. CKAE1/AE3 
was detected in epithelial elements of all CMMTs, and it was localised in the cytoplasm 
of the epithelial cells. The epithelial elements in PABs were positive for CKAE1/AE3 and 
the myxoid and chondroid tissues were strongly positive for vimentin (198). Han et al. 
(2016) reported that the epithelial cells in PABs demonstrated positivity for CKs and 
myoepithelial cells showed positivity for p63, S100 and αSMA (219). Sakuma et al. (2017) 
reported that  epithelial cells were stained with CKAE1/AE4, CK5/6, CK14 and CK34bE12 
(471). It has also been reported that the epithelial cells of MBCs label positively for 
CKAE1/AE3 (472).The presence of both keratin and vimentin proteins have been 
reported in spindle cell carcinoma, which some regard as a type of MBC (473).  
More than 92% of BMTs expressed at least one of the myoepithelial/basal cell 
markers CK5/6 and p63. In addition, 100% and 77% of malignant CMMTs were positive 
for CK5/6 and p63, respectively. A previous study demonstrated that the highest 
proportion of CK5 localisation was in the spindle shaped myoepithelial cells of human 
MBCs (474). P63 expression is localised to all spindle shaped myoepithelial cells of 
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human MBCs (475). In human breast tumours, p63 also appears to be a specific marker 
for myoepithelial elements and increased expression of this marker signifies myoepithelial 
differentiation (339). In CMTs, p63 has been confirmed as a useful myoepithelial marker 
and can differentiate epithelial or myoepithelial elements from mesenchymal elements 
(286). In this current study, all tumours had areas of chondroid/osseous differentiation 
were positive for p63, indicating differentiation towards myoepithelial cells. This is in 
agreement with other research suggesting that human MBCs are of epithelial origin and 
are related to a myoepithelial-like differentiation (277). Wang et al. (2002), demonstrated 
that p63 was localised in myoepithelial cells of normal mammary glands, partially 
expressed in ductal hyperplasia, rarely expressed in carcinoma in situ and not expressed 
in invasive carcinomas (476). A large series of 34 human metaplastic carcinomas were 
studied by Tse et al. (2006); MBCs that only had epithelial elements had p63 was only 
localised in the squamous cell element, but not in the adenocarcinomatous elements. 
Eight of the 10 tumours were positive for p63. For the tumours with sarcomatoid 
elements—either individually or together with carcinomatous elements—p63 was 
expressed in 14 out of 24 cases. Pure sarcomas and carcinomas were all negative for p63 
by IHC, indicating that p63 was specific for MBCs (477). 
It has been demonstrated that decreased expression of E-cadherin is related to 
malignancy, as all benign cancers have strong intercellular labelling with this marker 
(327). E-cadherin expression was reduced or absent in all metaplastic elements, while it 
was present in the epithelial glandular areas (271). In this study, the epithelial cells of 
75% of the BMTs showed membranous localisation of E-cadherin and 96% of these 
tumours had the preserved type of E-cadherin expression (Pr type). Malignant forms of 
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CMMTs had the reduced type of E-cadherin expression (Rd type) and cytoplasmic E-
cadherin expression. Membranous E-cadherin immunolabelling was detected in epithelial 
cells of benign lesions and a reduction or loss of E-cadherin was related to the 
development of several epithelial cancers (478).  
In conclusion, this research showed that CMMTs share similar histopathological 
and molecular features as MBC and PAB. It was demonstrated that, similar antigen 
localisation (for ER, PR, HER2, p63, CKs, vimentin and E-cadherin) indicating common 
pathogenetic mechanisms in the histogenesis of these tumours. Luminal B-like tumours 
were more likely to be found in CBMT samples and the basal-like subtype was more 
commonly found in CSs. This indicates that CBMTs may have a better prognosis than 
CSs, although larger sample sizes are needed to sufficiently confirm these findings. 
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3.4 Chapter summary  
This study examined CMMT samples histopathologically, histochemically and 
immunohistochemically. It supports the use of CMMT as a model to investigate PABs and 
MBCs. This study successfully subtyped malignant CMMTs based on a panel of six 
antibodies. However, a larger sample size is required to investigate the malignant form of 
these tumours. Most of the BMTs in this study were ERα positive and ERα localisation 
was absent in more than half of the malignant CMMTs. Additionally, most of the BMTs 
were positive for PR expression and less than half of the malignant tumours were positive 
for PR expression. In this study, 62% of malignant CMMTs overexpressed HER2. 
ER+/PR+ was the most common status in BMTs and CBMTs, while ER-/PR- was the most 
common in CSs. A higher Ki-67 labelling index was demonstrated in malignant CMMTs 
compared to benign ones. Vimentin was detected in the mesenchymal elements of 
CMMTs. CKAE1/AE3 was detected in epithelial elements of all CMMTs, where it was 
localised in the cytoplasm. CK5/6 and p63 have been confirmed as useful myoepithelial 
markers in CMMTs and can differentiate epithelial or myoepithelial elements from 
mesenchymal elements. Malignant CMMTs had a reduced type of E-cadherin expression 
and cytoplasmic E-cadherin expression. Membranous and a preserved type of E-cadherin 
immunolabelling was detected in epithelial cells of BMTs.  
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4.0 Immunohistochemical localisation of cartilage and bone 
biomarkers in CMMTs  
4.1 Introduction  
The presence of areas with cartilage and bone in canine mammary gland tumours 
is not uncommon (2, 3, 280). In the majority of cases, canine mixed mammary tumours 
are benign (252). Nederbragt and Erdelyi (2005) suggested that the origin of the cartilage 
in these tumours was from myoepithelial cells that had undergone EMT (479). Gartner et 
al. (1999) and Bertagnolli et al. (1997) suggested that CMMTs with epithelial and 
mesenchymal elements may have developed from stem cells that had a high level of 
divergent activity (282, 288). This suggestion is based on IHC studies and the observation 
that the epithelial and mesenchymal elements of mixed tumours are monoclonal (282, 
287, 288). 
In recent years, considerable progress has been made in the detection of early 
stage tumours in humans (480). However, there are still no single molecular markers that 
discriminate aggressive tumours from non-aggressive ones. New markers of tumour 
progression are required for better staging and evaluation of treatments for several 
cancers (481-484). Osteopontin (OPN) has been suggested as one candidate marker for 
the progression of malignant cancers (481-484). In tumours, OPN has been suggested 
to aid cell invasion, thereby, enhancing cancer progression and invasiveness (481-485). 
Therefore, the goal was to examine the immunohistochemical localisation of OPN in 
CMMTs and assess a potential relationship with tumour malignancy in CMMTs.  
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It has been reported that during cartilage formation, Sox9 protein transactivates 
the genes encoding ECM proteins, such as aggrecan and type II collagen, which can act 
as a stepping stone for mature cartilage cells (486). Recently, Sox9 has been 
demonstrated as a requirement in the initiation and/or development of breast cancers 
(486). Moreover, there are higher Sox9 expression levels in tumour cells compared with 
normal cells (486). Since CMMTs show cartilaginous differentiation, it is reasonable to 
surmise that Sox9 could be present. It would be interesting to determine if Sox9 has a 
role in the formation of CMMTs. 
BMPs are polypeptides belonging to the superfamily of TGF-β–related growth 
factors. They stimulate endochondral bone formation when embedded ectopically into 
experimental animals (487).  BMPs are involved in all stages of cartilage formation, but 
they specifically control the expression of numerous chondrocyte genes. They are also 
essential for appropriate cartilage formation (488, 489). BMPs do not merely activate the 
condensation of chondrocytes, but they also have a powerful impact on chondrocyte 
proliferation and matrix production (490). Immunohistochemical studies of BMP 
localisation in mixed tumours of the skin and pleomorphic adenomas of salivary glands 
have shown that myoepithelial cells are strongly positive for BMPs, indicating that BMP 
localisation in these cells may contribute to the development of cartilaginous tissues in 
these tumours (370, 491). 
The Runx proteins have been shown to play both positive and negative roles in 
tumourigenesis based on different cancer types including leukemia, breast and prostate 
cancers (492). During embryonic development, Runx2 is important in the process of bone 
formation (493). After birth, Runx2 regulates bone matrix deposition, particularly collagen 
Chapter 4 - Immunohistochemical localisation of cartilage and bone markers in CMMTs 
  
162 
 
I (493). In tumourigenesis, Runx2 is considered a controller of invasion and metastasis 
(494). Increased expression of Runx2 is also associated with the metastasis of the 
primary bone tumour (osteosarcoma) (495). Runx2 positivity has also been shown in 
normal ductal cells in human mammary tissue and in normal myoepithelial cells (342).  
No previous study has looked for the presence of BMP4, Runx2 and Sox9 in 
CMMTs. Since Sox9 and BMP4 are essential in cartilage formation (370, 488) and Runx2 
is crucial in bone formation (496), the localisation of these three markers should be 
investigated in CMMTs. These antigens were examined using IHC to see if these 
particular markers had potential roles in chondrogenesis and bone formation in CMMTs, 
similar to their role in HBCs. In addition, the immunohistochemical localisation of OPN 
was examined in CMMTs.  
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4.2 Results  
4.2.1 OPN is present in normal mammary and in CMMT tissues 
OPN may be one marker for the progression of malignant tumours in humans 
(293). In cancer, this protein can support cell invasion thus, enhancing tumour 
progression (293). The immunohistochemical localisation of OPN in CMMTs was 
investigated and a possible relationship of OPN expression with tumour grades (benign 
versus malignant) in CMMTs was examined. 
One hundred and one cases of CMMT (88 benign and 13 malignant) and 13 normal 
mammary tissues were stained with OPN antiserum and analysed. The thirteen cases of 
normal mammary glands (100%) were positive for OPN (see Figure 4.1A); OPN was 
present in normal fibroblasts, vascular smooth muscle cells and endothelial cells. All 101 
(100%) CMMTs expressed OPN (see Appendix 14), with benign tumours showing 
stronger immunolabelling compared with malignant tumours (see Figures 4.1B-4.1C). 
OPN was localised to the mesenchymal elements of CMMTs (see Figure 4.1D). The 
results of the analysis performed for OPN are presented in Table 4.1. The localisation of 
OPN differed significantly between normal mammary tissues, BMTs and malignant 
CMMTs (one-way ANOVA test; *p= 0.0417; see Figure 4.1E). There were significant 
differences between the localisation of OPN in normal and malignant tissues (Tukey’s 
multiple comparison test; *p= 0.0372; see Figure 4.1E). 
For the OPN immunostaining, the post hoc power was calculated using G*Power, 
and it was 0.95 (effect size f= 0.25). The calculated effect size indicated that the sample 
size was sufficient. 
Chapter 4 - Immunohistochemical localisation of cartilage and bone markers in CMMTs 
  
164 
 
 
Chapter 4 - Immunohistochemical localisation of cartilage and bone markers in CMMTs 
  
165 
 
Figure 4.1 Localisation of OPN in canine mammary tissues. (A) Strong staining for 
OPN in a normal canine mammary gland. (B) Intense expression of OPN in mesenchymal 
elements in a BMT. (C) Low OPN expression in mesenchymal elements of a CS. (D) 
Immunohistochemical staining for OPN in chondrocytes. IHC. Scale bar, 100µm. (E) The 
expression of OPN was significantly different between normal mammary, benign and 
malignant samples, *p= 0.0417. P was evaluated using one-way ANOVA test. There were 
significant differences between the localisation of OPN in normal and malignant tissues 
(Tukey’s multiple comparison test; *p= 0.0372).  
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Table 4.1 Summary of immunohistochemical localisation of OPN, Sox9, Runx2 and 
BMP4 in CMMTs. 
BMP4, bone morphogenetic protein; OPN, osteopontin; Runx2, Runt-related transcription factor 
2; Sox9, SRY-Box9. 
 
 
 
 
 
 
Molecular 
marker 
Normal mammary 
tissues 
Benign samples Malignant samples P value 
 Positive labelling 
n (%) 
Positive labelling 
n (%) 
Positive labelling 
n (%) 
 
OPN 13 (100) 88 (100) 13 (100) *0.0417 
Sox9 13 (100) 86 (98) 13(100) *0.0501 
BMP4 13 (100) 86 (98) 13 (100) **0.0022 
Runx2  13 (100) 87 (99) 13 (100) 0.3428 
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4.2.2 Sox9 protein had intracellular location in the normal mammary 
gland and in the CMMT samples 
Because of the presence of Sox9 in the nucleus or in the cytoplasm of some breast 
carcinomas (364), it was of interest to analyse its presence in CMMTs as well. Eighty-
eight BMTs, 13 malignant CMMTs and 13 normal tissues were stained with Sox9 
antiserum and analysed.  
Sox9 was demonstrated in the nuclei of epithelial cells in normal mammary, benign 
CMMT and malignant CMMT tissues (see Figure 4.2). Sox9 was also observed in the 
cytoplasm (see Figure 4.2E) of epithelial cells in malignant CMMTs. The thirteen cases 
of normal mammary glands (100%) were positive for Sox9 (see Figure 4.2A). Eighty-six 
of the 88 benign samples (98%) were positive for Sox9 (see Figure 4.2B) and only two 
(2%) were negative (see Appendix 14). All malignant CMMTs were positive for Sox9 (see 
Figure 4.2C) (see Appendix 14). Sox9 was absent in a case that had a mucoid myxoid 
matrix (no osseous or cartilage). Another case with no Sox9 expression had osteoid as a 
metaplastic tissue. There was greater Sox9 expression in malignant samples compared 
with normal or benign samples. The expression of Sox9 was significantly different 
between normal, benign and malignant samples (one-way ANOVA test; *p= 0.0501; see 
Figure 4.2F); Nuclear expression of Sox9 was more intense in malignant CMMTs than in 
benign ones. There were significant differences between the expression of Sox9 in 
normal and malignant sample groups (Tukey’s multiple comparison test; *p= 0.0396). The 
results of the analysis performed for Sox9 are presented in Table 4.1. 
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For the Sox9 immunostaining, the post hoc power was calculated using G*Power, 
and it was 0.95 (effect size f= 0.22). The calculated effect size was small, therefore, a 
larger sample size is needed in order to detect the difference between studied groups. 
Photomicrographs of Sox9 negative and positive control tissues are shown in 
Appendix 13. 
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Figure 4.2 Localisation of Sox9 in canine mammary tissues. (A) Nuclear localisation 
of Sox9 in the epithelial cells of normal mammary gland tissue. (B) Nuclear localisation of 
Sox9 in the epithelial cells of a BMT. (C) Nuclear localisation of Sox9 in the epithelial cells 
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of CS. (D) Strong nuclear localisation of Sox9 in the mesenchymal cells (chondrocytes) 
of a BMT. (E) Strong nuclear and weak cytoplasmic localisation of Sox9 was found in CS 
tissues. IHC. Scale bar, 100µm. (F) The expression of Sox9 was significantly different 
between benign and malignant tumours (*p= 0.0.501), p was evaluated by one-way 
ANOVA test. There were significant differences between the expression of Sox9 in normal 
and malignant sample groups (Tukey’s multiple comparison test; *p= 0.0396). 
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4.2.3 Increased localisation of BMP4 in CMMTs 
Due to their multifunctionality, BMPs have been studied as potential players in 
cancer (348). BMP4 localisation in tumours varies with both increased and decreased 
localisation depending on the tissue type (348). A possible role for BMP4 in CMMTs was 
investigated. 
Eighty-eight BMTs, 13 malignant CMMTs and 13 normal mammary tissues were 
immunostained with BMP4 antiserum and analysed. BMP4 expression was found in 86 
(98%) of BMTs (see Appendix 14). All malignant CMMTs (100%) were positive for BMP4 
expression (Table 4.1) (see Appendix 14).  
In normal mammary tissues, the expression pattern of BMP4 was in the cytoplasm 
and nuclei of the epithelial cells (see Figure 4.3A). In BMTs and malignant CMMTs, the 
expression pattern of BMP4 was diffused within the cytoplasm of tumour epithelial cells 
(see Figure 4.3B, 4.3C). Myoepithelial cells of normal mammary gland and BMTs were 
also positive for BMP4 (see Figure 4.3A–4.3B). Many mesenchymal cell types in these 
mixed tumours, such as osteoblasts, chondrocytes and fibroblast cells, were strongly 
positive for BMP4 (see Figure 4.3D). No immunoreactivity for BMP4 was detected in the 
myoepithelial cells in malignant CMMTs. BMP4 was absent in a case that had a mucoid 
myxoid matrix (no bone or cartilage) and had no Sox9 expression. Another case with no 
BMP4 expression did have osteoid as a metaplastic tissue. 
The expression of BMP4 was significantly different between normal, benign and 
malignant sample groups (one-way ANOVA test;**p= 0.0022; see Figure 4.3E). There 
was greater BMP4 expression in malignant samples compared with normal or benign 
samples. There were significant differences between the expression of BMP4 in normal 
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and benign sample groups (Tukey’s multiple comparison test; **p= 0.0054). There were 
also significant differences between the expression of BMP4 in normal and malignant 
sample groups (Tukey’s multiple comparison test; *p= 0.0173; see Figure 4.3E). 
 
For the BMP4 immunostaining, the post hoc power was calculated using G*Power, 
and it was 0.95 (effect size f= 0.08). The calculated effect size was small, therefore, a 
larger sample size is needed in order to detect the difference between studied groups. 
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Figure 4.3 Localisation of BMP4 in canine mammary tissues. (A) Cytoplasmic and 
nuclear expression of BMP4 in the epithelial cells of normal mammary tissue. (B) Diffuse 
cytoplasmic expression of BMP4 in the tumour epithelial cells of a BMT. (C) Cytoplasmic 
expression of BMP4 in the tumour epithelial cells of a CS. (D) Nuclear and cytoplasmic 
localisation of Runx2 in the mesenchymal cells (chondrocytes) of a BMT. IHC. Scale bar, 
100µm. (E) The expression of BMP4 was significantly different between normal, benign 
and malignant sample groups (**p= 0.0022). P was calculated by the one-way ANOVA 
test. There were significant differences between the localisation of BMP4 in normal and 
benign sample groups (Tukey’s multiple comparison test; **p= 0.0054). There were also 
significant differences between the localisation of BMP4 in normal and malignant sample 
groups (Tukey’s multiple comparison test; *p= 0.0173). 
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4.2.4 Runx2 is present in mammary epithelial cells of normal mammary 
tissue and in CMMT tissues 
Increased staining of Runx2 is associated with a poorer prognosis in human breast 
cancer (342). This current study was the first to examine Runx2 in benign and malignant 
CMMTs. It aimed to identify if this marker was significantly associated with a specific 
CMMT type. Eighty-eight BMTs, 13 malignant CMMTs and 13 normal mammary tissues 
were immunostained with Runx2 antiserum and analysed. 
Runx2 expression was demonstrated in epithelial cells of normal mammary gland 
tissues (see Figure 4.4A). Runx2 expression was also present in epithelial cell tumours 
and the chondrocytes of CMMTs (see Figures 4.4B–4.4D). Eighty-seven of the 88 benign 
CMMTs (99%) were positive for Runx2 and one (1%) was negative (a benign CMMT with 
chondroid metaplasia) (see Appendix 14). All malignant CMMTs were positive for Runx2 
(see Table 4.1) (see Appendix 14). The localisation of Runx2 was not significantly 
different between benign and malignant CMMTs (Kruskal–Wallis test; p= 0.3428; see 
Figure 4.4E). In this current study, mesenchymal cells such as fibroblasts, fibrocytes and 
myofibroblasts, in normal mammary tissues were not positive for Runx2. However, 
mesenchymal cells in myxomatous areas within CMMTs demonstrated Runx2 positivity. 
Runx2 positivity was not limited to nuclear localisation. Both benign and malignant 
CMMTs had nuclear and cytoplasmic Runx2 localisation. 
For the Runx2 immunostaining, the post hoc power was calculated using G*Power, 
and it was 0.95 (effect size f= 0.18). The calculated effect size was small, therefore, a 
larger sample size is needed in order to detect the difference between studied groups.
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Figure 4.4 Localisation of Runx2 in normal mammary and CMMT samples. (A) 
Nuclear localisation of Runx2 in the epithelial cells of normal mammary tissue. (B) Nuclear 
and cytoplasmic localisation of Runx2 in the epithelial cells of a BMT. (C) Nuclear and 
cytoplasmic localisation of Runx2 in the epithelial cells of a CS. (D) Strong nuclear 
localisation of Runx2 in the mesenchymal cells (osteocytes) of CMMT. IHC. Scale bar, 
100µm. (E) The expression of Runx2 was not significantly different between normal 
mammary, BMTs and malignant CMMTs (Kruskal–Wallis test; p= 0.3428).  
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4.3 Discussion  
Benign mixed mammary tumours are characterised by the presence of benign 
epithelial components (ductal and myoepithelial cells) and stromal cells with cartilage 
and/or bone formation. Mixed mammary tumours are categorised as malignant when the 
epithelial component changes into a malignant form (i.e. invasive carcinoma cells) (255). 
In this current study, OPN, Sox9, BMP4, and Runx2 were successfully localised in 
CMMTs. Neoplastic epithelial cells in CMMTs had higher cytoplasmic immunolabelling of 
Sox9, BMP4 and Runx2 in comparison with normal mammary glands. Runx2, BMP4, 
Sox9 and OPN were also localised in the metaplastic tissues.  
4.3.1 OPN is present in CMMTs and strong expression of OPN in 
CMMTs may not be specifically associated with malignancy.  
OPN is a non-collagenous glycoprotein that exists in mineralised tissues (497). 
Increased levels of OPN expression have been found in many types of human cancers 
including breast cancers (481, 483, 498-500). In this current study, the presence of OPN 
in benign and malignant CMMTs by IHC was investigated. In the present study, an 
increased OPN expression in normal mammary and benign tumour samples compared 
to malignant tumours was observed. Mazzali et al. (2002) demonstrated that in the human 
mammary gland, OPN was localised in epithelial cells, myoepithelial cells, fibroblasts 
and/or chondroblasts. The expression of OPN by fibroblasts indicated that OPN could 
have a role in the growth of fibrous tissue (361). It has been reported that OPN could be 
a marker of aggressive HBC and its high expression level in tumours could predict 
metastasis (501). Wang et al. (2008) reported that OPN has a higher expression in triple-
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negative human breast tumours and the presence of this molecule could be linked to 
basal-like breast tumours (502). These data contrast with our results, because BMTs had 
slightly higher immunostaining compared to malignant tumours in the present study. 
Consequently, strong expression of OPN in CMMTs may not be specifically associated 
with malignancy. It has been demonstrated that OPN was expressed in the stroma of the 
myxoid and hyaline areas of human pleomorphic adenomas (503). It has been reported 
that OPN expression was associated with malignancy of canine mammary tumours (i.e. 
adenocarcinoma) (363). 
The mechanisms by which OPN may promote malignancy are still unknown. 
Nonetheless, many theories have been proposed through studies in cultured cells. First 
of all, the capability of cells to grow in the absence of adhesion is closely related to 
tumourigenicity (504). Second, the capability of cells to migrate might be directly 
associated with their tumourigenicity and OPN is involved in pathways regulating 
migration in different cell types including osteoclasts, fibroblasts, macrophages and 
cancer cells (505). 
4.3.2 Sox9 is present in the nuclei of epithelial cells of benign and 
malignant CMMTs and cytoplasmic localisation of Sox9 is present 
in malignant CMMT tissues 
This study is the first to characterise the immunohistochemical expression of Sox9 
in CMMTs. This study reported that, in normal mammary and in BMT samples, Sox9 was 
localised in the nuclei of epithelial cells. Sox9 expression was present in both the 
cytoplasm and nuclei of epithelial cells of malignant CMMTs. Sox9 was localised in the 
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nuclei and in the cytoplasm of metaplastic tissues (i.e. chondrocytes). Chakravarty et al. 
(2011) showed that by infiltrating the ductal carcinoma of the breast, the accumulation of 
Sox9 in the cytoplasm was associated with enhanced cell proliferation (364). Gary et al. 
(2009) demonstrated that Sox9 was expressed in the nuclei of four out of four MBCs with 
chondroid metaplasia (506). It has been demonstrated that Sox9 generally plays a role in 
the transformation of mesenchymal cells to chondrocytes during the development of bone 
and cartilage. Because some metaplastic carcinomas show chondrocytic differentiation, 
it is reasonable to assume that Sox9 may be active in these cells (506).  
It was demonstrated that cytoplasmic Sox9 expression was limited to malignant 
CMMTs. This indicates that Sox9 could be a useful prognostic marker for CMMTs, similar 
to its use in human cancers. The results of this study suggest that Sox9 may be involved 
in the carcinogenesis and progression of malignant CMMTs. Its cytoplasmic expression 
could represent a potential predictive biomarker for tumour aggressiveness. Higher 
localisation of cytoplasmic Sox9 in breast cancers was associated with ER-status and a 
reduced survival rate (507). It has been suggested that cytoplasmic localisation of Sox9 
was associated with increased proliferation in breast tumour cell lines. Likewise, 
cytoplasmic Sox9 expression was associated with tumour progression and its nuclear 
expression was more frequent in earlier stages of differentiation (507). 
Overexpression of Sox9 in malignant cancers was associated with unfavorable 
prognoses in patients with various types of malignant cancers which include 
osteosarcoma (508), gastric carcinoma (509), colon cancer (510), hepatocellular 
carcinoma (511), liver and pancreatic cancer (512), ovarian cancer (513), pancreatic 
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ductal adenocarcinoma (512), esophageal and gastric cancers (514) and prostate cancer 
(515). 
4.3.3 Benign and malignant CMMTs had greater BMP4 localisation than 
normal mammary gland tissues indicating that strong localisation 
of BMP4 is cancer specific. 
The histogenesis of bone and/or cartilage in CMMTs remains unclear. 
Nevertheless, three possible origins of stromal tissues have been suggested: metaplasia 
from ductal epithelial cells, stromal connective tissues and myoepithelial cells. It has also 
been reported that the osseous tissue in canine mixed tumours is derived by 
endochondral ossification of the cartilage formed by myoepithelial cells. Moreover, it has 
been reported  that bone tissue originates by intramembranous ossification of interstitial 
connective tissues (516). Several processes in early stage development are reliant on 
BMPs for cellular growth and differentiation. BMPs also have roles in regulating 
homeostasis, which include the preservation of joint integrity, initiation of fracture healing, 
and vascular remodeling (517-519). This current study confirmed BMP4 localisation in 
ductal epithelial and myoepithelial cells in normal mammary and BMT tissues, and in 
epithelial neoplastic cells in malignant CMMTs. These findings are almost identical with 
those of cutaneous mixed tumours and salivary pleomorphic adenomas in humans (491, 
520). Ectopic endochondral ossification within mixed tumours of the foot pad in C3 (1)/Tag 
transgenic mice is associated with higher BMP2  and TGF-β-1 expression, and the 
osteoid tissue is believed to be formed by the ossification of cartilage derived from 
metaplastic myoepithelial cells (487). Furthermore, it has been reported that fibroblast 
Chapter 4 - Immunohistochemical localisation of cartilage and bone markers in CMMTs 
  
182 
 
cells and chondrocytes overexpress BMPs at the time of experimentally induced bone 
formation (521). Corresponding to ectopic cartilage and bone formation in CMMTs, the 
BMP4–positive stromal cells could also be involved, although the histogenesis of these 
mesenchymal cells in CMMTs remains to be studied. 
Yet in humans, only a few studies have examined BMP4 localisation within a 
particular tumour type (355, 522, 523). For instance, in breast tumours, the information is 
very limited (355). It has been reported that BMP4 is strongly expressed in breast cancer 
cell lines and primary breast cancers (522, 523). In this current study, benign and 
malignant CMMTs had greater BMP4 expression than normal mammary gland tissues 
implying that strong expression of BMP4 is cancer specific. In summary, the current study 
is the first of its kind to investigate the localisation of BMP4 in CMMTs.  
4.3.4 Runx2 localisation was higher in malignant than normal and 
benign samples 
The Runx gene family consists of three transcription factors, which are included in 
the differentiation of many haematopoietic lineages (Runx1), bone and cartilage (Runx2) 
and epithelial tissues (Runx3). However, these genes are involved in tumourogenesis by 
activation of Runx1 and Runx2 or suppression of Runx3 in neoplastic transformation 
(492). Runx2 antigen has the highest basal expression out of all the Runx proteins. An 
increase of Runx2 in malignant specimens contributes to carcinogenesis in esophageal 
squamous cell carcinoma (524). The results in this current study demonstrated that 
nuclear and cytoplasmic localisation of Runx2 was observed in epithelial and 
mesenchymal cells in normal mammary tissues, benign and malignant CMMT tissues. In 
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addition, although Runx2 expression was higher in malignant than normal and benign 
samples, no significant difference in Runx2 expression was observed between the 
different sample groups. Several studies suggested that high expression of Runx2-target 
genes was linked with triple negative breast cancers (10, 11). It has also been shown that 
Runx2 directs mesenchymal stem cells to an osteoblastic lineage, and prevents them 
from differentiating into the chondrocytic and adipocytic lineages (525). Also, Runx2 
overexpression in chondrocytes controls chondrocyte maturation (526). This current 
study showed no significant differences in Runx2 expression between CMMTs and 
normal tissues and this could indicate that Runx2 might play an important role in normal 
mammary gland development.  
In conclusion, there appears to be a a potential role for Sox9, Runx2 and BMP4 in 
chondrogenesis and bone formation within CMMTs. High expression of osteopontin in 
CMMTs does not appear to be related to malignancy. Future investigations on OPN, 
Sox9, BMP4 and Runx2 are necessary to further clarify the role of these biomarkers in 
CMMTs. Protein extraction is required so that quantitative analysis of Sox9, BMP4, 
RUNX2 and OPN proteins using western blotting could be carried out. Also mRNA 
expression in CMMTs could be detected by real-time reverse transcription-polymerase 
chain reaction (RT-PCR). These tumour markers could be used as an adjunct to other 
diagnostic markers in primary diagnosis and utilised as tools to indicate the presence of 
metaplastic tissues (i.e. bone and/or cartilage) in tumour.  
One of the limitations of this study was the small sample size. Only 13 malignant 
CMMT cases were available. This current research was also limited regarding its ability 
to recognise relationships between IHC staining status and survival. It would be useful to 
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investigate the expression of the OPN, Sox9, RUNX2 and BMP4 proteins and genes in 
CMMTs, and this could provide a clearer picture of the role of these proteins/genes in 
these tumours. Although our findings were very promising, a small sample size can cause 
bias and further studies are required before these conclusions can be made. 
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4.4 Chapter summary 
 
The localisation of OPN, Sox9, BMP4 and Runx2 markers were investigated in 
CMMTs. These antigens were defined using IHC in order to determine whether particular 
markers have potential roles in chondrogenesis and bone formation in CMMTs, similar to 
their role in HBCs. High expression of OPN in CMMTs does not appear to be related to 
malignancy. 
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5.0 Determination of proliferative activities in CMMT samples: A 
comparison of three methods 
5.1 Introduction  
It is challenging to suggest the biological behaviour of CMMTs by microscopical 
examination alone. Therefore, assessment of other biological variables including markers 
of cellular proliferation and expression of  steroid receptors and other biomarkers are 
useful adjuncts in forming a diagnosis and prognosis (527). Cellular proliferation is 
considered to be the most crucial biological mechanism in tumourigenesis (528). It has 
been shown that determining proliferative activity is important in cancer prognosis (528). 
In the early stages of human breast cancer, the measurement of proliferation—together 
with tumour size, lymph node status, grade of tumour and hormone receptor status—can 
be useful prognostic indicators (529). The cell cycle is composed of four different phases 
in which the cell enlarges (G1), copies its DNA (S), prepares for division (G2), and divides 
(M). The phases G1, S and G2 form interphase, which account for the span between cell 
divisions (529). Metaphase is a stage during which comparatively slight morphological 
alteration occurs in the mitotic nucleus (530). 
In addition to enumerating mitotic figures and using Ki-67 IHC, other methods have 
been used  for determining the proliferative status of cells in tissue sections, such as DNA 
flow cytometry (531), ISH (532), the use of radiolabelled molecules, and non-specific 3H-
labelling of proteins followed by the autoradiography (533-535). The main disadvantages 
of these methods are that they are costly and time-consuming (388). 
Cancer is recognised as an increasingly main cause of human death in low- and 
middle-income countries, already responsible for more mortalities than malaria, 
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tuberculosis and the acquired immunodeficiency syndrome (AIDS) (536). However, 
development of pathology services in these countries faces many challenges because of 
insufficient funds. Physicians working in low- and middle-income countries must improve 
cancer therapy by improving pathological diagnostic abilities often against a background 
of limited resources. The Argyrophilic nucleolar organiser region (AgNOR) staining 
technique is relatively simple and rapid and malignant tumours have higher level of 
AgNORs than normal tissue, reactive tissue or tissue from benign tumours (537). 
Therefore, AgNORs could help differentiate malignant from benign tumours in low 
economic settings where IHC is not available. It has been reported that some of the 
proteins in the nucleolus—including the largest RNA polymerase I subunit, upstream 
binding factor (UBF) and nucleolin—are stained with a silver staining technique that is 
utilised to visualize the NORs on metaphase chromosomes (538). Ki-67 expression 
begins at the G1 phase and this expressions enhanced during the S phase and reaches 
its highest level during metaphase, or the M phase. During the stage of anaphase and 
telophase, the Ki67 expression begins to reduce (539). 
CMMTs have been validated as a model for human mixed mammary tumours (9). 
The study of biomarkers in CMMTs could therefore provide insight into their roles in 
human mixed mammary tumours. To the best of our knowledge, there are no studies that 
have compared the diagnostic utility of the mitotic index, Ki-67 labelling index and 
expression of AgNORs in CMMTs. Therefore, the objective of this study was to evaluate 
these three markers of cellular proliferation in CMMTs. The specific aims were: 
1. To determine whether AgNORs can differentiate between BMTs and malignant 
CMMTs. 
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2. To determine whether there is relationship between (i) mean AgNOR count/nucleus, 
(ii) mean AgNOR area (pixels2)/nucleus, (iii) the mitotic index, and (iv) the Ki-67 labelling 
index.  
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5.2 Results 
5.2.1 Mitotic scores were significantly higher in the malignant CMMTs 
than in normal and BMT tissues  
Seventy-seven cases of CMMT and 30 normal mammary tissues were studied by 
histochemical, immunohistochemical and morphometric methods. Mitotic index, AgNOR 
count, AgNOR area and Ki-67 labelling index were examined.  
Of the CMMTs, 68 (88%) were benign and nine (12%) were malignant mixed 
tumours. Microscopically, all normal mammary gland tissues (100%) and all cases of 
BMTs (100%) had low mitotic scores (i.e. a score of 1). Three of the nine malignant 
CMMTs (33%) had high mitotic scores (i.e. a score of 3), and six (67%) had lower mitotic 
scores; four (45%) had of a score 1 and two (22%) had of a score 2 (Figure 5.1A, 5.1B) 
(see Appendix 15). Higher mitotic scores occurred more frequently in the malignant 
CMMTs than in the normal mammary tissues and samples of BMT. The Kruskal-Wallis 
test demonstrated a significant difference (****p< 0.0001) between the median mitotic 
score in each group. The Dunn's multiple comparison test (540) showed significant 
differences between normal mammary tissues and malignant CMMT tissues (****p< 
0.0001) and between benign and malignant tumours (****p< 0.0001) (Figure 5.1C).  
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Figure 5.1 Mitotic score determination in CMMT tissues. (A) BMT showing low mitotic 
scores. H&E. Scale bar, 100µm. (B) Malignant CMMT showing frequent mitotic figures 
(black arrows). H&E. Scale bar, 100µm. (C) Scatter dot plot depicting mitotic scores in 
normal mammary tissue and samples of BMTs and malignant CMMTs. Mitotic scores 
were significantly different between normal mammary tissue, BMTs and malignant 
CMMTs (Kruskal-Wallis test; ****p< 0.0001). Dunn's multiple comparison test showed 
significant differences between normal mammary tissues and malignant CMMTs (****p< 
0.0001) and between benign and malignant tumours (****p< 0.0001). 
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5.2.2 Malignant CMMTs demonstrated a higher proliferation index than 
normal mammary and BMT tissues  
Ki-67 immunolabelling was restricted to the nuclei of the epithelial cells of normal 
mammary tissues and samples of CMMTs (Figure 5.2A-5.2C). High Ki-67 localisation 
in tumour cells indicated higher proliferation rates. Eight of the nine malignant CMMTs 
(88%) had high proliferation rates (Ki-67 labelling index ≥10%). Only three of the 30 
normal mammary tissues (10%) and 11 of the 68 BMT tissues (16%) had high proliferation 
rates (Ki-67 labelling index ≥10%). Ki-67 labelling index varied between the normal 
tissues and the different histological subtypes of CMMTs (Kruskal-Wallis test; ****p< 
0.0001) (Figure 5.2D). The Dunn's multiple comparison test showed significant 
differences between normal mammary tissues and malignant CMMTs (****p< 0.0001) and 
between benign and malignant tumours (*p= 0.0222) (Figure 5.2D). 
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Figure 5.1 Ki-67 localisation in normal mammary tissue and samples of CMMTs. (A) 
Low Ki-67 labelling index in normal canine mammary tissue. (B) Low Ki-67 labelling index 
in a BMT. (C) High Ki-67 labelling index in a malignant CMMT. Ki-67 IHC. Scale bar, 
100µm. (D) Ki-67 labelling index is significantly different between normal mammary 
tissue, BMTs and malignant CMMTs (****p< 0.0001, Kruskal-Wallis test). Dunn's multiple 
comparison test showed significant differences between normal mammary tissue and 
malignant tumours (****p< 0.0001) and between benign and malignant tumours (*p= 
0.0222). 
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5.2.3 Pleomorphism of AgNORs in normal mammary tissues and in 
CMMT samples 
The AgNOR silver-stained slides of the 30 samples of normal mammary tissue and 
the 77 CMMTs showed brown to black dots within the orange-stained nuclei (Figure 5.3). 
The AgNOR dots were spread around the nucleus as satellites or gathered together as 
clusters. Satellite AgNORs (single and scattered) were predominant in normal tissues and 
CMMTs. Small, well defined (Figures 5.3A, 5.3B and 5.3D) and single (Figures 5.3A-
5.3C) dots were noted more frequently in the epithelial cells of normal mammary tissue 
and BMTs. In addition, single and irregular dots were noted in the epithelial cells of BMTs 
(Figure 5.3C). Medium, large, irregular, coarse and semi-solid dots were noted more 
frequently in the epithelial cells of malignant CMMTs (Figures 5.3E-5.3G). Moreover, fine 
granular dots of AgNORs in the nucleoli were more frequently found in the epithelial cells 
of malignant CMMTs (Figure 5.3H). The AgNOR dots in the cartilage cells (Figure 5.3I) 
were spread around the nucleus as single to numerous satellite dots in the chondrocytes.  
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Figure 5.2 The patterns of AgNOR silver staining in normal mammary and CMMT 
tissues. (A) Small, satellite, symmetrical and regular dots in normal mammary gland. (B) 
Small, satellite, symmetrical and regular dots in a BMT. (C) Single and irregular dots in a 
BMT. (D) Small, single or multiple and regular AgNOR dots in a BMT. (E) Regular and 
large AgNOR dots in a malignant CMMT. (F) Irregular and large AgNOR dots in a 
malignant CMMT. (G) Kidney-shaped AgNOR dot in a malignant CMMT. (H) Fine 
granular AgNORs in a malignant CMMT. (I) Small, satellite, symmetrical and regular dots 
in mesenchymal tissue (i.e. chondrocytes). AgNOR silver stain. Scale bar, 100µm. 
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5.2.4 Mean AgNOR count/nucleus was significantly higher in the 
malignant CMMTs than in normal mammary and BMT tissues 
The mean number of AgNORs/nucleus ± SEM for the normal mammary tissues 
was 0.57 ± 0.04 and the median was 0.76 (Figure 5.4A). For the BMTs, the mean number 
of AgNORs/nucleus was 0.56 ± 0.02 and the median was 0.52 (Figure 5.4B). For the 
malignant CMMTs the mean number of AgNORs/nucleus was 0.83 ± 0.08 and the median 
was 0.81 (Figure 5.4C) (see Appendix 15). The Kruskal-Wallis test showed a significant 
difference (*p= 0.0087) between the median number of AgNORs in each group. The 
AgNOR count/nucleus was higher in malignant CMMTs than in normal or BMT tissues. 
There were significant differences between the mean number of AgNORs/nucleus in 
normal and malignant tissues (Dunn's multiple comparison test; *p= 0.0220). There were 
also significant differences between the mean number of AgNORs/nucleus in benign and 
malignant tumours (Dunn's multiple comparison test; **p= 0.0064) (Figure 5.4D). 
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Figure 5.3 Determination of the mean AgNOR count/nucleus in normal mammary tissue and CMMTs. (A) Small and 
single AgNOR dots in normal mammary tissue. (B) AgNOR dots in a BMT; epithelial element in a BMT showing 1-2 nuclear 
dots of AgNORs. (C) AgNORs in a malignant CMMT; malignant CMMT showing small, medium, single and/or scattered fine 
dots of AgNORs. AgNOR silver stain. Scale bar, 100µm. (D) Scatter dot plot depicting the mean AgNOR number/nucleus 
in normal tissue and samples of CMMT. The Kruskal-Wallis test shows a significant difference (**p= 0.0087) between the 
median numbers of AgNORs in each group. The mean AgNOR number/nucleus was significantly different between normal 
tissue and malignant tumours (*p= 0.0220) using Dunn’s Multiple Comparison test. The mean AgNOR number/nucleus was 
also significantly different between benign and malignant tumours (**p= 0.0064) using Dunn’s Multiple Comparison test.  
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5.2.5 Mean AgNOR area (pixel2)/nucleus among the malignant CMMTs 
was significantly higher than in the normal mammary and BMT 
tissues 
The mean area of AgNORs (pixel2)/nucleus ± SEM for the normal tissues was 1.50 
± 0.06 and the median area of AgNORs (pixel2)/nucleus was 1.44. For the BMTs the 
mean area of AgNORs (pixel2)/nucleus was 2.47 ± 0.09 and the median was 2.28. For 
the malignant CMMTs the mean area of AgNORs (pixel2)/nucleus was 6.61 ± 2.89 and 
the median was 3.90 (Figure 5.5A-5.5C) (see Appendix 15). The Kruskal-Wallis test 
showed a significant difference (****p< 0.0001) between the median area of AgNORs in 
each group that was studied. The AgNOR area/nucleus was higher in malignant CMMTs 
than in normal or BMT tissues. There were also significant differences between the mean 
area of AgNORs/nucleus in normal mammary tissues and samples of BMTs (Dunn's 
multiple comparison test; ****p< 0.0001). There were significant differences between the 
mean area of AgNORs/nucleus in normal mammary tissue and BMTs (****p< 0.0001), as 
well as between BMTs and malignant CMMTs (Dunn's multiple comparison test; *p= 
0.0407) (Figure 5.5D).    
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Figure 5.4 Determination of the mean AgNOR area/nucleus in normal mammary tissue and CMMTs. (A) Normal 
canine mammary tissue displaying small and regular shaped AgNORs. (B) BMT showing small and regular shaped 
AgNORs. (C) Malignant CMMT showing large and (coarse to semi-solid) AgNORs in the nucleoli. AgNOR silver stain. Scale 
bar, 100µm. (D) Scatter dot plot depicting the mean AgNOR area/nucleus in normal mammary tissue and BMTs and 
malignant CMMTs; Kruskal-Wallis test shows a significant difference (****p< 0.0001) between the median area of AgNORs 
in each group. Dunn’s multiple comparison test shows significant differences between normal mammary tissue and BMTs 
(****p< 0.0001) between normal mammary tissue and malignant CMMTs (****p< 0.0001) and between benign and malignant 
tumours (*p= 0.0407).  
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5.2.6 Correlations between Ki-67, mitotic score index and AgNORs in 
CMMTs 
By using linear regression analysis, there was a significant correlation between the 
Ki-67 labelling index and the AgNOR count/nucleus among CMMTs (r2= 0.056; p< 
0.0373; it's very low but significant) (Figure 5.6 A). A high mitotic score was associated 
with an elevated Ki-67 labelling index (r2= 0.058; p< 0.0346; it's very low but significant) 
(Figure 5.6B). There was a significant relationship between the mitotic score and the 
AgNOR count/nucleus (r2= 0.13; p< 0.0011) (Figure 5.6C). A significant correlation 
between the mean mitotic score and the AgNOR area/nucleus (r2= 0.34; p< 0.0001) was 
demonstrated (Figure 5.6D). However, there was no significant correlation between the 
AgNOR count/nucleus and AgNOR area/nucleus (r2= 0.017; p= 0.2492) (Figure 5.6E). 
No significant positive correlation was found between Ki-67 labelling index and AgNOR 
area/nucleus (Figure 5.6F) (r2= 0.012; p= 0.3351). 
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Figure 5.5 Linear regression analysis of the Ki-67 labelling index, mean AgNOR 
count/nucleus, mean AgNOR area/nucleus and mean mitotic score. (A) A significant 
correlation was found between the Ki-67 labelling index and the AgNOR count/nucleus 
among CMMTs (linear regression analysis; r2= 0.056; p= 0.0373). (B) A Significant 
correlation was found between the mitotic count and Ki-67 labelling index (linear 
regression analysis; r2= 0.058; p= 0.0346). (C) A Significant relationship was found 
between mitotic score and AgNOR count/nucleus (linear regression analysis; r2= 0.13; p= 
0.0011). (D) A significant correlation between the mean mitotic score and the AgNOR 
area/nucleus (linear regression analysis; r2= 0.34; p< 0.0001) was demonstrated. (E) No 
significant correlation was found between the AgNOR count/nucleus and AgNOR 
area/nucleus (linear regression analysis; r2= 0.017; p= 0.2492). (F) No significant positive 
correlation was found between Ki-67 labelling index and AgNOR area/nucleus (linear 
regression analysis; r2= 0.012; p= 0.3351). 
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5.3 Discussion  
The present study was carried out to assess the utility of the silver 
staining technique (AgNOR method) in differentiating between BMTs and malignant 
CMMTs. Furthermore, this experiment was conducted to find an affordable and simple 
way to measure tumour proliferation in CMMTs as an alternative to the use of 
immunohistochemical techniques. 
The management of human breast cancer relies on evaluation of several 
morphological and biological variables. These involve the type of tumour and its grade, 
the presence of local invasion and nodal metastases, the degree and quantity of nuclei 
displaying atypia (e.g. mitotic activity, pleomorphism and hyperchromatism) and the 
presence or lack of hormone receptors (541). Pleomorphism is the variation in the size 
and shape of the cell or nucleus. Factors including nucleolar-nuclear ratios, nuclear-
cytoplasmic ratios and cellular and nuclear areas have been used to define dysplasia  
(541). The silver staining technique (AgNOR) does not detect rRNA nor rDNA, but detects 
the acidic proteins associated with the sites of rRNA transcription (542).  
AgNOR proteins are a group of nuclear proteins that are found in highly 
proliferating cells (542). In proliferating cells, the amount of interphase AgNOR proteins 
gradually increase from the early G1 phase to a maximum concentration at the end of the 
S-phase, which remains at that level until the G2 phase. Studying the quality of AgNOR, 
which is dependent on their size, shape and distribution pattern, permits identification of 
the stage of differentiation of the altered cells (542). AgNOR pleomorphism is the product 
of cellular alterations that are obviously associated with the progression of the lesion to 
malignancy (542). This study found that The AgNOR dots tend to be small and regular in 
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the normal or benign lesions and as the lesions turn into malignancy, the AgNOR dots 
became irregular, large dots or bizarre dots. 
The results of the present study showed a significant increase in the mean AgNOR 
values (number and area) among the different tissues that were studied. The mean 
AgNOR area/nucleus in the normal mammary tissues was lower than the mean values in 
the BMTs and malignant CMMTs. The mean AgNOR count/nucleus was also lower in the 
normal mammary tissue and in samples of BMTs than in malignant CMMTs. The mean 
AgNOR count/nucleus and AgNOR area/nucleus were significantly higher in the 
malignant CMMTs than in the BMTs. AgNOR numbers rise with increased cell ploidy and 
with increased transcriptional activity in the phases of active cell proliferation. Differences 
in the size and/or count of the AgNOR dots might depend on the stage of the cell cycle, 
and the transcriptional and metabolic activity of the cell (543). 
Previously, AgNOR counts have been used to distinguish between various grades 
of human malignancies. Correlations between AgNOR counts and the histological grade 
of salivary gland carcinomas, central nervous system tumours and pulmonary carcinomas 
have been reported (544-546). The inclusion of area measurements utilizing image 
analysis provides enhanced diagnostic and prognostic accuracy (547). 
Increased AgNOR areas have been shown with increased grades of malignancy 
in many human tumour types including breast cancers (537), non-Hodgkin’s lymphoma 
(548), colon cancers (549) and  melanocytic tumours of the skin (550). They  have also 
been demonstrated in the oral cavity, where increased mean AgNOR area/cell was 
observed in patients with moderate and severe dysplasia in comparison to those with mild 
dysplasia (551). High AgNOR counts indicate increased cellular proliferative status (548) 
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and a worse prognosis in malignant human tumours (552). Cabrini et al. (1992) also 
demonstrated increasing AgNOR area when normal human oral epithelium transformed 
firstly to benign neoplasia and then to squamous cell carcinoma (553). It has been found 
that high grade human breast tumours have increased AgNOR number/size compared 
with low grade tumours (547). The relationship between the number/size and histological 
grade demonstrated that, in normal human breast tissue, one or two AgNORs may be 
found, but this number increased in neoplasia and with the extent of dedifferentiation of 
neoplastic tissues (547). Derenzini et al. (1988) demonstrated that the number or size of 
AgNORs was not only closely associated with cellular proliferative activity, but also with 
cellular differentiation. Therefore, assessment of AgNORs could be a tool for identifying 
malignancy and the grade of the tumour (554).  
The relationship of prognostic parameters including the mitotic index, AgNOR 
count/nucleus, AgNOR area/nucleus and Ki-67 labelling index in CMMTs was evaluated 
in this current study. A significant correlation between AgNOR count/nucleus, mitotic 
indices and Ki-67 labelling index was identified between BMTs and malignant CMMTs. In 
addition, a significant correlation between AgNOR area/nucleus and mitotic indices was 
identified. In human neoplasia, Sennerstam and Auer (1990) reported that although the 
mitotic index is considered to be a good indicator of cellular proliferation, there are 
restrictions to its reliability, as mitosis rates differ specifically in aneuploid cancers (555). 
Moreover, the cell cycle itself varies in duration and blocks may occur in mitotic 
metaphase. All of these variables might change the percentage of visible mitosis within 
the specific tumour at various times (556). Different studies in human breast cancers have 
showed that the cellular proliferation markers, including the mitotic index and Ki-67 
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labelling index, were positively correlated and were related to breast cancer prognosis 
(557-560).  
Mitotic activity is a commonly used criterion for evaluating cancers in humans and 
animals (561). Counting the number of mitotic figures in 10 high-power fields results in a 
mitotic count (561). Mitotic count is determined most commonly in veterinary oncology, 
often at 400x magnification, but the area counted is infrequently defined, and the term 
usually reported is mitotic index (561). Mitotic index is the number of cells undergoing 
mitosis divided by the number of cells not undergoing mitoses. This could be recognised 
in histologic sections and is documented as a percentage, or mitoses per 1000 cancerous 
cells (561). Each parameter that estimates cell proliferation has advantages and 
disadvantages (561). Mitotic count is simple, economical and rapid for pathologists to 
determine. Standardisation of mitotic count could increase the important of this parameter 
(561). Most studies in veterinary pathology report mitotic index when counting mitotic 
figures, but mitotic index is not a standardised technique and does not take into account 
cell size and the impact of time prior to sample fixation on identification of mitosis (561, 
562). In some circumstances, pathologists may have challenges in discriminating mitoses 
and necrosis and some phases (i.e. prophase and anaphase) are hard to recognise in 
H&E-stained sections. Despite this, the determination of mitotic index or count on H&E-
stained sections of tumour tissue has some clinical significance (562). The main 
advantage is that histopathologic diagnosis and mitotic activity can be evaluated 
simultaneously, making determination of the mitotic index one of the most practical 
techniques for assessing cellular proliferation (562). Mitotic activity could also be 
determined in a particular area or volume of tumour and is defined as number of mitotic 
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figures per given volume of tumour. Meuten et al. (2016) reported that mitotic index 
correlates with other proliferative indices better than mitotic count or mitotic activity index. 
Nevertheless, determining the mitotic index would require counting cells not in mitosis in 
addition to those in mitosis (561).  
The Ki-67 labelling index is commonly used for measuring cellular proliferation in 
tissue sections. The Ki-67 labelling index is represented as the labelled proportion of the 
total number of tumour cells evaluated (563). It has been shown that higher grade tumours 
have a higher Ki-67 labelling index (563). 
Instead of identifying which cells are involved in specific phases of the cell growth 
cycle, an alternative approach to evaluating cellular proliferation is to identify antigens 
that are related to proliferation by IHC. This approach is quicker, less expensive and less 
complicated than flow cytometry or autoradiography and is also more accurate and 
reproducible than simple measurements of mitotic figures (529). 
In AgNOR staining, the quantity of silver deposited in the nucleus, reflects the 
amount of NORs that are involved in protein synthesis, and therefore is associated with 
the proliferative activity of the cell (388). Therefore, the evaluation of AgNORs is useful 
for determining the malignancy of tumours when more expensive methods are 
uneconomical or not available (388). Measurement and quantification of AgNORs could 
be valuable in predicting the behavior of a several human tumours, specifically in 
instances where mitotic index is a poor determinative of ultimate recurrence of metastasis 
(564). 
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In some tumours, elevated AgNOR expression is associated with increased Ki-67 
expression (565) and  with mitotic activity, while in others AgNOR expression might also 
be associated with aneuploidy (565-567). Ki-67 labelling provides a more precise index 
of proliferation because it identified all the phases of the cell cycle except for G0. 
Nevertheless, it requires conventional IHC for reliable results. The use of AgNOR staining 
has the benefit that it can be used with samples that have been received for routine 
procedures in anatomical pathology laboratories.  Moreover,  tumour sections do not need 
special fixation which is required for Ki-67 and AgNORs have a longer half-life than Ki-67  
(547). 
The main limitation of this study was the relatively small number of high grade 
tumours. Future studies should correlate AgNORs, flow cytometry or the incorporation of 
thymidine or BrdU, to examine if AgNORs is a useful method for tumour grading. Each of 
these techniques has been demonstrated to have prognostic value in breast tumours. 
The present study has concluded that AgNOR size and number correlate well with 
different histological types of CMMTs. AgNOR count correlates better than AgNOR area 
with the Ki-67 labelling index.  Thus, AgNOR count may be more important than area 
alone for evaluating malignant CMMTs. AgNOR staining, which is cheaper than 
immunohistochemical methods can be a useful tool for distinguishing benign from 
malignant tumours.  
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5.4 Chapter summary 
Apart from the mitotic index and Ki-67/MIB1 IHC, other methods have been used 
in the past for determining proliferative cells in tissue sections (DNA fluorocytometry, ISH 
and autoradiography). The main disadvantages of these methods are that they are costly 
and time-consuming. NORs are known to selectively stain using silver-based histological 
stains. AgNORs are increased in malignant CMMTs compared to normal mammary and 
benign CMMT tissues. The three main proliferative biomarkers (mitotic index, Ki-67 
labelling index and AgNOR values) were examined to determine the role of AgNORs in 
differentiating benign from malignant CMMTs. Furthermore, a correlation between mean 
AgNOR values with the mitotic figure count and with Ki-67 labelling index was 
investigated. It was discovered that the staining of AgNORs is one method that can be 
used to assess if a tumour is benign or malignant. Moreover, this method has many 
advantages to become more preferable: convenience, affordability and correlates well 
with other proliferative markers. 
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6.0 Immunohistochemical localisation of receptor activator of 
nuclear factor kappa-B ligand (RANKL) and its receptor RANK in 
canine mixed mammary tumours 
6.1 Introduction 
The receptor activator of nuclear factor kappa-Β ligand (RANKL) is the only known 
ligand for RANK (568). In humans, RANKL is localised in many tissues and organs such 
as mammary glands (569), thymus (570), small intestine (571), lymph node (572), liver 
(573), prostate (574), skeletal muscle (575) and bone (568).  
RANKL is secreted by osteoblasts and binds to RANK on the osteoclast to 
enhance osteoclastogenesis, which leads to the resorption of bone, osteoporosis and 
bone metastasis (576). Inhibiting the RANK/RANKL signalling appeared as a realistic 
strategy to stop osteoporosis. As a result, the anti-RANKL monoclonal antibody 
Denosumab is used for treating osteoporosis and bone-related events secondary to 
osseous metastases (577). RANKL is also an important paracrine influencer of the 
mitogenic activity of progesterone in breast epithelium (578). RANK expression is not 
confined to the bone, as it has been described in other human tissues, such as cartilage 
(579), mammary gland (580), kidney (581), brain (582) and lung (583). 
Regardless of the improvements made in breast cancer care and programs, breast 
cancer still imposes a significant load on health care systems, in particular when there 
are metastatic tumours (584). Most mammary gland tumours develop in women during 
their 6th decade of life. Roughly 5–10% of mammary gland tumours are attributable to 
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inherited mutations (585), although, for most cases, a specific causative mutation cannot 
be identified. These situations are termed “familial breast and ovarian cancer syndrome” 
and are identified by the recurrent occurrence of mammary and ovarian tumours 
throughout a family line. The pathogenesis is multifactorial and can result from numerous 
mutations that increase susceptibility to tumourigenesis (586). Of the inherited breast 
tumours cases, a large proportion is triggered by mutations in the BRCA1 and BRCA2 
genes. BRCA1-mutation carriers have an 85% risk of acquiring breast tumours and 
roughly 45% risk of acquiring ovarian tumours (586). The BRCA2 gene mutation 
increases the lifetime threat of developing a breast tumour to around 66% and an ovarian 
tumour to around 12% (587). Sigl et al. (2016) examined RANK expression in human 
breast cancers that had BRCA1/BRCA2 mutations, and in non-BRCA1/2 mutated 
carriers. High RANK expression was identified in BRCA1/2 carriers but only with lower 
levels in  BRCA1/BRCA2 WT tumours (588). 
Mammary gland tumours (particularly those that develop in BRCA1-mutation 
carriers) usually show basal-like features and they are identified by the expression of 
genes specific to the myoepithelial cells of the breast (589). Furthermore, BRCA1-
mutated mammary gland tumours often do not express ER or PR and lack overexpression 
of the HER2 oncogene (589), therefore, they are considered as triple negative tumours. 
In contrast, 77% of mammary gland tumours in BRCA2-mutation carriers are ER-positive 
and only about 16% are triple negative (12, 590). Women with a BRCA1 mutation have 
higher progesterone and estrogen levels during the luteal phase of the menstrual cycle in 
comparison with their siblings who lack the mutation (12, 591). Moreover, it was proven 
that serum concentrations of RANKL and its decoy receptor osteoprotegerin (OPG) are 
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dysregulated in the germ line of BRCA1-mutation carriers (591). It is well known that 
reduced OPG serum levels are related to a higher risk of mammary tumour development 
(591). Inhibition of RANKL could present a promising strategy to minimise the risk for 
developing mammary tumours in BRCA1-mutation carriers (592).  
Many of the human tumour predisposition genes have been demonstrated in the 
constitutional DNA of dogs with CMTs, including BRCA1/BRCA2 germline mutations 
(593, 594), which cause hereditary breast and ovarian cancer syndrome in humans. 
Also TP53 germline mutations in dogs have been found (595), which cause Li–Fraumeni 
syndrome (LFS) in humans that result in a range of tumours. The tumour suppressor 
gene, PTEN is downregulated in a high number of canine osteosarcoma cell lines and 
cancers and it probably has a role in the histogenesis of canine mammary tumours (596).  
It has been reported that BRCA1 and BRCA2 mutations promote the risk of canine 
mammary tumour in English Springer Spaniels, indicating that dogs may be a good model 
for human breast cancer (597). The utilisation of CMMT in this project—as a model for 
human mixed mammary tumours—has previously been validated (9), taking into 
consideration the parallels between HBCs and CMTs histopathologically, 
epidemiologically and genetically. A BRCA1 mutation is expected to promote tumour 
development in all tissues (586). More specifically, BRCA1-mutation carriers develop 
breast and ovarian tumours more regularly than non-carriers (586). Therefore, the aim of 
this study was to localise RANKL and its receptor RANK in CMMTs and to identify if these 
markers were significantly associated with CMMT histological types (i.e. BMTs, CBMTs 
and CSs).  
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6.2 Results 
6.2.1 Clinical epidemiological findings 
In this current study, there were 20 (30%) normal mammary glands, 37 (55%) 
cases of BMTs and 10 (15%) cases of malignant CMMTs. Of the ten malignant cases, 
five (7.5 %) were CSs and five (7.5 %) were CBMTs. All 67 cases had a mean age of 
9.329 ± 2.456 years.   
6.2.2 RANKL is present in canine mammary gland tissue and its 
positivity is progressively increased in canine neoplastic lesions 
Thirty-seven BMTs, 10 malignant CMMTs (five CBMTs and five CSs) and 20 
normal mammary tissues were stained with RANKL antiserum and examined (see Table 
6.1). Overall RANKL positivity was greater in malignant CMMTs when compared with 
normal mammary and BMT tissues. 
RANKL immunolabelling was in the cytoplasm of epithelial cells of normal 
mammary and CMMT samples (see Figure 6.1). The same antigen was identified in the 
cytoplasm of chondrocytes in all cases involving cartilaginous metaplasia (see Figure 
6.1E). Diffused cytoplasmic staining was seen in CMMT samples.  
Eleven of the 20 (55%) normal samples were positive for RANKL and nine (45%) 
were RANKL negative. Thirty-one of the 37 (84%) BMTs were RANKL positive and six 
(16%) were RANKL negative. RANKL positivity was higher in CBMTs and CSs. Four of 
the five (80%) CBMTs were RANKL positive and five of the five (100%) CSs were also 
RANKL positive tumours (see Table 6.1) (see Appendix 16).  
Chapter 6 - Immunohistochemical localisation of RANKL and its receptor RANK in CMMTs 
218 
 
Table 6.1 Distribution of RANKL positive samples in normal mammary, BMT, CBMT 
and CS tissues. 
Case No. of cases  RANKL positive cases  
n (%) 
Normal mammary tissue 20 11 (55) 
Benign  37 31 (84) 
BMT 37 31 (84) 
Malignant  10 9 (90) 
CBMTs 5 4 (80) 
CSs 5 5 (100) 
BMT, benign mixed mammary tumour; CBMT, carcinoma in benign mixed mammary tumour; CS, 
carcinosarcoma; RANKL, receptor activator of nuclear factor kappa-B ligand. 
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Figure 6.1 Localisation of RANKL in normal mammary and CMMT tissues. (A) The 
localisation of RANKL in the cytoplasm of the epithelial cells of normal mammary tissue. 
(B) The localisation of RANKL in the cytoplasm of the epithelial cells of a BMT. (C) The 
localisation of RANKL in the cytoplasm of the epithelial tumour cells of a CBMT. (D) The 
localisation of RANKL in the cytoplasm of the epithelial cells of a CS. (E) The localisation 
of RANKL in the cytoplasm of chondrocytes in a CBMT. IHC. Scale bar, 100 µm. 
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The mean number of the RANKL H-score ± SEM for the normal mammary tissues 
was 11.85 ± 3.20 and the median was 8.21 (see Figure 6.2).  For the BMTs, the mean 
was 53.98 ± 5.38 and the median was 58.37 (see Figure 6.2). For the CBMTs the mean 
was 71.96 ± 18.37 while the median was 84.26 (see Figure 6.2), and for the CSs the 
mean was 78.77 ± 25.13 and the median was 88.49 (see Figure 6.2). The Kruskal–Wallis 
test showed that there was a significant difference in the localisation of RANKL between 
the normal control group and the different types of CMMTs with the highest variation 
observed between the normal mammary tissue samples and the BMTs (see Figure 6.2). 
The Kruskal–Wallis test showed a statistically significant difference (****p< 0.0001) 
between the median H-scores for RANKL in each group studied (see Figure 6.2). The 
Dunn’s multiple comparison test showed that there were statistically significant 
differences for the comparisons between normal mammary and BMT samples, between 
normal and CBMT samples and also between normal and CS samples (****p= 0.0001), 
(**p= 0.0074) and (p= 0.0085) respectively (see Figure 6.2). 
 
For the RANKL immunostaining, the post hoc power was calculated using 
G*Power, and it was 0.98 (effect size f= 0.93). The calculated effect size indicated that 
sample size was more than sufficient. 
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Figure 6.2 Comparison of the mean H-scores for RANKL in canine mammary 
samples. The localisation of RANKL was significantly different between normal 
mammary and CMMT tissues ****p< 0.0001. P was assessed by the Kruskal–Wallis test. 
The graph showing statistically significant differences between normal mammary and 
BMT samples, the normal and CBMT samples and also between normal and CS samples 
(***p= 0.0001), (**p= 0.0074) and (**p= 0.0085) respectively by using Dunn’s multiple 
comparison test. 
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6.2.3 RANK is present in normal mammary, BMT, CBMT and CS 
samples 
To evaluate whether CMMTs express RANK, IHC was used to assess the 
localisation of RANK in 37 BMTs, five CBMTs, five CSs and 20 normal control tissues 
(see Table 6.2). As shown, the normal mammary and CMMT tissues exhibited positive 
staining for RANK (see Figure 6.3). RANK was located in the cytoplasm of epithelial cells 
of ducts and glands found in normal mammary tissues, BMTs and cancerous epithelial 
cells in CBMTs and CSs (see Figure 6.3). However, some cases presented nuclear (see 
Figures 6.3B, 6.3D & 6.3F) and membranous RANK expression (see Figure 6.3F). RANK 
was located in the cytoplasm and nuclei of chondrocytes in CMMTs (see Figure 6.3E). 
As can be seen in Table 6.2, normal mammary tissues were positive for RANK in 20 
(100%) samples. All (100%) BMTs, (100%) CBMTs and (100%) CSs were RANK positive 
(see Appendix 16). 
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Table 6.2 Distribution of cases stained for RANK. 
Case No. of cases  RANK positive cases  
n (%) 
Normal mammary tissue 20 20 (100) 
Benign  37 37 (100) 
BMT 37 37 (100) 
Malignant  10 10 (100) 
CBMTs 5 5 (100) 
CSs 5 5 (100) 
BMT, benign mixed mammary tumour; CBMT, carcinoma in benign mixed mammary tumour; CS, 
carcinosarcoma; RANK, receptor activator for nuclear factor Kappa-B. 
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Figure 6.3 Localisation of RANK in canine mixed mammary tumours. (A) 
Cytoplasmic localisation of RANK in the epithelial cells of normal mammary tissue. (B) 
Cytoplasmic localisation of RANK in the epithelial cells of a BMT. (C) The localisation of 
RANK in the cytoplasm of the epithelial tumour cells of a CBMT. (D) The localisation of 
RANK in the cytoplasm and nuclei of the epithelial cells of a CS. (E) The localisation of 
RANK in the cytoplasm and nuclei of chondrocytes in a CS. (F) Cytoplasmic and 
membranous localisation of RANK was observed in a BMT. IHC. Scale bar, 100 µm. 
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The mean number of the RANK H-score ± SEM for the normal mammary tissues 
was 67.49 ± 9.93 and the median was 66.44 (see Figure 6.4).  For the BMTs, the mean 
was 113.3 ± 8.80 and the median was 98.72 (see Figure 6.4). For the CBMTs, the mean 
was 159.8 ± 36.96 and the median was 125.2 (see Figure 6.4), and for the CSs the mean 
was 221.2 ± 18.32 and the median of the RANK H-score was 207.0 (see Figure 6.4). The 
Kruskal–Wallis test showed that there was a significant difference in the localisation of 
RANK between all four types of canine mammary tissue with the highest variation 
observed between the normal mammary and the CS samples (see Figure 6.4). The 
Kruskal–Wallis test showed a statistically significant difference (****p< 0.0001) among the 
median H-score RANK in each studied group (see Figure 6.4). The Dunn’s multiple 
comparison test showed that there were statistically significant differences between 
normal mammary and CS samples and also between BMT and CS samples (***p= 
0.0001) and (*p= 0.0200) respectively (see Figure 6.4). 
 
For the RANK immunostaining, the post hoc power was calculated using G*Power, 
and it was 0.99 (effect size f= 1.8). The calculated effect size indicated that sample 
size was more than sufficient. 
Photomicrographs of positive control tissues for all the series of experiments are 
shown in Appendix 13. 
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Figure 6.4 Comparison of the mean H-scores for RANK in tissue samples. The 
localisation of RANK was significantly different between normal and CSs ****p< 0.0001. 
P was assessed by the Kruskal–Wallis test. The graph shows statistically significant 
differences for the comparison between normal mammary and CS samples and also 
between BMT and CS samples (***p= 0.0001) and (*p= 0.0200) respectively by using 
Dunn’s multiple comparison test. 
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6.3 Discussion 
In certain malignant lesions (multiple myeloma, breast cancer and prostate cancer) 
that have bony involvement, have impaired regulation of the RANK/RANKL/OPG pathway 
(598). This pathway is involved in osteoclastic-independent mechanisms, including 
mammary gland physiology and breast tumours (373). An invasion of cancer cells in the 
osteoid tissue is often related to osteolytic lesions (i.e. breast tumours and multiple 
myeloma) and, more infrequently, with bone metastases (i.e. prostate cancer). The 
correlation between the cancer cells and the boneʼs micro-environment, depends on the 
concept of the “soil and seed” theory, and is important for the onset of osteolytic bone 
metastasis (598). Cancer cells secrete soluble cytokines and growth factors, which 
stimulate osteoclasts leading to the breakdown of bone. The parathyroid hormone-related 
protein secreted by cancers induces the enhanced expression of RANKL by the 
osteoblast stromal cells, also causing osteoclast stimulation (598). Osteoclastic bone 
resorption liberates TGF-β and BMPs from bone matrix, which can contribute to the 
enhanced proliferation of cancer cells. This causes a vicious cycle participating in the 
increased proliferation of cancer cells and increased osteolysis (598). 
Basal-like subtypes of breast cancer (‘triple negative’) are more frequent in African-
American women and are more prevalent in BRCA1-mutation carriers (599). Of these 
breast carcinoma patients, 2-10% are a result of BRCA1- and BRCA2-mutations (6). The 
BRCA1 and BRCA2 genes—together with progesterone—increase breast cancer risk in 
women (591). Progesterone has been shown to play a role in mammary carcinogenesis 
in the carriers of BRCA1/p53 mutant rats (379). Previously it was demonstrated that 
ovarian and breast cancers are more likely to occur in BRCA1/2 mutation carriers and 
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almost all of these are basal-like subtypes of breast tumours (600). The receptor OPG 
binds to and prevents the cytokine RANKL from triggering its receptor RANK (600).  
The suppression of RANKL dramatically inhibited BRCA1-mammary 
tumourigenesis indicating that this could be a target for prevention in women at  risk of 
acquiring breast tumour because of an inherited BRCA1 mutation (601). The RANK 
pathway activation by (progesterone) PgR-mediated RANKL upregulation plays a major 
role in breast tumourigenesis (602), partly by increasing breast stem cell proliferation 
(603). Furthermore, removing RANK from the breast epithelium reduces the incidence of 
PgR-mediated breast cancer (604), suggesting that RANK signalling suppression could 
be an excellent target for breast tumour prevention. Whereas anti-PgR therapy inhibits 
breast carcinogenesis in BRCA1/p53-deficient mice by reducing alveolar proliferation. 
Since OPG is not controlled by the menstrual cycle, it displayed a more robust inverse 
relationship in BRCA-mutation carriers versus controls (379). 
In this current study, the localisation of RANK and RANKL in CMMTs was 
examined. To assess the localisation of RANKL and RANK for each tumour, the H-score 
was obtained for each sample to perform a statistical analysis. The H-score was 
calculated using the ImageScope ‘IHC Cytoplasmic V2’ algorithm. The H-score cut-off 
value ≥8.5 was used to determine cases with a high localisation of RANKL and RANK 
according to Pfitzer et al. 2014 (405). RANKL and RANK immunostaining was seen in the 
epithelial cells and chondrocyte-like cells. Kiesel and Khol (2016) showed that 
RANKL/RANK has an important role in epithelial cell growth and cellular survival as well 
as in  lobulo-alveolar development (373). RANKL and RANK were in the cytoplasm of the 
luminal epithelial cells of normal, BMT, CBMT and CS samples. Nuclear and 
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membranous RANK staining was also seen in some cases of CMMTs. These findings are 
consistent with the results of Wood et al. (2013) (605) which showed that staining was 
both cytoplasmic and membranous for RANK and RANKL, but usually with a granular 
cytoplasmic appearance for RANKL. This distribution of RANK and RANKL within the 
CMMT samples was identical to that seen in mice, monkeys and tissue from normal 
human breast (381, 606). Labovsky et al. (2012) also demonstrated similar findings in 
epithelial metastatic breast cancer cell lines in their study (607).  
RANKL and RANK localisation has not only been observed in neoplastic lesions 
but also in normal mammary tissues (608). Therefore, in this current study, adjacent 
normal mammary gland tissue with RANKL localisation in normal epithelial cells was an 
in-built positive control. Additionally, RANK immunolabelling of the surrounding skin tissue 
was an in-built positive control. This current study found that 55% of normal mammary 
tissues were positive for RANKL expression. Our observations were that 80-100% of 
CMMTs were positive for RANKL expression, suggesting that the percentage of RANKL 
immunolabelling was increased in CMMTs compared to normal mammary samples.  
In humans, Cross and colleagues (2006) observed a positive correlation between 
RANKL expression of primary cancer cells and the tumour histologic grading indicating 
that the expression of RANKL was increased with the increase in tumour histologic 
grading  (609). In their study, Ney et al. (2012) found that over 50 % of primary breast 
cancer cells expressed RANK and OPG, while RANKL could be detected only in 14–60 % 
(598). It has been suggested that RANK expression is found in the ductal and lobulo-
alveolar elements (605, 610). Likewise, it has been demonstrated that RANK expression 
was found in 53% of lobular breast carcinomas and 39% of ductal carcinomas (605, 610). 
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In this current study, RANK was expressed in all the epithelial and mesenchymal 
elements of CMMTs. RANK and RANKL expression were found in the epithelial 
carcinoma elements in human IDC NST using IHC (611). RANK and RANKL expression 
were also observed in normal mammary epithelium adjacent to breast tumours (611).  
In primary mammary tumours, it has been demonstrated that increased RANK 
expression is related to malignancy and bone metastases (610). Additionally, there is a 
relationship between high RANK mRNA expression and poor prognostic factors, such as 
a tumour size more than 2 cm, tumour histological grade III and an absence of ER (610). 
Remarkably, when Santini and colleagues (2011) divided their cases into poor and good 
prognosis categories, depending on their microarray data, the expression of RANK mRNA 
was considerably higher in the poor prognosis group, while OPG and RANKL mRNA 
expression were higher in the favourable prognosis group (610).  
To conclude, RANKL and RANK were successfully localised in the FFPE of canine 
normal mammary and CMMT samples. Histological types of CMMTs were linked to the 
expression of RANKL and its receptor RANK. High RANKL and RANK localisation was 
significantly associated with CSs. One of the limitations of this current study was the small 
sample size. Only 47 cases were available. Although our findings were very promising, 
factors such as a small sample size can cause bias and further studies are required before 
definitive statements can be made should be considered. 
6.4 Chapter summary 
RANKL and RANK were successfully localised in CMMT samples. RANKL and 
RANK had a widespread distribution in the cytoplasm of epithelial cells of the ducts. They 
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were also localised in the cytoplasm of mesenchymal stromal cells (i.e. chondrocytes) of 
BMTs, CBMTs and CSs. Nuclear and membranous RANK was also observed in some 
cases of CMMTs. The histological tumour type had an effect on the expression of RANKL 
and its receptor RANK. High RANKL and RANK expression was found in CSs.  
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7.0 General discussion  
This project was directed at a specific mammary tumour which is challenging to 
treat properly. Metaplastic breast cancer (MBC) is aggressive as it results in extensive 
systemic metastasis (220). Because the enormous heterogeneity in MBCs by definition, 
large cohort samples are needed to provide valuable data. Canine mixed mammary 
tumours (CMMTs) in the veterinary community occur at a higher frequency (154, 155) 
and like in the human situation they have complicated morphology developing epithelial, 
mixed and mesenchymal elements (109, 250). CMMTs have a firm and generally 
cartilaginous or bony consistency (109). One way to improve outcomes of patients with 
MBC as well as to understand the process about the clinical habits of this tumour type is, 
the use of better animal models. CMMT can possibly be an excellent model for human 
MBC, on account of the similarities between CMMTs and human mixed mammary 
tumours.  
In this thesis, the suitability of CMMTs as a model for human mixed mammary 
tumours was examined. This hypothesis was built on evidence regarding the similarities 
of CMMTs to PABs and MBCs. Spontaneous CMTs have been suggested as analogous 
models for the study of human breast cancer, because these tumours share behavioural, 
clinical, epidemiological and antigenic characteristics (612-615). This study has 
demonstrated shared marker expression, which may be relevant to tumourigenesis. By 
comparing data on CMMTs with published studies of human mixed mammary tumours 
(277, 319, 337, 340, 422, 423, 476, 477, 616-620), this study has demonstrated 
similarities in the localisation of tumour biomarkers (CK5/6, CKAE1/AE3, vimentin, E-
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cadherin, p63, ERα, PR, HER2 and Ki-67) in mixed mammary tumours of both dogs and 
humans, which has improved our understanding of this tumour type. This demonstrates 
that canine and human mixed mammary tumours share a similar tumour biomarker 
profile. It was found that some commercially accessible antibodies available for the 
examination of human cancers can be used to identify antigenic expression in CMMTs. 
Moreover, similar antigenic expressions (for CKs, vimentin, E-cadherin, p63, ERα, PR, 
HER2 and Ki-67) were identified in CMMTs, indicating common pathogenetic 
mechanisms in the histogenesis of these mixed tumours. 
In general, epithelial tumours (i.e. carcinomas) express CKs, while mesenchymal 
tumours express vimentin. Nevertheless, there are carcinomas that demonstrate a loss 
of CKs expression, as well as carcinomas that co-express vimentin and CKs and 
uncommonly, some carcinomas that express both CKs and vimentin. Additionally, 
mesenchymal tumours can express epithelial markers (424). Non-epithelial cancers with 
a glandular epithelial element are very unusual, almost always biphasic tumours, which  
distinguish them from carcinomas (424). In human mixed tumours, it has been reported 
that both the spindle and epithelial cells express CKAE1/AE3, CK5/6, CK14 and SMA but 
not desmin or S100 (424). In my study, the CMMTs showed a loss of the epithelial marker 
(CKAE1/AE3) and the acquisition of mesenchymal markers (vimentin) in the 
mesenchymal components.  
Currently, CK5 is known to be a myoepithelial cell marker and a progenitor cell 
biomarker in breast cancers (422). In this current research, most glandular and basal 
epithelial cells in BMT samples stained strongly for CKAE1/AE3. The basal cells, 
however, showed a weak to moderate immunolabelling for CK5/6. All the myoepithelial 
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cells in BMTs expressed CKAE1/AE3, CK5/6 and vimentin. Most of the interstitial spindle 
cells, chondrocytes and osteoblasts in the stromal elements expressed vimentin. It has 
been reported that CK5 expression suggests a basal epithelial phenotype (423) and is 
related to a worse prognosis in HBCs (621). A strong relationship between CK5 and p63 
localisation was recently found in HBCs, suggesting that p63, similar to CK5, could be 
considered a biomarker for the basal phenotype of breast tumours (340). In the present 
study, p63 immunostaining was limited to myoepithelial cells in benign CMMTs and to 
areas of myoepithelial differentiation in malignant CMMTs, although the lower staining 
intensity in the latter may indicate some loss of differentiation. Similar observations were 
found for HBCs where the latest studies have shown that myoepithelial cells in the 
mammary gland express p63 (277, 340, 476, 616). Wang et al. (2002), demonstrated that 
p63 was localised in myoepithelial cells of normal mammary glands, partially expressed 
in ductal hyperplasia, rarely expressed in carcinoma in situ and not expressed in invasive 
carcinomas (476). A large series of 34 human metaplastic carcinomas were studied by 
Tse et al. (2006); MBCs that only had epithelial elements had p63 was localised in the 
squamous cell elements, but not in the adenocarcinomatous elements. Eight of the 10 
MBCs were positive for p63. For the tumours with sarcomatoid elements—either 
individually or together with carcinomatous elements—p63 was expressed in 14 out of 24 
cases. Pure sarcomas and carcinomas were all negative for p63 by IHC, indicating 
that p63 was specific for MBCs (477). 
MBCs are a highly heterogeneous group of cancers characterised by the presence 
of epithelial (ductal) carcinoma with areas of spindle, squamous, cartilaginous and/or 
osseous metaplasia. Cartilaginous and/or osseous differentiation occurs in 0.2% of all 
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breast cancers and osseous metaplasia is the rarest component. It has been 
demonstrated that the five-year disease-free survival of MBCs was significantly worse 
than IDC NST. Using a univariate analysis, advanced cancer stage at diagnosis, HER1 
overexpression and high Ki-67 labelling, were associated significantly with decreased 
disease-free survival (DFS) (620). The present study showed that osseous metaplasia 
was observed in 10% of benign mixed tumours and in 23% of malignant mixed mammary 
tumours. The factors associated with the development of osseous metaplasia in mixed 
tumours and their relationships with histological patterns is still unclear. The matrix 
synthesis in CMTs is not fully understood. Based on the cell types and ECM elements 
present in the tumour, they are categorised histologically as simple, mixed and complex 
tumours. Mixed and complex tumour types are the most frequent types of benign CMTs 
and histologically they demonstrate high resemblance with the pleomorphic adenoma of 
the human salivary gland. Simple tumours are made up of only one type of epithelial cell, 
whereas mixed and complex tumours are characterised by the presence of spindle-
shaped cells indicating a myoepithelial origin. Moreover, the stroma of mixed tumours 
includes cartilaginous tissue and/or bone (432). Traditionally, the chondroid tissue of 
mixed tumours was considered to have arisen from myoepithelial cells (622), but there 
are studies contradicting this, in favour of epithelial (623), stem cell (624) or fibroblastic 
origin (625).  
We found that OPN was localised to the myoepithelial cells, fibroblasts and/or 
chondroblasts and OPN localisation was higher in normal mammary and benign tumour 
samples than in malignant tumours. We hypothesised that strong expression of OPN in 
CMMTs could be associated with malignancy. Brown et al. (1994) were the first to show 
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increased OPN in human cancers (626). In comparison with normal tissue, they observed 
increased expression of OPN mRNA in three mammary glands, two lungs, six colons, 
one thyroid carcinoma, one endometrial carcinoma, and one gastric carcinoma (483, 498-
500, 626, 627). These data contrast with our results, because BMTs had slightly higher 
immunostaining compared to malignant tumours in the present study. 
We also hypothesised that because CMMTs show cartilaginous and/or osseous 
differentiation, it is reasonable to surmise that BMP4, Sox9 and Runx2 could be present 
in CMMTs and may be relevant to tumourigenesis of these tumours. This study 
demonstrated that BMP4 was localised in ductal epithelial and myoepithelial cells in 
normal mammary and BMT tissues, and in neoplastic epithelial cells in malignant CMMTs. 
Similar observations were found for cutaneous mixed tumours, pleomorphic adenomas 
and breast cancers in humans (491, 520). Increased expression of BMP4 has been 
detected in Barrett’s oesophagus and oesophagitis where BMP4 induces the metaplastic 
conversion of squamous epithelial cells to columnar cells (628). Recent studies of BMPs, 
initially extracted from bovine bone extracts, have reported that BMPs play an essential 
role in bone development, including the process of ectopic ossification (629-631). 
Immunohistochemical studies of BMP expression in salivary pleomorphic adenomas and 
mixed tumours of the skin have demonstrated that myoepithelial cells are strongly positive 
for BMP1, BMP2A, BMP3 and BMP6 (491, 632), indicating that the expression of BMPs 
in these cells plays a part in the formation of chondroid tissues in these tumours (491, 
632). It was shown that, benign and malignant CMMTs had greater BMP4 expression 
than normal mammary gland tissues indicating that increased expression appears to be 
correlated with tumourigenesis. Only 13 malignant CMMT cases were available. Although 
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our findings were very promising, a small sample size can cause bias and further studies 
are required before these conclusions can be made. 
It was found that 100% of normal mammary glands, 98% of benign CMMTs and 
100% of malignant CMMTs were positive for Sox9. It has been demonstrated that Sox9 
normally maintains the transformation of mesenchymal cells to chondrocytes in the 
development of bone and cartilage (506). Because some metaplastic carcinomas show 
chondrocytic differentiation it is reasonable to think that Sox9 may be active in these cells 
(506). It was demonstrated that cytoplasmic Sox9 expression was limited to malignant 
CMMTs, which may indicate that Sox9 could be a useful prognostic marker for CMMTs, 
similar to its use in human cancers. Cytoplasmic expression of Sox9 in CMMTs could 
represent a potential predictive biomarker for tumour aggressiveness. In normal 
mammary glands and BMTs, Sox9 antigen was limited to the nuclei of epithelial cells. The 
localisation of Sox9 in normal mammary gland tissue suggests that Sox9 has a role in 
breast development.  
We found that 99% of BMTs and 100% of malignant tumours were positive for 
Runx2. In humans, Runx2 is highly expressed in a small percentage of breast tumours 
and its expression is associated with basal tumours (633). The results in this study 
demonstrated that nuclear and cytoplasmic localisations of Runx2 were observed in 
epithelial and mesenchymal cells in normal mammary tissues, benign and malignant 
CMMT tissues. It has been reported that strong Runx2 positivity was detected in HBCs 
especially in the area of squamous metaplasia (633). This indicates a correlation between 
Runx2 localisation and a highly proliferative population of squamous metaplastic cells, 
which could possess cancer stem cell features (633). Although Runx2 expression was 
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higher in malignant than normal and benign samples, no significant differences in Runx2 
expression were observed between the different sample groups in the present study.  
We found that the majority of CMMT samples were positive for RANKL, with the 
staining detectable in epithelial neoplastic cells and chondrocyte-like cells. It was found 
that 55% of normal mammary tissues and 80-100% of CMMTs were positive for RANKL 
expression. The difference between CMMTs compared to normal mammary samples 
suggests that RANKL may play a role in tumour development in CMMTs. In humans, 
Cross and colleagues (2006) observed a positive correlation between RANKL expression 
in primary cancer cells with the tumour’s histological grading, indicating that the 
expression of RANKL increased with an increase in the histological grading  (609). 
Another study reported that RANKL plays a crucial role in cancer progression and 
metastasis (634). The RANKL/RANK system has been shown to regulate the functional 
capacity of stem cells on a BRCA1/p53 mutant background and, crucially, on mammary 
stem cells from women with BRCA1 mutations (12). It has been demonstrated that 
women who have germline mutations in BRCA1 have about a 65% cumulative risk of 
getting breast cancer by the age of 70 (635). IHC of CMMT samples showed that RANKL 
and RANK expression was elevated in CMMTs compared to normal mammary samples. 
 
Initially, when AgNORs were utilised as a parameter for the detection of 
malignancy, the AgNOR value was found to be helpful in evaluating cancer prognosis 
(636). It was observed that NOR patterns in neoplasms were different, and after the 
development of the silver staining method for the detection of NORs, it was decided that 
this method could be utilised for defining malignancy (637). The number of AgNORs and 
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their area represents the proliferative activity of the cell, and hence, it can be used for 
determining malignancy and tumour grading (637). It was able to successfully differentiate 
between normal, benign, and malignant lesions of canine mammary glands in this study. 
Differences in the number, shape and size of the AgNORs in the normal mammary and 
CMMT samples was also demonstrated. It was found that the AgNOR dots tended to be 
small, regular and homogenously stained in the nucleus of the epithelial cells in normal 
mammary and BMT tissues while there were significant variations (irregular, large and 
bizarre clusters) in malignant CMMTs. In CMMT samples, the increased AgNOR count 
correlated with increased Ki-67 localisation and hence with mitotic activity. Studies have 
demonstrated a significant correlation between AgNOR count and grades of malignancy 
in several tumour types (breast cancers, non-Hodgkin’s lymphoma, melanocytic tumours 
of skin and colon cancers) (537, 548, 549, 638). Silver staining for AgNORs is simple and 
does not need any special fixation or treatment of tissue. It could be performed on FFPE 
sections. It does not require any special tools or expensive reagents and be done by an 
expert technician. Thus, at centres where more expensive techniques such as IHC are 
not available for evaluating tumour aggressiveness, the examination of the AgNOR could 
become a useful test for determining the patient outcomes. In this study, it was 
demonstrated that a quantitative study of AgNOR (by using a Java-based image 
processing program) was valuable in measuring the number and area of the AgNOR and 
provided useful morphometric data. The present findings clearly indicate that the mean 
number and area of AgNOR per nucleus is directly related to the histological type of 
tumour. The AgNOR count correlated better than the AgNOR area with Ki-67 and mitotic 
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indices. Thus, the mean number of AgNORs per nucleus could be useful as an index of 
proliferative activity and may be a good prognostic tool. 
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7.1 Study limitation 
Despite the promising results presented in this research, there were limitations. 
The small sample size of CMMTs especially malignant CMMT cases (CBMTs n=8 and 
CSs n=5) was the main limitation; the rarity of malignant form of CMMT poses a challenge 
in conducting research with sufficient numbers to provide adequate power. The current 
study is limited regarding its ability to recognise relationships between IHC staining status 
and survival, because of the small number of cases and difficulty in collection of some 
crucial data from veterinary laboratories and clinics. In particular, the veterinary practice 
where a CMMT was excised was not reported and if recurrent tumours were found in 
following visits, these sites were not always recorded. It was also difficult to collect some 
essential data from veterinary clinics such as clinical features for comparison between 
CMMT types. Additionally, the survival data for each dog was not available to us. 
Unfortunately, insufficient malignant samples were available to draw prognostic 
significance from these studies. 
Another limitation of the present study was the limited accessibility of CMMT tissue 
material for protein extraction that would have been needed to carry out quantitative 
analysis of RANKL and RANK protein using western blotting. Another limitation was the 
validation of IHC HER2 2+ (equivocal) cases using fluorescence in situ hybridization 
(FISH). Extraction of RNA from FFPE CMMT tissue for RNA sequencing was attempted 
but was found to be unsuccessful. Due to the lack of fresh frozen samples we had to 
utilise FFPE samples for the extraction of RNA. The RNA quality was not good enough 
due to RNA degradation which may be due to prolonged formalin fixation in CMMT 
(639). 
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Although IHC is a relatively simple method, but its results depend on several 
factors. Immunostaining technique needs rigor and reproducibility in its analysis. 
Therefore, technical results have to be interpreted carefully. The handling, fixation and 
antigen retrieval are all critical variables for IHC. The selection of antibody panels is one 
of the most significant factors for IHC quality. Together the antigen retrieval, antibody 
panel selection and the staining interpretation were strictly controlled to limit the variability 
of the final diagnostic outcome (640). 
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7.2 Future studies 
Future studies should seek to increase the sample number of CMMTs, especially 
malignant ones to provide adequate power for any new studies. Both formalin-fixed and 
frozen samples need to be collected. Formalin-fixed CMMT samples could be stored at 
room temperature and they work well in IHC staining and morphology analyses. Frozen 
samples of CMMTs should be collected and stored to be used for molecular analysis (or 
tissue banking). The larger sample size of malignant CMMTs, the power calculation 
would be made and then the relevant statistical calculations could be performed. 
Future studies could use modern molecular sequencing methods such as RNA 
sequencing to examine the changes in gene expression in the different histological types 
of CMMTs and compare the results with the gene expression in MBCs. Sequencing 
studies can be used to identify somatic variants and predict their functional impact. RNA 
sequencing of human MBCs demonstrated mutations commonly in the TP53 and PIK3CA 
genes (641). Programmed death-ligand 1 (PD-L1)/programmed cell death 1 (PD-1) 
inhibitors and PIK3CA/mTOR pathway inhibitors could be useful in the treatment of 
aggressive MBCs (641). RNA sequencing of 30 patients with MBCs reported enrichment 
of TP53 and PTEN mutations, and interestingly, simultaneous mutations of TP53, PTEN, 
and PIK3CA. Mutations in neurofibromatosis‐1 were also overrepresented (642). In 
human breast cancers, Tp53 mutations are the most frequent somatic genetic 
abnormality and present in 15–34% of  breast cancers  (643, 644). The deduced amino 
acid sequence of Tp53 of dogs was almost 80% identical to that of the human proteins 
(645). Therefore, Tp53 mutations should be followed up in dogs to further validate the 
canine model. 
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It was shown that overexpression of RANKL and RANK is related to increased 
malignancy: high RANKL and RANK expression was observed in CSs, which is more 
aggressive than CBMTs. Hence, future experiments using larger sample sizes would be 
useful to investigate the expression of the RANKL and RANK proteins and genes, and 
this will provide a clearer picture of the role of RANKL/RANK in these tumours.  
Additionally, fluorescence in situ hybridization (FISH) should be carried out to validate the 
results of IHC HER2+. HER2 status is detected using IHC or FISH. IHC evaluates the 
localisation of the HER2 antigen in cell membranes and FISH determines if there 
is HER2 gene amplification (646). The IHC gives a score of 0 to 3+ that measures the 
amount of HER2 on the surface of cells in a breast tumour tissue. If the score is 0 to 1+, 
it’s called “HER2 negative.” If the score is 2+, it's called "borderline." A score of 3+ is 
called “HER2 positive”. The ASCO/CAP guidelines recommend HER2 testing by FISH in 
cases of IHC 2+ test results (moderate staining) (646). Finally, it would be useful to 
investigate the correlation of different types of CMMTs (histological classification) with the 
pathological characteristics and prognosis of patients. The association between these 
histological factors (grade, lymphatic invasion, infiltration of the margins of excision, and 
tumour diameter) and IHC results can yield more useful information. This may allow us to 
see if any of these biomarkers could be diagnostic or prognostic markers. These markers 
could be used in grading malignancies, and they could determine which therapies are 
needed (or not) and that would provide treatment rational for animal. 
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7.3 Conclusion  
Spontaneous CMMTs exhibit a number of clinical and molecular similarities to 
human mixed mammary tumours. Besides the spontaneous tumour presentation, the 
clinical parallels between human MBCs and CMMTs, such as histopathological,  
histochemical and the molecular characteristics of hormone receptors, epidermal growth 
factor (HER2), proliferation markers (Ki-67, AgNOR), the immunostaining patterns of the 
localisation of the biomarkers, which include CKs, E-cadherin, vimentin, p63, Sox9, 
BMP4, Runx2, OPN, RANKL and RANK in CMMT all mimic HBCs. Taking these findings 
together, we conclude that the spontaneous and heterogeneous nature of CMMTs mimic 
HBCs this makes CMMT a useful model of PABs and MBCs. 
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Appendix 1 
Appendix Table 1. Clinicopathological data for the 101 dogs with CMMTs. 
No. Case ID 
number  
Diagnosis   Breed  Gender   Age  Neuter status 
1 14p4 BMT Miniature Pinscher F 12 Yes  
2 14p5 CS Shih Tzu F 10.5 No  
3 14p6 BMT Labrador Retriever F 8 Yes  
4 14p10 BMT Staffordshire bull Terrier F 10 No  
5 14P24 CS Labrador Retriever F 9 Yes  
6 14p27    BMT German Shepaherd F 11 No  
7 14p28 BMT German Shorthair Pointer F 6 No  
8 14p33 BMT Pomeranian F 8 No  
9 14p35 CS Labrador Retriever F 11 No  
10 14p48 CS Kelpie F 11 No  
11 14p54 BMT Kelpie F 7 Yes  
12 14p76 BMT Border Collie F 9 No  
13 14p81 BMT Bulldog F 7 No  
14 10p2 BMT Terrier  F 14 No  
15 10p8 BMT Australian Terrier F 11 Yes  
16 10p9 BMT Mini Dashund F 5 No  
17 10p10 BMT Staghound  F 9 Yes  
18 10p12 BMT Border Collie F 9 Yes  
19 10p26 BMT Staffordshire Bull Terrier  F 6 Yes  
20 10p37 BMT Jack Russell Terrier F 11 Yes  
21 10p43 CBMT Border Collie  F 13 No  
22 10p45 BMT Jack Russell Terrier F 5 Yes  
23 10p49 BMT Labrador  F 12 Yes  
24 10p55 BMT Shih Tzu F 10 No  
25 10p60 BMT Kelpie F 9 Yes 
26 10p66 BMT Fox Terrier Smooth F 9 Yes  
27 10p71 BMT English Springer Spaniel F 7 Yes  
28 10p75 CBMT Maltese Shih Tzu  F 13 Yes   
29 10p76 BMT Greyhound  F 8 Yes   
30 10p84 BMT Border Collie  F 5 No  
31 10p87 CBMT Golden Retriever F 6 Yes  
32 10p90 BMT Australian Cattle dog F 9 Yes  
33 10p95 BMT Golden Retriever F 7 Yes  
34 10p98 BMT Terrier  F 8 No  
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35 10p99 CBMT Maltese Shih Tzu  F 8 Yes  
36 10p115 BMT N/A  F 8 Yes   
37 10p125 BMT Fox Terrier  F 9 Yes  
38 10p126 BMT Staffordshire Bull Terrier F 3 Yes  
39 10p137 BMT Maltese Shih Tzu  F 9 Yes  
40 10p147 CS Jack Russell Terrier F 13 Yes   
41 10p174 CBMT N/A F 8 No  
42 10p176 BMT Beagle F 9 No  
43 10p210 BMT German Shepherd F 8 Yes  
44 10p213 BMT Fox Terrier Smooth F 6 No  
45 10p221 BMT Bulldog F 8 Yes  
46 10p222 BMT Jack Russell Terrier F 9 Yes  
47 10p224 BMT Cocker Spaniel F 9 Yes  
48 10p232 BMT Labrador retriever F 9 Yes  
49 10p255 BMT Jack Russell Terrier F 8 Yes  
50 10p271 BMT N/A F 8 No    
51 10p283   BMT Jack Russell Terrier  F 4 Yes  
52 07-1801 BMT Cocker Spaniel F 12 No   
53 06-1555 BMT West Highland White 
Terrier 
F 9 No  
54 10-1089 CBMT N/A F N/A N/A 
55 06-0926 BMT Cocker Spaniel F 8 No  
56 04-0843 BMT Miniature Schnauzer F 8 Yes  
57 02-1051 CBMT N/A F 7 No  
58 05-1334 CBMT Bearded Collie F 12 Yes  
59 15-0581 BMT Staffordshire Bull F 12 Yes  
60 15-0632 BMT Springer Spaniel F 9 No  
61 06-0448 BMT Border Collie F 11 Yes  
62 00-216 BMT Springer Spaniel F 10 No  
63 04-0004 BMT German Shepherd F 8 No  
64 03-0678 BMT Bassot F 3 No  
65 03-0511 BMT Great Dane F 6 Yes  
66 03-0422 BMT Lurcher F 10 No  
67 15-0587 BMT Staffordshire Bull Terrier F 9 No  
68 05-1492 BMT Cocker Spaniel F 10 No  
69 04-0022 BMT Miniature Dachshund F 4 Yes  
70 00-1003 BMT Collie F 10 Yes  
71 02-171 BMT Doberman F 9 Yes  
72 04-0706 BMT German Shepherd F 9 No  
73 08-1087 BMT Labrador F 10 No  
74 08-0385 BMT ES Spaniel F 8 Yes  
75 07-1812 BMT Scottish Terrier F 10 Yes  
76 06-1351 BMT Pomeranian F 15 No  
77 15-0048 BMT German Shepherd F 8 No  
78 14-1542 BMT Rottweiler F 9 Yes  
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79 14-1315 BMT Border Collie F 5 No  
80 14-0725 BMT Jack Russell Terrier F 10 No  
81 14-0612 BMT Australian Shepherd F 7 No 
82 14-0358 BMT Chihuahua F 8 No 
83 13-1296 BMT Russian Terrier F 8 No 
84 13-0372 BMT Yorkshire Terrier Cross F 7 Yes  
85 13-0151 BMT Jack Russell Terrier F 7 No 
86 12-0885 BMT Chihuahua Cross F 13 No 
87 12-0419 BMT X-Breed F 10 No 
88 12-0416 BMT Dachshund F 9 No 
89 11-1201 BMT X-Breed F 6 No 
90 10-0781 BMT Yorkshire F 14 No 
91 10-0302 BMT Husky F 8 No  
92 09-1075 BMT German Shepherd F 9 No  
93 09-0232 BMT Lurcher F 10 Yes  
94 05-1434 BMT Springer Spaniel F 11 No  
95 10p59 BMT Border Collie  F 11 Yes  
96 07-1208 BMT Collie  F 8 No  
97 02-1154 BMT Yorkshire Terrier F 13 Yes  
98 05-0416 BMT Springer Spaniel F 14 Yes  
99 04-1754 BMT Miniature Poodle F 9 No  
100 03-0018 BMT Cross F 10 No 
101 14p60 BMT Cocker Spaniel F 9 Yes  
BMT, benign mixed mammary tumour; CBMT, carcinoma in benign mixed mammary tumour; CS, 
carcinosarcoma; F, female; N/A, not available. 
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Appendix 2  
Appendix Table 2. Progressive H&E stain method. 
Steps Time (min) 
Xylene 3 
Xylene 2 
100% alcohol 1 
100% alcohol 1 
70% alcohol 1 
Wash, tap water 2 
Mayer’s haematoxylin 3 
Wash, tap water 2 
Scott’s tap water 1 
Wash, tap water 1 
70% alcohol 1 
100% alcohol 1 
100% alcohol 1 
Xylene  2 
Xylene 3 
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Appendix 3  
Appendix Table 3. Toluidine blue staining method. 
Steps Time (min) 
Xylene 3 
Xylene 2 
100% alcohol 1 
100% alcohol 1 
70% alcohol 1 
Distilled water 2 
Toluidine blue working solution (pH 2.0~2.5) 3 
Wash, tap water (3 changes) 2   
70% alcohol 1 
100% alcohol 1 
100% alcohol 1 
Xylene  2 
Xylene  3 
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Appendix 4  
Appendix Table 4. Masson’s trichrome staining protocol.  
Solution Time (min) 
Xylene  3 
Xylene  2 
100% alcohol 1 
100% alcohol 1 
70% alcohol 1 
Distilled water 2 
Bouin’s fluid 60oC 30 
Wash, tap water 5-10 
Weigert’s Haematoxylin 10 
Wash, tap water 5-10 
0.5% acid alcohol  <5 sec 
Wash, tap water 1 
1% Brilliant Crocein and  
1% Phosphotungstic acid 
10-15 
1% Phosphotungstic acid Rinse 
0.5% Aniline Blue and 1% acetic acid 5-10 
1% acetic acid Rinse 
70% alcohol 1 
100% alcohol 1 
100% alcohol 1 
Xylene  2 
Xylene  3 
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Appendix 5 
Appendix Table 5. Von Kossa saining protocol for calcium. 
Solution  Time (min) 
Xylene  3 
Xylene  2 
100% alcohol 1 
100% alcohol 1 
70% alcohol 1 
Distilled water 2 
1% silver nitrate solution 20 
Wash, distilled water 5-10 
5% sodium thiosulphate 5 
Nuclear red fast  5 
Wash, tap water 5 
70% alcohol 1 
100% alcohol 1 
100% alcohol 1 
Xylene  2 
Xylene  3 
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Appendix 6 
Appendix Table 6. The silver-staining protocol for AgNOR. 
Solution  Time (min) 
Xylene  3 
Xylene  2 
100% alcohol 1 
100% alcohol  1 
70% alcohol 1 
Distilled water 2 
Incubate, working silver staining solution in 
dark 
30-40 
Wash, deionized water 10-15 
70% alcohol 1 
100% alcohol 1 
100% alcohol 1 
Xylene  2 
Xylene  3 
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Appendix 7 
IHC Nuclear V9 algorithm inputs (Aperio Technologies) applied to analyse CMMT samples. 
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Appendix 8  
Parameters of the IHC Membrane V1 algorithm (Aperio Technologies) applied to analyse HER2 and E-cadherin 
immunostaining. 
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Appendix 9  
Parameters of the IHC Cytoplasmic V2 algorithm (Aperio Technologies) applied to 
analyse CMMT samples. 
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Appendix 10  
Appendix Table 7. Immunostaining of Ki-67 in CMMTs. 
Case ID number  Diagnosis   Percentage of Ki-67-
positive tumour cells 
Ki-67 labelling index 
14p4 BMT 7.40 Low 
14p6 BMT 14.0 High  
14p10 BMT 0.00 Low 
14p27    BMT 8.50 Low 
14p28 BMT 6.00 Low 
14p33 BMT 7.40 Low 
14p54 BMT 4.80 Low 
14p76 BMT 7.80 Low 
14p81 BMT 0.00 Low 
10p2 BMT 6.00 Low 
10p8 BMT 9.00 Low 
10p9 BMT 8.00 Low 
10p10 BMT 3.10 Low 
10p12 BMT 12.0 High  
10p26 BMT 18.44 High  
10p37 BMT 0.00 Low 
10p45 BMT 0.26 Low 
10p49 BMT 7.34 Low 
10p55 BMT 4.00 Low 
10p60 BMT 15.00 High  
10p66 BMT 5.71 Low  
10p71 BMT 0.00 Low 
10p76 BMT 20.57 High  
10p84 BMT 0.00 Low 
10p90 BMT 20.0 High  
10p95 BMT 3.63 Low  
10p98 BMT 7.33 Low 
10p115 BMT 0.56 Low 
10p125 BMT 0.00 Low 
10p126 BMT 0.00 Low 
10p137 BMT 0.00 Low 
10p150 BMT 0.00 Low 
10p176 BMT 0.00 Low 
10p210 BMT 13.5 High  
10p213 BMT 14.5 High  
10p221 BMT 0.00 Low 
10p222 BMT 0.43 Low 
10p224 BMT 0.00 Low 
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10p232 BMT 0.00 Low 
10p255 BMT 9.00 Low 
10p271 BMT 0.00 Low 
10p283   BMT 2.00 Low 
07-1801 BMT 6.00 Low 
06-1555 BMT 20.0 High  
06-0926 BMT 7.00 Low 
04-0843 BMT 1.00 Low 
15-0581 BMT 0.00 Low 
06-0448 BMT 0.00 Low 
00-216 BMT 0.00 Low 
04-0004 BMT 9.00 Low 
03-0678 BMT 0.00 Low 
03-0511 BMT 0.00 Low 
03-0422 BMT 15.00 High  
15-0587 BMT 0.00 Low 
05-1492 BMT 0.00 Low 
04-0022 BMT 0.00 Low 
00-1003 BMT 1.00 Low 
02-171 BMT 0.00 Low 
04-0706 BMT 0.00 Low 
08-1087 BMT 0.00 Low 
08-0385 BMT 0.00 Low 
07-1812 BMT 9.00 Low 
06-1351 BMT 0.00 Low 
15-0048 BMT 1.00 Low 
14-1542 BMT 2.00 Low 
14-1315 BMT 11.00 High  
14-0725 BMT 0.00 Low 
14-0612 BMT 0.00 Low 
14-0358 BMT 0.00 Low 
13-1296 BMT 3.00 Low 
13-0372 BMT 0.00 Low 
13-0151 BMT 0.00 Low 
12-0885 BMT 6.00 Low 
12-0419 BMT 0.00 Low 
12-0416 BMT 0.00 Low 
11-1201 BMT 1.00 Low 
10-0781 BMT 1.00 Low 
10-0302 BMT 1.00 Low 
09-1075 BMT 0.00 Low 
09-0232 BMT 9.00 Low 
14p60 BMT 9.30 Low 
10p59 BMT 0.00 Low 
07-1208 BMT 0.00 Low 
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02-1154 BMT 2.0 Low 
05-0416 BMT 12.0 High  
04-1754 BMT 0.00 Low 
03-0018 BMT 0.00 Low 
14p5 CS 34.50 High  
14P24 CS 25.85 High  
14p35 CS 38.00 High  
14p48 CS 21.30 High  
10p43 CBMT 12.30 High  
10p75 CBMT 13.00 High  
10p87 CBMT 11.70 High  
10p99 CBMT 15.43 High  
10p147 CS 24.00 High  
10p174 CBMT 14.89 High  
10-1089 CBMT 18.00 High  
02-1051 CBMT 9.00 Low  
05-1334 CBMT 7.00 Low  
BMT, benign mixed mammary tumour; CBMT, carcinoma in benign mixed mammary tumour; CS, 
carcinosarcoma. 
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Appendix 11 
Appendix Table 8. Immunostaining of ER-ɑ and PR in CMMTs. 
Case ID 
number  
Diagnosis   ER-ɑ H-score  ER-ɑ 
immunostaining 
ER-ɑ Allred 
score  
ER-ɑ 
immunostaining 
IRS PR PR 
immunostaining 
14p4 BMT 33.34 Positive  4 Positive 8 Positive 
14p6 BMT 60.55 Positive 5 Positive 4 Positive 
14p10 BMT 41.50 Positive 4 Positive 6 Positive 
14p27    BMT 28.99 Positive 4 Positive 10 Positive 
14p28 BMT 42.39 Positive 5 Positive 4 Positive 
14p33 BMT 41.51 Positive 5 Positive 8 Positive 
14p54 BMT 37.22 Positive 5 Positive 8 Positive 
14p76 BMT 0.00 Negative  0 Negative  8 Positive 
14p81 BMT 39.38 Positive 5 Positive 6 Positive 
10p2 BMT 120.25 Positive 6 Positive 4 Positive 
10p8 BMT 16.07 Positive 4 Positive 3 Positive 
10p9 BMT 5.98 Positive 3 Positive 8 Positive 
10p10 BMT 0.00 Negative  0 Negative  4 Positive 
10p12 BMT 56.63 Positive 5 Positive 6 Positive 
10p26 BMT 125.28 Positive 6 Positive 4 Positive 
10p37 BMT 9.35 Positive 3 Positive 4 Positive 
10p45 BMT 56.15 Positive 5 Positive 6 Positive 
10p49 BMT 109.41 Positive 6 Positive 4 Positive 
10p55 BMT 2.76 Positive 2 Negative  10 Positive 
10p60 BMT 190.51 Positive 8 Positive 8 Positive 
10p66 BMT 6.18 Positive 3 Positive 0 Negative 
10p71 BMT 46.67 Positive 5 Positive 6 Positive 
10p76 BMT 106.24 Positive 6 Positive 8 Positive 
10p84 BMT 0.00 Negative  0 Negative  4 Positive 
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10p90 BMT 107.02 Positive 6 Positive 8 Positive 
10p95 BMT 47.50 Positive 5 Positive 8 Positive 
10p98 BMT 111.09 Positive 6 Positive 4 Positive 
10p115 BMT 56.93 Positive 5 Positive 6 Positive 
10p125 BMT 32.79 Positive 4 Positive 3.5 Positive 
10p126 BMT 74.09 Positive 5 Positive 4 Positive 
10p137 BMT 0.00 Negative  0 Negative  4 Positive 
10p150 BMT 12.09 Positive 4 Positive 8 Positive 
10p176 BMT 130.70 Positive 6 Positive 6 Positive 
10p210 BMT 33.51 Positive 4 Positive 4 Positive 
10p213 BMT 0.00 Negative  0 Negative  6 Positive 
10p221 BMT 95.17 Positive 6 Positive 6 Positive 
10p222 BMT 24.22 Positive 4 Positive 6 Positive 
10p224 BMT 44.39 Positive 5 Positive 4 Positive 
10p232 BMT 7.49 Positive 3 Positive 6 Positive 
10p255 BMT 22.42 Positive 4 Positive 8 Positive 
10p271 BMT 86.69 Positive 6 Positive 10 Positive 
10p283   BMT 40.25 Positive 5 Positive 6 Positive 
07-1801 BMT 28.02 Positive 4 Positive 6 Positive 
06-1555 BMT 3.83 Positive 3 Positive 0 Negative  
06-0926 BMT 45.00 Positive 3 Positive 8 Positive 
04-0843 BMT 66.00 Positive 3 Positive 6 Positive 
15-0581 BMT 68.50 Positive 4 Positive 10 Positive 
06-0448 BMT 63.00 Positive 4 Positive 4 Positive 
00-216 BMT 64.00 Positive 4 Positive 4 Positive 
04-0004 BMT 59.00 Positive 4 Positive 6 Positive 
03-0678 BMT 58.00 Positive 4 Positive 10 Positive 
03-0511 BMT 70.00 Positive 4 Positive 4 Positive 
03-0422 BMT 65.00 Positive 4 Positive 6 Positive 
15-0587 BMT 65.00 Positive 4 Positive 6 Positive 
05-1492 BMT 56.00 Positive 4 Positive 8 Positive 
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04-0022 BMT 65.00 Positive 4 Positive 4 Positive 
00-1003 BMT 45.00 Positive 4 Positive 6 Positive 
02-171 BMT 65.00 Positive 4 Positive 8 Positive 
04-0706 BMT 65.00 Positive 4 Positive 4 Positive 
08-1087 BMT 46.00 Positive 4 Positive 4 Positive 
08-0385 BMT 65.00 Positive 4 Positive 8 Positive 
07-1812 BMT 69.44 Positive 4 Positive 4 Positive 
06-1351 BMT 65.00 Positive 4 Positive 8 Positive 
15-0048 BMT 65.00 Positive 4 Positive 4 Positive 
14-1542 BMT 65.00 Positive 4 Positive 8 Positive 
14-1315 BMT 65.00 Positive 4 Positive 4 Positive 
14-0725 BMT 63.00 Positive 4 Positive 8 Positive 
14-0612 BMT 85.00 Positive 4 Positive 4 Positive 
14-0358 BMT 65.00 Positive 4 Positive 6 Positive 
13-1296 BMT 65.00 Positive 4 Positive 0 Negative  
13-0372 BMT 91.00 Positive 4 Positive 0 Negative  
13-0151 BMT 65.00 Positive 4 Positive 4 Positive 
12-0885 BMT 96.00 Positive 4 Positive 4 Positive 
12-0419 BMT 65.00 Positive 4 Positive 4 Positive 
12-0416 BMT 65.00 Positive 4 Positive 0 Negative  
11-1201 BMT 65.00 Positive 4 Positive 4 Positive 
10-0781 BMT 74.00 Positive 4 Positive 8 Positive 
10-0302 BMT 54.00 Positive 4 Positive 2 Positive 
09-1075 BMT 52.00 Positive 4 Positive 3 Positive 
09-0232 BMT 88.00 Positive 4 Positive 4 Positive 
14p60 BMT 65.00 Positive 4 Positive 6 Positive 
10p59 BMT 65.00 Positive 4 Positive 4 Positive 
07-1208 BMT 65.00 Positive 4 Positive 8 Positive 
02-1154 BMT 65.00 Positive 4 Positive 8 Positive 
05-0416 BMT 61.00 Positive 4 Positive 8 Positive 
04-1754 BMT 58.00 Positive 4 Positive 4 Positive 
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03-0018 BMT 41.4982 Positive 5 Positive 8 Positive 
14p5 CS 0.00 Negative  0 Negative  6 Positive  
14P24 CS 0.00 Negative  0 Negative 0 Negative  
14p35 CS 0.00 Negative  0 Negative 1 Negative 
14p48 CS 0.00 Negative  2 Negative 1 Negative 
10p43 CBMT 89.5801 Positive 4 Positive  1 Negative 
10p75 CBMT 51.8335 Positive 0 Negative 6 Positive 
10p87 CBMT 0 Negative 5 Positive  0 Negative 
10p99 CBMT 0 Negative 4 Positive  1 Negative 
10p147 CS 65.00 Positive 0 Negative 1 Negative 
10p174 CBMT 70.00 Positive 5 Positive  6 Positive 
10-1089 CBMT 41.00 Positive 3 Positive  5 Positive 
02-1051 CBMT 35.00 Positive   2 Negative 6 Positive 
05-1334 CBMT 72.00 Positive 0 Negative  6 Positive 
BMT, benign mixed mammary tumour; CBMT, carcinoma in benign mixed mammary tumour; CS, carcinosarcoma;  ER, estrogen 
receptor; PR, progesterone receptor. 
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Appendix 12 
Appendix Table 9. Immunostaining of CK5/6, p63, CKAE1/AE3, vimentin and E-cadherin in CMMTs. 
Case ID 
number  
Diagnosis   CK5/6 
Immunostaining 
p63 
immunostaining 
CKAE1/AE3 
immunostaining 
Vimentin 
immunostaining 
E-cadherin 
immunostaining 
14p4 BMT Negative  Positive  Positive  Positive  Positive  
14p6 BMT Positive  Positive Positive Positive Positive 
14p10 BMT Positive Positive Positive Positive Positive 
14p27    BMT Positive Positive Positive Positive Positive 
14p28 BMT Positive Positive Positive Positive Positive 
14p33 BMT Positive Positive  Positive  Positive  Positive  
14p54 BMT Positive  Positive Positive Positive Positive 
14p76 BMT Positive Positive Positive Positive Positive 
14p81 BMT Positive Positive Positive Positive Positive 
10p2 BMT Positive Positive Positive Positive Positive 
10p8 BMT Positive Positive  Positive  Positive  Positive  
10p9 BMT Negative  Negative  Positive  Positive  Positive  
10p10 BMT Positive Positive  Positive Positive Positive 
10p12 BMT Positive Positive Positive Positive Positive 
10p26 BMT Positive Positive Positive Positive Positive 
10p37 BMT Positive Positive Positive Positive Positive 
10p45 BMT Positive Positive Positive  Positive  Positive  
10p49 BMT Positive Negative  Positive Positive Positive 
10p55 BMT Positive Positive Positive Positive Positive  
10p60 BMT Positive Positive Positive Positive Positive 
10p66 BMT Positive Positive Positive Positive Positive 
10p71 BMT Positive Negative  Positive  Positive  Positive 
10p76 BMT Positive Positive  Positive  Positive  Positive 
10p84 BMT Positive Positive Positive Positive Positive  
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10p90 BMT Positive Positive Positive Positive Positive 
10p95 BMT Positive Positive Positive Positive Positive 
10p98 BMT Positive Positive Positive Positive Positive 
10p115 BMT Positive Positive  Positive  Positive  Positive 
10p125 BMT Positive Positive Positive Positive Positive  
10p126 BMT Positive Positive Positive Positive Positive  
10p137 BMT Positive Negative  Positive Positive Positive 
10p150 BMT Negative Positive Positive Positive Positive 
10p176 BMT Positive Positive  Positive  Positive  Positive 
10p210 BMT Positive Positive Positive  Positive  Positive 
10p213 BMT Positive Positive Positive Positive Positive  
10p221 BMT Positive Positive Positive Positive Positive 
10p222 BMT Negative  Positive Positive Positive Positive  
10p224 BMT Positive Positive  Positive Positive Positive 
10p232 BMT Positive Positive Positive  Positive  Positive 
10p255 BMT Positive Positive Positive Positive Positive 
10p271 BMT Positive Positive Positive Positive Positive 
10p283   BMT Positive Positive Positive Positive Positive  
07-1801 BMT Negative  Positive  Positive Positive Positive 
06-1555 BMT Positive Positive Positive  Positive  Positive 
06-0926 BMT Positive Positive Positive  Positive  Positive 
04-0843 BMT Positive Positive Positive Positive Positive 
15-0581 BMT Positive Positive Positive Positive Positive  
06-0448 BMT Positive Positive  Positive Positive Positive  
00-216 BMT Positive Positive Positive Positive Positive 
04-0004 BMT Positive Positive Positive  Positive  Positive 
03-0678 BMT Positive Positive Positive Positive Positive 
03-0511 BMT Positive Positive Positive Positive Positive 
03-0422 BMT Positive Positive  Positive Positive Positive  
15-0587 BMT Positive Positive Positive Positive Positive 
05-1492 BMT Positive Positive Positive  Positive  Positive  
04-0022 BMT Positive Positive Positive  Positive  Positive 
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00-1003 BMT Positive Positive Positive Positive Positive 
02-171 BMT Positive Positive  Positive Positive Positive 
04-0706 BMT Positive Positive Positive Positive Positive 
08-1087 BMT Positive Positive Positive Positive Positive  
08-0385 BMT Positive Positive Positive  Positive  Positive 
07-1812 BMT Positive Positive Positive Positive Positive 
06-1351 BMT Positive Positive  Positive Positive Positive 
15-0048 BMT Positive Positive Positive Positive Positive 
14-1542 BMT Positive Positive Positive Positive Positive  
14-1315 BMT Positive Positive Positive  Positive  Positive  
14-0725 BMT Positive Positive Positive  Positive  Positive 
14-0612 BMT Positive Positive  Positive Positive Positive 
14-0358 BMT Positive Positive Positive Positive Positive 
13-1296 BMT Positive Positive Positive Positive Positive 
13-0372 BMT Positive Positive Positive Positive Positive  
13-0151 BMT Positive Positive Positive  Positive  Positive 
12-0885 BMT Positive Positive  Positive Positive Positive  
12-0419 BMT Positive Positive Positive Positive Positive 
12-0416 BMT Negative  Positive Positive Positive Positive 
11-1201 BMT Positive Negative  Positive Positive Positive 
10-0781 BMT Positive Positive Positive  Positive  Positive 
10-0302 BMT Positive Positive  Positive  Positive  Positive  
09-1075 BMT Negative  Positive Positive Positive Positive 
09-0232 BMT Positive Positive Positive Positive Positive 
14p60 BMT Positive Positive Positive Positive Positive 
10p59 BMT Positive Positive Positive Positive Positive 
07-1208 BMT Positive Positive  Positive  Positive  Positive  
02-1154 BMT Positive Positive Positive Positive Positive  
05-0416 BMT Positive Positive Positive Positive Positive 
04-1754 BMT Positive Positive Positive Positive Positive 
03-0018 BMT Positive   Positive Positive Positive Positive 
05-1434 BMT Positive Positive  Positive  Positive  Positive 
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14p5 CS Positive Negative  Positive  Positive  Negative  
14P24 CS Positive Negative  Positive Positive Negative  
14p35 CS Positive Negative  Positive Positive Negative  
14p48 CS Positive Positive Positive Positive Positive 
10p43 CBMT Positive Positive Positive Positive Positive 
10p75 CBMT Positive Positive Positive  Positive  Positive 
10p87 CBMT Positive Positive  Positive Positive Positive 
10p99 CBMT Positive Positive Positive Positive Positive 
10p147 CS Positive Positive Positive Positive Positive 
10p174 CBMT Positive Positive Positive Positive Positive 
10-1089 CBMT Positive Positive  Positive  Positive  Positive 
02-1051 CBMT Positive Positive Positive  Positive  Positive  
05-1334 CBMT Positive Positive Positive  Positive  Positive  
BMT, benign mixed mammary tumour; CBMT, carcinoma in benign mixed mammary tumour; CS, carcinosarcoma; CK5/6, cytokeratin 
5/6. 
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Appendix 13 
Photomicrographs of positive control tissues for all the series of experiments in 
this study. 
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Appendix 14 
Appendix Table 10. Immunostaining of OPN, Sox9, BMP4 and Runx2 in CMMTs. 
Case ID 
number  
Diagnosis   OPN 
Immunostaining 
Sox9 
immunostaining 
BMP4 
immunostaining 
Runx2 
immunostaining 
14p4 BMT Positive  Positive  Positive  Positive 
14p6 BMT Positive Positive  Positive  Positive  
14p10 BMT Positive Positive Positive Positive 
14p27    BMT Positive Positive  Positive  Positive 
14p28 BMT Positive Positive Positive Positive 
14p33 BMT Positive  Positive Positive Positive  
14p54 BMT Positive Positive Positive Positive 
14p76 BMT Positive Positive Positive Positive 
14p81 BMT Positive Positive  Positive  Positive 
10p2 BMT Positive Positive Positive Positive 
10p8 BMT Positive  Positive Positive Positive  
10p9 BMT Positive  Positive Positive Positive 
10p10 BMT Positive Negative Negative Positive 
10p12 BMT Positive Positive  Negative Positive 
10p26 BMT Positive Positive  Positive  Positive  
10p37 BMT Positive Positive Positive Positive 
10p45 BMT Positive  Positive Positive Positive 
10p49 BMT Positive Positive Positive Positive 
10p55 BMT Positive Positive Positive Positive 
10p60 BMT Positive Positive  Positive  Positive  
10p66 BMT Positive Positive Positive Positive 
10p71 BMT Positive  Positive Positive Positive 
10p76 BMT Positive  Positive Positive Positive 
10p84 BMT Positive Positive Positive Positive 
10p90 BMT Positive Positive  Positive  Positive  
Appendix 
332 
 
10p95 BMT Positive Positive  Positive  Positive 
10p98 BMT Positive Positive  Positive  Positive 
10p115 BMT Positive  Positive Positive Positive 
10p125 BMT Positive Positive Positive Positive 
10p126 BMT Positive Positive Positive Positive  
10p137 BMT Positive Positive Positive Positive  
10p150 BMT Positive Positive  Positive  Positive 
10p176 BMT Positive  Positive Positive Positive 
10p210 BMT Positive  Positive Positive Positive  
10p213 BMT Positive Positive Positive Positive 
10p221 BMT Positive Positive  Positive  Positive 
10p222 BMT Positive Positive Positive Positive 
10p224 BMT Positive Positive Positive Positive  
10p232 BMT Positive  Positive Positive Positive 
10p255 BMT Positive Positive Positive Positive 
10p271 BMT Positive Positive  Positive  Positive 
10p283   BMT Positive Positive Positive Positive 
07-1801 BMT Positive Positive Positive Positive  
06-1555 BMT Positive  Positive Positive Positive 
06-0926 BMT Positive  Positive  Positive  Positive 
04-0843 BMT Positive Positive Positive Positive 
15-0581 BMT Positive Positive Positive Positive  
06-0448 BMT Positive Positive Positive Positive 
00-216 BMT Positive Positive Positive Positive 
04-0004 BMT Positive  Positive  Positive  Positive 
03-0678 BMT Positive Positive Positive Positive 
03-0511 BMT Positive Positive Positive Positive  
03-0422 BMT Positive Positive Positive Positive 
15-0587 BMT Positive Positive  Positive Positive 
05-1492 BMT Positive  Positive Positive  Positive 
04-0022 BMT Positive  Positive Positive Positive 
00-1003 BMT Positive Positive Positive Positive  
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02-171 BMT Positive Positive Positive Positive 
04-0706 BMT Positive Positive  Positive Positive 
08-1087 BMT Positive Positive Positive  Positive 
08-0385 BMT Positive  Positive Positive  Positive 
07-1812 BMT Positive Positive Positive Positive  
06-1351 BMT Positive Positive  Positive Positive  
15-0048 BMT Positive Positive Positive Positive 
14-1542 BMT Positive Positive Positive Positive 
14-1315 BMT Positive  Positive Positive  Positive  
14-0725 BMT Positive  Positive Positive Positive 
14-0612 BMT Positive Positive  Positive Positive 
14-0358 BMT Positive Positive Positive Positive 
13-1296 BMT Positive Positive Positive Positive 
13-0372 BMT Positive Positive Positive  Positive  
13-0151 BMT Positive  Positive  Positive  Positive  
12-0885 BMT Positive Positive Positive  Positive  
12-0419 BMT Positive Positive Positive Positive 
12-0416 BMT Positive Positive Positive Positive 
11-1201 BMT Positive Positive Positive Positive 
10-0781 BMT Positive  Positive  Positive Positive 
10-0302 BMT Positive  Positive Positive  Positive  
09-1075 BMT Positive Positive Positive Positive 
09-0232 BMT Positive Positive Positive Positive 
14p60 BMT Positive Positive Positive Negative  
10p59 BMT Positive Positive  Positive  Positive 
07-1208 BMT Positive  Positive Positive Positive  
02-1154 BMT Positive Positive Positive Positive 
05-0416 BMT Positive Positive Positive Positive 
04-1754 BMT Positive Positive  Positive Positive 
03-0018 BMT Positive Positive  Positive  Positive 
10p152 BMT Positive  Negative  Positive  Positive  
14p5 CS Positive  Positive Positive Positive  
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14P24 CS Positive Positive  Positive Positive  
14p35 CS Positive Positive Positive  Positive 
14p48 CS Positive Positive Positive Positive 
10p43 CBMT Positive Positive Positive Positive 
10p75 CBMT Positive  Positive Positive Positive 
10p87 CBMT Positive Positive  Positive Positive  
10p99 CBMT Positive Positive Positive Positive 
10p147 CS Positive Positive Positive Positive 
10p174 CBMT Positive Positive Positive Positive 
10-1089 CBMT Positive  Positive Positive Positive 
02-1051 CBMT Positive  Positive Positive Positive 
05-1334 CBMT Positive  Positive Positive Positive 
BMT, benign mixed mammary tumour; CBMT, carcinoma in benign mixed mammary tumour; CS, carcinosarcoma; BMP4, bone 
morphogenetic protein; OPN, osteopontin; Runx2, Runt-related transcription factor 2;  Sox9, SRY-Box9. 
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Appendix 15 
Appendix Table 11. Mean number of AgNORs, mean area of AgNORs and mitotic scores in CMMTs. 
Case ID 
number  
Diagnosis   Mean number of 
AgNORs/nucleus 
Mean area of 
AgNORs/nucleus 
Mitotic score 
NC1 Normal mammary tissue 0.72 1.34 1 
NC2 Normal mammary tissue 0.61 1.63 1 
NC3 Normal mammary tissue 0.815 2.21 1 
NC4 Normal mammary tissue 0.95 1.07 1 
NC5 Normal mammary tissue 0.68 0.99 1 
NC6 Normal mammary tissue 0.95 1.06 1 
NC7 Normal mammary tissue 0.62 1.80 1 
NC8 Normal mammary tissue 0.62 1.49 1 
NC9 Normal mammary tissue 0.59 1.59 1 
NC10 Normal mammary tissue 0.41 1.23 1 
NC11 Normal mammary tissue 0.47 1.35 1 
NC12 Normal mammary tissue 0.51 1.36 1 
NC13 Normal mammary tissue 0.42 1.35 1 
NC14 Normal mammary tissue 0.38 1.38 1 
NC15 Normal mammary tissue 0.43 1.38 1 
NC16 Normal mammary tissue 0.65 1.44 1 
NC17 Normal mammary tissue 0.66 1.39 1 
NC18 Normal mammary tissue 0.106 1.23 1 
NC19 Normal mammary tissue 0.58 1.34 1 
NC20 Normal mammary tissue 0.56 1.97 1 
NC21 Normal mammary tissue 0.31 1.45 1 
NC22 Normal mammary tissue 0.3 1.46 1 
NC23 Normal mammary tissue 0.36 1.43 1 
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NC24 Normal mammary tissue 0.57 1.54 1 
NC25 Normal mammary tissue 0.34 1.54 1 
NC26 Normal mammary tissue 0.73 1.55 1 
NC27 Normal mammary tissue 0.31 1.97 1 
NC28 Normal mammary tissue 0.52 2.23 1 
NC29 Normal mammary tissue 0.96 2.04 1 
NC30 Normal mammary tissue 0.88 1.35 1 
14p27    BMT 0.91 3.30 1 
14p28 BMT 0.86 2.12 1 
14p33 BMT 0.46 3.50 1 
14p54 BMT 0.38 1.69 1 
14p76 BMT 0.70 3.38 1 
14p81 BMT 0.56 0.99 1 
10p2 BMT 0.41 2.36 1 
10p8 BMT 0.88 1.69 1 
10p9 BMT 0.43 2.17 1 
10p10 BMT 0.32 1.79 1 
10p12 BMT 0.52 1.52 1 
10p49 BMT 0.41 2.54 1 
10p55 BMT 0.34 2.22 1 
10p60 BMT 0.66 2.51 1 
10p66 BMT 0.52 1.92 1 
10p76 BMT 0.63 1.57 1 
10p84 BMT 0.63 1.169 1 
10p90 BMT 0.58 2.24 1 
10p95 BMT 0.50 1.82 1 
10p98 BMT 0.49 3.46 1 
10p115 BMT 0.38 2.09 1 
10p125 BMT 0.83 1.65 1 
10p126 BMT 0.69 3.0281 1 
10p224 BMT 0.72 2.89 1 
10p232 BMT 0.33 2.74 1 
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07-1801 BMT 0.94 1.31 1 
06-1555 BMT 0.53 2.80 1 
15-0581 BMT 0.61 2.12 1 
06-0448 BMT 0.76 3.13 1 
00-216 BMT 0.61 1.94 1 
04-0004 BMT 0.45 3.48 1 
03-0678 BMT 0.54 1.94 1 
03-0511 BMT 0.36 3.41 1 
03-0422 BMT 0.55 1.65 1 
15-0587 BMT 0.32 1.91 1 
05-1492 BMT 0.51 2.74 1 
04-0022 BMT 0.46 1.49 1 
00-1003 BMT 1.07 2.75 1 
02-171 BMT 0.33 3.63 1 
04-0706 BMT 0.44 2.21 1 
08-1087 BMT 0.41 3.11 1 
08-0385 BMT 0.52 2.35 1 
07-1812 BMT 0.39 1.73 1 
06-1351 BMT 0.41 3.66 1 
15-0048 BMT 0.66 2.19 1 
14-1542 BMT 0.79 2.09 1 
14-1315 BMT 0.57 2.13 1 
14-0725 BMT 0.32 3.45 1 
14-0612 BMT 0.47 2.99 1 
14-0358 BMT 0.45 3.08 1 
13-1296 BMT 0.51 2.13 1 
13-0372 BMT 0.52 2.22 1 
13-0151 BMT 0.61 1.62 1 
12-0885 BMT 0.4 1.87 1 
12-0419 BMT 0.60 2.90 1 
12-0416 BMT 0.45 4.55 1 
11-1201 BMT 0.38 2.39 1 
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10-0781 BMT 0.68 2.14 1 
09-1075 BMT 0.34 1.86 1 
09-0232 BMT 0.39 3.58 1 
14p60 BMT 0.41 1.67 1 
10p59 BMT 0.82 2.94 1 
07-1208 BMT 0.45 3.67 1 
02-1154 BMT 0.41 2.32 1 
05-0416 BMT 0.91 2.43 1 
04-1754 BMT 0.73 3.28 1 
03-0018 BMT 1.11 4.56 1 
05-1434 BMT 0.79 2.38 1 
14p5 CS 1.07 29.43 3 
14p35 CS 1.24 7.16 3 
14p48 CS 0.65 3.50 3 
10p43 CBMT 0.81 4.03 2 
10p75 CBMT 0.79 1.91 1 
10p87 CBMT 0.92 3.28 1 
10p99 CBMT 0.99 3.90 1 
10p147 CS 0.52 4.00 2 
02-1051 CBMT 0.53 2.28 1 
AgNORs, argyrophilic nucleolar organizer regions; BMT, benign mixed mammary tumour; CBMT, carcinoma in benign mixed mammary 
tumour; CS, carcinosarcoma. 
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Appendix 16 
Appendix Table 12. RANKL and RANK immunostaining in CMMTs. 
No. Case ID 
number 
Diagnosis  RANKL H-score  RANKL 
immunostaining  
RANK H-score  RANK 
Immunostaining  
1 NC1 Normal mammary tissue 0.00 Negative  179.07 Positive  
2 NC2 Normal mammary tissue 3.78 Negative  127. 11 Positive 
3 NC3 Normal mammary tissue 8.73 Positive  81.67 Positive 
4 NC4 Normal mammary tissue 8.85 Positive  104.00 Positive 
5 NC5 Normal mammary tissue 49.65 Positive 86.00 Positive 
6 NC6 Normal mammary tissue 39.97 Positive 103.01 Positive 
7 NC7 Normal mammary tissue 0.00 Negative  91.80 Positive 
8 NC8 Normal mammary tissue 29.27 Positive 89.40 Positive 
9 NC9 Normal mammary tissue 22.89 Positive 87.50 Positive 
10 NC10 Normal mammary tissue 17.42 Positive 101.13 Positive 
11 NC11 Normal mammary tissue 5.20 Negative  10.61 Positive 
12 NC12 Normal mammary tissue 0.00 Negative  26.28 Positive 
13 NC13 Normal mammary tissue 0.00 Negative 29.98 Positive 
14 NC14 Normal mammary tissue 0.00 Negative 51.21 Positive 
15 NC15 Normal mammary tissue 0.00 Negative 36.04 Positive 
16 NC16 Normal mammary tissue 20.87 Positive  16.96 Positive 
17 NC17 Normal mammary tissue 8.64 Positive 11.91 Positive 
18 NC18 Normal mammary tissue 0.00 Negative  33.60 Positive 
19 NC19 Normal mammary tissue 8.52 positive  37.52 Positive 
20 NC20 Normal mammary tissue 8.60 Positive   45.00 Positive 
21 10p2 BMT 68.05 Positive   85.61 Positive 
22 10p71 BMT 6.18 Negative  89.87 Positive 
23 10p12 BMT 86.20 Positive   178.10 Positive 
24 10p210 BMT 67.80 Positive   158.31 Positive 
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25 10p125 BMT 67.35 Positive   133.50 Positive 
26 14p54 BMT 51.70 Positive   10.40 Positive 
27 10p37 BMT 9.58 Positive   96.35 Positive 
28 10p10 BMT 0.00 Negative  91.39 Positive 
29 10p213 BMT 99.05 Positive   93.67 Positive 
30 14p6 BMT 49.75 Positive   191.76 Positive 
31 10p115 BMT 0.00 Negative  91.67 Positive 
32 14p10 BMT 69.76 Positive   64.02 Positive 
33 14p60 BMT 58.37 Positive   87.93 Positive 
34 10p232 BMT 98.57 Positive   137.20 Positive 
35 10p271 BMT 109.88 Positive   21.25 Positive 
36 14p28 BMT 70.26 Positive   175.58 Positive 
37 10p224 BMT 95.02 Positive   61.73 Positive 
38 14p33 BMT 67.73 Positive   72.21 Positive 
39 10p95 BMT 85.33 Positive   79.38 Positive 
40 14p27 BMT 25.99 Positive   136.45 Positive 
41 10p49 BMT 76.04 Positive   103.03 Positive 
42 10p150 BMT 34.72 Positive   83.54 Positive 
43 14p4 BMT 58.76 Positive   107.72 Positive 
44 10p221 BMT 1.89 Negative  83.70 Positive 
45 10p220 BMT 50.48 Positive   163.18 Positive 
46 10p9 BMT 0.00 Negative  183.13 Positive 
47 10p60 BMT 113.67 Positive   125.77 Positive 
48 10p66 BMT 47.62 Positive   98.72 Positive 
49 10p126 BMT 59.26 Positive   90.47 Positive 
50 10p137 BMT 81.46 Positive   76.91 Positive 
51 14p76 BMT 40.12 Positive   109.37 Positive 
52 10p255 BMT 4.51 Negative  194.99 Positive 
53 10p84 BMT 24.93 Positive   136.92 Positive 
54 10P283 BMT 41.34 Positive   259.25 Positive 
55 10p176 BMT 40.79 Positive   20.47 Positive 
56 10p26 BMT 84.33 Positive   142.97 Positive 
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57 14P81 BMT 50.78 Positive   69.80 Positive 
58 14P48 CS 18.25 Positive   200.56 Positive 
59 10P75 CBMT 84.26 Positive   125.17 Positive 
60 14p5 CS 92.33 Positive   207.04 Positive 
61 10p147 CS 160.63 Positive   181.90 Positive 
62 14p24 CS 88.49 Positive   228.37 Positive 
63 14p35 CS 34.14 Positive   288.19 Positive 
64 10p174 CBMT 61.67 Positive   198.70 Positive 
65 10p43 CBMT 5.79 Negative    88.14 Positive 
66 10p87 CBMT 98.74 Positive   286.25 Positive 
67 10p99 CBMT 109.35 Positive   100.74 Positive 
BMT, benign mixed mammary tumour; CBMT, carcinoma in benign mixed mammary tumour; CS, carcinosarcoma; RANKL, receptor 
activator of nuclear factor kappa-B ligand; RANK, receptor activator for nuclear factor Kappa-B. 
 
 
 
 
